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Chapter 1: Introduction.
1.1. DNA m ethylation and enigenetics.
1.1.1 Genetic and Epigenetic inform ation.
The function of DNA is to encode the information needed to enable an organism to grow, live 
and reproduce itself. Our knowledge o f how this information is used in the cell, to create the 
complex regulatory networks which govern processes such as day-to-day functioning and the 
reproduction o f the cell has undergone an extraordinary expansion in the half century since the 
structure of DNA was elucidated by Watson and Crick (Watson and Crick 1953.) However, the 
more we discover about the extraordinary complexity of the cell, the more we realise how much is 
still unknown. In particular, the understanding o f the process of gene regulation has undergone a 
major paradigm shift over the last few decades. It was initially thought that all the information 
encoded by DNA was genetic, i.e. contained within the primary sequence of the DNA molecule. 
As our knowledge has expanded, however, it has become clear that there is much more 
information encoded within the structure o f  DNA, at levels which vary from alterations o f  the 
bases themselves, such as 5-methylcytosine (5mC) through alterations in the proteins which 
package the DNA, to the higher-order topology o f the DNA molecule as it resides in the nucleus. 
These extra levels of information are described as epigenetic, in that they lie ‘above and outside 
o f  the primary structure. Epigenetic alterations allow stable, heritable changes in gene expression 
to persist through the life of the organism and across generations, with no detectable change in the 
primary structure o f  the DNA. Epigenetic effects are involved in processes as diverse as X- 
chromosome silencing, DNA repair and genomic imprinting and can be thought of as creating a 
number of extra, regulatory ‘layers’ within the genome (see fig 1.1.)
1.1.2. M ethylation o f DNA.
DNA can be methylated by the covalent addition of a methyl (CH3) group at the 5 position of 
cytosines to form 5 methyl cytosine (5mC); in mammals the bulk of this methylation occurs at 
cytosines 5’ to guanines, to form a symmetrical CpG dinucleotide (fig. 1.1.) and these methylated 
CpGs are the most common epigenetic modification of the vertebrate genome (Ballestar and 
Wolffe 2001) and are formed by the actions of a family of DNA methyltransferase (DNMT) 
enzymes, using S-adenosyl-L-methionine (AdoMet) as the methyl donor (Svedruiic et al 2004.)
Fie 1.1. The formation o f  5-methvcvtosine.
Fie 1.1. Formation o f 5-mC
The positive charge on the sulphonium atom o f S-adenosyl-L-methionine (AdoMet) makes it a powerful 
alkylating agent. The methyl group of AdoMet is hound to a sulphonium atom, which thermodynamically 
destabilises the molecule and makes the otherwise rather inert methylthiol group of the 
methionine moiety susceptible to nucleophilic attack by nitrogen, sulphur and oxygen atoms and carbanions. 
Sucleophilic attack by the Dnmt enzyme on the C6 o f the target cytosine is carried out by the thiol group of 
the cysteine residue in a conserved PCQ motif (motif IV) within the active site. The formation o f the covalent 
bond thus activates the C5 atom and leaves it susceptible to electrophilic attack. The DMNT enzyme is 
known to f l ip ' the base out of its regular configuration in order to proceed with the reaction. The target 
base is rotated on its sugar phosphate bonds so that it projects into the concave catalytic site. This process 
requires no breaking o f covalent bonds, although the H-bonds between bases and the stacking n interactions 
between adjacent bases are lost (Klimavsaukas et a! 1994, Svedruiic et a! 2004.)
Motif VI
(From Svedruiic et al 2004)
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Although methylation can occur at the N6  position of adenosines and the N4 and C5 position of 
cytosines, only the latter modification is seen in mammals (Hendrich and Tweedie 2003.) These 
methylation marks are key mediators of many epigenetic processes; they can recruit proteins to the 
DNA to remodel chromatin and silence genes, they are involved in genomic imprinting, X- 
chromosome inactivation and genomic stability, and are implicated as having roles in DNA repair 
and apoptosis (Holiday and Ho 2002.) We are beginning to understand how methylation relates to 
normal and abnormal ageing (Liu et al 2003), and how errors and defects in the methylation 
patterns or the proteins which form or read them are involved in diseases such as cancer (Feinberg 
and Tycko 2004), as well as many congenital disorders such as Rett syndrome, ICF syndrome and 
perhaps even autism (Levin et al 2003.)
1.1.3. Patterns o f methylation: CpG s and m ethylated CpGs are non-randomly distributed 
in the mammalian genome.
Methylated CpG dinucleotides are non-randomly distributed in the mammalian genome due to 
the hypermutability of the methylated CpG, which is prone to undergo deamination to form a T«A 
pair, leading to a depletion of CpGs from the genome (Jones and Takai 2001.) This leads to an 
under-representation of CpG in the genome (Jones and Takai 2001.) Methylated CpG 
dinucleotides are also non-randomly distributed: the vertebrate genome is globally methylated, i.e. 
methylated cytosine residues are found over the entire genome apart from short (around 1 kb) 
unmethylated regions where CpG is found at its expected ratio, called CpG islands (Bird 1987.) 
CpG islands are thought to account for around 1% of the genome (Hendrich and Tweedie 2003) 
and are frequently found in association with genes, most often in the promoters, first exons and 
regions towards the 3’ end of a gene (Jones and Takai 2001.) CpG islands coincide with the 
promoters of an estimated 60% o f RNA Pol II transcribed genes (Svedruzic et al 2004,
Zuckercandl 2002.) The original definition of a CpG island, proposed by Gardinier-Garden and 
Frommer was of a region greater than 200bp region with a high GC content and an 
observed/expected CpG ratio of >0.6 (Gardinier-Garden and Frommer 1987) but this has now been 
made more stringent in terms of length and CpG content to exclude a number o f  small exonic 
regions and various parasitic DNAs (Jones and Takai 2001.) CpG islands are unmethylated in the 
germline and thus are not subjected to the mutagenic pressure put upon methylated cytosines 
(Jones and Takai 2001.) However, the reason why these particular sequences are not methylated, 
and the mechanisms which keep them unmethylated have not been fully elucidated. A physical 
barrier to methylation of CpG islands may be formed by the protein Spl (specificity protein 1) -  
when Spl binding sites are removed from DNA flanking a CpG island, the sequence becomes 
methylated (Macleod et al 1994, Brandeis et al 1994.) It appears, therefore, that CpG islands act 
to keep frequently transcribed promoters in a state conducive to transcription. Since so much of the 
genome is non-coding sequence, and due to the heavy burden of repetitive elements such as Alu, 
LINES (Long interspersed nuclear elements) and SINES (short interspersed nuclear elements) it is 
thought that the genome is kept in a default state of repression (Bird 1995.) This would prevent 
transcriptional ‘noise' caused by random transcripts as well as chromosomal re-arrangements 
between repeated sequences (Carter and Segal 2001.)
Although repression of potentially deleterious rogue sequences is a function o f  DNA 
methylation, it really tells us little of how, when and why methylation evolved (Hendrich and 
Tweedie 2003.) Also, although CpG islands are generally unmethylated, there do exist exceptions; 
a number of CpG islands have been found to be methylated in a tissue-specific manner, namely the 
testis-specific H2b gene in the rat and the germline-specific MAGE (melanoma associated antigen) 
gene family in the human germline (Newell-Price et al 2000.)
1.1.4. M ethylation of PNA in O ther Species.
DNA methylation is found in a wide range of eukaryotes, including insects, mammals, birds, 
fish and amphibians; it is also found in some plants, such as Arabidopsis (Adams 1996.) Plant 
genomes contain relatively high levels of 5-methylcytosine (5mC) around 5-25% depending on the 
species examined (Hendrich and Tweedie 2003, Adams 1996.) Unlike mammals, where 5mC is 
mainly found in the context o f  CpG dinucleotides, the major 5mC content of the plant genome can 
be found in three different contexts; CpG, symmetrical CpNpG sites and asymmetric CpHpH sites 
(where N is any nucleotide and H is A,C or T) (Rangwala and Richards 2004.)
In plants, 5mC is concentrated in heterochromatic regions of DNA such as long repeated arrays 
(e.g. the rRNA genes) (Rangwala and Richards 2004.) Plant methylation patterns appear to be 
highly compartmentalised with expressed genes being generally unmethylated and embedded 
within a heavily methylated region; studies in maize have shown that exons are generally 
unmethylated whereas the majority of transposons are methylated (Rabinowicz et al 2003, Palmer 
et al 2003.) Methylation patterns in plants are laid down by Dnmtl class methyltransferases (such 
as Metl in Arabidopsis) at CpG sites, and plants also contain distinct enzyme activities that can 
methylate cytosine at other, non CpG nucleotide sequences. The chromodomain containing 
methyltransferase Cmt3 and the Dnmt3-related methyltransferases Drml and Drm2 are responsible 
for these activities and are directed by DNA methylation independent cues (Rangwala and 
Richards 2004, Cao et al 2002.)
Although it was known that Drosophila melanogaster carried genes with homology to the 
vertebrate methylation machinery, for a long time it was believed that insect species such as 
Drosophila had no methylated bases in their genomes (Lyko 2001.) The overall methylation levels 
in D. melanogaster are extremely low, and are thought to be less than 1% of cytosines (Lyko et al
2000, Govvher et al 2000.) Most 5-Me-C modifications are not based within CpG pairs and were 
thus not spotted by traditional assays (Field et al 2004.) Methylation in D. melanogaster is formed 
by a D N \fT 2 -like enzyme, mainly at CpT and CpA dinucleotides (Kunert et al 2003.) It is not 
clear how this methylation is maintained in the absence of the symmetrical CpG dinucleotides 
which direct the mammalian machinery (Field et al 2004.)
U .S . Functions o f DNA methylation
DNA methylation has been found to be connected to many diverse functions in the normal cell, 
including transcriptional repression, genomic imprinting, X-chromosome inactivation, and roles in 
the control o f  gene expression in fundamental embryonic development, normal tissue function and 
DNA repair (Umov and Wolffe 2001, Zuckercandl 2002.) Disregulation of the chromatin 
environment and defects in the methylation machinery are now known to be the cause of a number 
of human pathologies such as ICF syndrome (Immunodeficiency, centromere instability and facial 
anomlies syndrome) (Xu et al 1999) and disregulation of epigenetic mechanisms have been found 
to play an important role in the formation o f  cancer (Verma et al 2004.) With so much still 
unknown about the origins and functions of DNA methylation, this is a rich and diverse field that 
undoubtedly still holds many surprises.
1.2. Genomic Imnrinting.
Imprinted genes are those which are expressed differentially depending on their parent of origin, 
not due to any significant difference (beyond normal allelic variation) in primary sequence, but due 
to different sex-specific imprint ‘marks’ which generally lead to silencing of one allele and 
expression of the other (Verona et al 2003.) Genomic imprinting is therefore an epigenetic
mechanism of transcriptional regulation in which the expression of a small subset of genes is 
restricted to or predominantly expressed from one parental allele (Verona et al 2003.) In order to 
be differentially expressed, the alleles must be different in some way; these differences are not in 
the primary sequence of the DNA (beyond normal allelic variation) but are due to epigenetic 
differences. The two parental alleles of an imprinted gene often show different chromatin structure, 
DNA methylation, histone modifications and asynchronous replication (Bartolomei and Tighman 
1997.) The exact ways in which the epigenetic differences result in differential expression are 
well-characterised for some genes (e.g. the Igf2/H19 system) (Amey 2003.)
Imprinting was first identified in mammals in the early 1980s, when mouse embryos were 
created carrying chromosomes derived solely from the male or female parent; although they were 
diploid, these embryos failed to develop (McGrath and Solter 1984.) This ran counter to the then - 
accepted dogma that the function of genetic material was independent of the parent it was derived 
from, and implied that alleles could be differentially expressed depending on their parent of origin 
(Verona et al 2003.) Further experiments in the early 1990s identified the first paternally- 
expressed gene {Igf2) (DeChiara et al 1991) and the first maternally expressed genes (Igf2r) 
(Wilson 1991.)
Since then, many more imprinted genes have been discovered 
(www.mgu.har.mrc.ac.uk/research/imprinting) and the often complex mechanisms which underlie 
epigenetic control mechanism have been partially unravelled. For example; imprinted genes are 
unusually enriched in CpG islands, with 88% of mouse imprinted genes having a CpG island 
compared with the average figure of 47% (Reik and Walter 2001.) This implies that methylation 
may play a role in the regulation of imprinted regions (fig 1.2.) That methylation is important for 
imprinting has been proven (Li et al 1993.)
Imprinted genes also often cluster on the chromosome, to form large, imprinted domains 
(Verona et al 2003, www.mgu.har.mrc.ac.uk/research/imprinting.) This implies that a common 
mechanism or group of mechanisms may control whole imprinting domains and that there may be 
cis-acting imprinting control regions that function across the domain to regulated imprinting for all 
the genes in that cluster (Verona et al 2003.)
However, many intriguing questions remain: how and in response to what pressures did 
imprinting evolve? What advantages does it confer? Why are only a small fraction of our genes 
imprinted? Perhaps the most currently socially relevant effect of imprinting relates to the emergent 
technologies of reproductive and therapeutic cloning. Many mammalian embryos are extremely 
difficult to clone, possibly in part due to the complexity of the epigenetic ‘reprogramming’ events 
which occur around fertilisation, development and germ cell formation (Verona et al 2003.) An 
increased understanding of the role o f  epigenetics in normal development would have massive 
implications for the efficiency of reproductive and therapeutic technologies, and therefore human 
health.
The study of imprinted genes such as Igf2 has also allowed us to understand epigenetic 
mechanisms such as chromatin boundary elements, enhancer blockers and insulators (Engel et al 
2004, Thorvaldson and Bartolomei 2000.) Imprinted expression at the HJ9/Igf2 locus, for 
example, depends on a 2 kb, differentially-methylated domain (DMD) that acts as a maternal- 
specific insulator which is maternally-expressed and is paternally hypermethylated (Engel et al 
2004, Thorvaldson and Bartolomei 2000.) (Fig 1.2.)
Fie 1.2. Imprint ins, insulators and enhancer blocking at the HI 9/Ie f2 locus.
y ?  y ?  , y p  ?,
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Fie 1.1. Model for Ief2/H19 regulation, (from BelI et al 2001)
Igfl and H19 are located on mouse chromosome 7. Both genes require a set o f enhancers located downstream 
of H19 (grey ovals) for high-level expression. The maternal allele of H19 is unmethylated and recruits CTCF, 
functioning as an insulator and preventing Igfl accessing the downstream enhancer. H19 gains enhancer access 
and is expressed. On the paternal chromosome, the H!9 DMD is methylated, and the CTCF cannot bind, so 
there is no insulator activity. The downstream enhancers are now free to activate expression of paternal Igfl. 
Inactivation of the paternal HI 9 is accomplished by a separate mechanism (Bel! et al 1000, Drewell et al 1000.)
1.2.1. Evolution of Imprinting in Mammals.
An imprinted gene is expressed only from one parental allele, which leads to it being 
functionally haploid (Murphy and Jirtle 2003.) How such a mechanism could have evolved is a
puzzle, as diploidy prevents the deleterious effects o f recessive alleles in the heterozygous state 
and must therefore be a selectable advantage (Murphy and Jirtle 2003.) Functional haploidy 
‘unmasks’ these effects, which would be expected to lead to a drop in fitness for the individual 
organism (Murphy and Jirtle 2003.) Clearly then, the benefits gained by having a certain locus 
imprinted must be greater than the risks o f haploidy at that locus. This may also explain why such 
a small proportion o f our genes are imprinted - the number of loci at which haploidy can be 
tolerated in a diploid organism is probably very low (Murphy and Jirtle 2003.)
A number o f theories have been advanced to explain how imprinting may have arisen; the three 
leading theories are the conflict (also called the kinship) theory (Wilkins and Haig 2003), the 
ovarian time bomb (OTB) theory (Varmuza and Mann 1994) and the evolvability theory (Beaudet 
and Jiang 2002.) O f the three, the most accepted is the conflict theory (Wrzeska and Rejduch 
2004.)
The evolvability theory, proposed by McGaudet and Martin, and Beaudet and Jiang, (Beaudet 
and Jiang 2002, Wilkins and Haig 2003) states that imprinting has evolved because functional 
haploidy at imprinted loci increases ‘evolvability’ i.e. the ability o f a genetic system to generate 
novel adaptations to selection pressures (Wilkins and Haig 2003.) In other words, an imprinted 
allele is ‘hidden’ from the pressure o f natural selection pressure and can generate new mutations 
which may be beneficial if that allele is then not in a silenced state (Wilkins and Haig 2003.) The 
theory does have shortcomings; the time an allele spends silenced may not be enough to 
accumulate new mutations, and the theory does not explain why specific, small numbers o f loci 
should be imprinted or in which sex, or in which phyla, since in the evolvability model, the 
benefits are identical for all diploid organisms, whereas imprinting is only seen in a subset of 
mammals (Wilkins and Haig 2003.)
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The ovarian time bomb (OTB) theory put forward by Varmuza and Mann proposes that 
imprinting has evolved to prevent female mammals from ovarian trophoblastic disease (Varmuza 
and Mann 1994.) If an unfertilised oocyte spontaneously develops, it may form a teratoma, (a 
tumour consisting o f multiple tissue types) but because the paternal genes are needed for full 
development o f an invasive trophoblast, the ovarian teratoma is relatively benign (Varmuza and 
Mann 1994.) However, the theory does not explain how genes which are not involved in 
trophoblast development come to be imprinted, nor does it explain why imprinting (of Ig/2) is 
present in marsupials, which lack a fully invasive placenta, or in eutherians with non-invasive 
placentas such as sheep (Wilkins and Haig 2003.)
The leading theory for the evolution o f genomic imprinting is the ‘conflict theory’, sometimes 
also called the ‘kinship theory’ (Moore and Haig 1991.) This states that differential imprinting of 
genes depending on their parent o f origin depends on the differing strategies each gene needs to 
maximise its likelihood of being carried to the next generation (Moore and Haig 1991.) These 
strategies are carried out within the context o f maternal provisioning of resources for the foetus. It 
is generally more advantageous for the foetus to take maximal nourishment from the mother, but 
this may weaken the mother and reduce her own chances o f survival and future reproductive rate.
Maternally and paternally derived genes in an offspring may be in conflict thus; a mother is 
equally related to all her offspring, with each maternal gene having a 50% probability on average 
of being in any of her other offspring (Moore and Haig 1991.) In a species with any degree of 
multiple paternity, the father cannot guarantee that the mother is not unfaithful and thus the 
chances of a paternally derived gene being represented in any other offspring from the same 
mother are less than 50%. Hence it is advantageous, the conflict theory states, for paternally- 
derived genes to drive foetal growth in order to obtain maximal resource provisioning from a 
(potentially unfaithful) mother (Moore and Haig 1991.) A large foetus however, is not optimal for
- 11 -
the mother, as it is both a drain on her resources and a potential danger to give birth to. Therefore, 
the conflict theory states that maternally-derived genes should serve to check foetal growth (Moore 
and Haig 1991.) One imprinted system which supports this theory is the paternally-expressed Ig/2, 
which encourages foetal growth and the maternally expressed H I9 transcript, which is reciprocally 
expressed (Wrzeska and Rejduch 2004, Murphy and Jirtle 2003.) Imprinting defects in 
chromosome 11 around the IGF2 locus in humans are associated with Beckwith-Wiedemann 
syndrome, a human foetal overgrowth syndrome (Reik and Mayer 1997, Nicholls et al 1998.) 
There is also some data which does not support the conflict theory of imprinting -  one study of 
UPDs (uniparental disomies) in humans found that some paternal UPDs were in fact growth 
retarding (Miozzo and Simoni 2002.) However, the duplication o f an entire chromosome is an 
extremely blunt way in which to extrapolate data concerning individual genes or gene clusters, and 
so is by no means a strong refutation o f the conflict theory. Other, gene specific studies have 
produced results which support the conflict theory; Peg3 (paternally expressed 3) is a paternally- 
expressed imprinted gene and so would be expected to be a growth promoter and indeed the Peg3 
knockout mouse is smaller than normal wild type mice (Li et al 1999.)
Imprinted genes have been found in marsupial (metatherian) and placental (eutherian) 
mammals, but as yet, no imprinted genes have been found in monotremes (prototherians) implying 
that imprinting arose after the divergence o f the common ancestor o f the marsupials and placental 
mammals from the ancestor of the monotremes (Murphy and Jirtle 2003, John and Surani 2000.) 
Since many imprinted genes are involved in foetal growth and development, this does back the 
conflict theory as it would allow the mother to exercise control over foetal resource provisioning.
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1.2.2. X-Chromosome Inactivation.
In mammals, males have a single X chromosome and a single Y chromosome and females have 
two X chromosomes (Heard 2004.) The X-chromosome carries around 1500 genes and if both Xs 
were expressed in the female, there would be significant problems with gene dosage effects -  
female mammals have resolved this problem by inactivating one X chromosome (Lyon 1961.) The 
silencing occurs early in development and thus female mammals are mosaic for their X-linked 
gene expression (Heard 2004.) This has obvious advantages in that random inactivation leading to 
random mosaicism will to a certain extent mask the effects of being haploid for either X- 
chromosome (Heard 2004.) Males have no such advantage and so suffer more frequent and severe 
X-linked defects, such as colour blindness (Deeb 2005.) Not all X-linked genes are subject to 
inactivation, with an estimated 15% escaping X-inactivation (Carrel and Willard 2005.)
The initiation o f X silencing is dependent on a master control locus, the X-inactivation centre 
(Xic) (Heard 2004.) At the heart o f the Xic is the Xist (X-inactivation specific transcript) gene, 
which does not produce protein, but instead makes a 17kb long untranslated RNA that coats the 
entire X in cis and triggers its inactivation (see fig 1.3) (Heard 2004.) Initially this phase is 
reversible, but it becomes ‘locked in’ through a cascade of protein interactions and DNA 
methylation (Heard 2004.) The Polycomb group proteins Eed (embryonic ectoderm expression) 
and Enxl (The mouse homologue o f enhancer o f zeste) seem to be implicated in the process and 
their association is accompanied by H3K27 methylation (Plath et al 2003.) H3K9 di-methylation is 
also observed (Heard et al 2001.) These histone modifications are followed by DNA methylation, 
which may keep the X-chromosome in its final, inactive state (see fig 1.3) (Silva et al 2003, Plath 
et al 2003.)
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E is- 1.3. X-Chromosome Inactivation.
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13. The Chromatin Environment and the Histone Code.
DNA does not exist in isolation within the cell; the huge length of the naked DNA molecule - 
almost two metres in an average eukaryotic nucleus of 10pm diameter (Peterson and Laniel 2004) 
- requires a sophisticated nucleoprotein ‘scaffold’ to package it in a manner which allows storage, 
usage and replication at defined times in the life cycle of the cell (Peterson and Laniel 2004.)
Fie 1.4. The structure o f  chromatin
(from Felsenfeld and Groudine 2003 and Alberts et al 1998.)
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This scaffold is far from being an inert support for DNA; as our knowledge o f the structure of 
chromatin expands, it is clear that the components o f the chromatin environment play a key part in 
the modulation of gene expression (Peterson and Laniel 2004.)
1.3.1. The histone code.
Each histone has an amino terminal ‘tail’ consisting of 20-35 residues and histone H2A also has 
a -37  residue carboxy terminal tail (Peterson and Laniel 2004.) The histones can undergo a range 
of post translational modifications, mainly on the tails, although new modifications in the central 
histone domains are being discovered; given the massive number of potential modifications, some 
believe that virtually all accessible histone residues may be modified (Peterson and Laniel 2004.) 
Modification o f histone tails changes the way they interact with each other to form higher-order 
nucleosomal arrays, and so modification o f histones is a key part of the chromatin remodelling 
process (Peterson and Laniel 2004.) Modifications include acetylation of lysines (K) and arginines 
(R,) phosphorylation o f serines (S) and threonines (T,) the ubiquitination and sumoylation of 
lysines and the ribosylation o f lysines (Peterson and Laniel 2004.) Each lysine residue can be 
mono-, di- or tri-methylated and arginine residues can be mono- or di-methylated (Peterson and 
Laniel 2004.)
In recent years, the patterns o f histone modifications have begun to be correlated with specific 
chromatin and transcriptional states, which has lead to the concept of the so-called ‘histone code’ 
(Jenuwein and Allis 2001.) For example, transcriptionally active chromatin is often associated 
with H4 K8 acetylation, H3 S10 phosphorylation and H3 K14 acetylation (Peterson and Laniel 
2004.) Transcriptional repression in higher eukaryotes, on the other hand, is frequently associated 
with H3 K9 tri-methylation and the loss o f H3 and H4 acetylation (Peterson and Laniel 2004.) The
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histone modification patterns also seem to change with global changes in chromatin structure; for 
example, H2A SI and H2A T119 phosphorylation and H3 T3, H3 S10 and H3 S28 
phospohorylation are associated with highly condensed mitotic chromatin (Peterson and Laniel 
2004.) Some histone modifications are shown in fig 1.5.
Fig /■& Some histone modifications
(Adaptedfrom Peterson and Laniel 2004.)
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The code itself appears to be highly flexible rather than an absolute correlation o f state-to- 
modification (Peterson and Laniel 2004.) Since MeCP2, Mbd2 and some Dnmts recruit chromatin 
remodelling activities such as Hdacl and Hdac2, there are clear mechanistic links between histone 
modifications and the methylation machinery o f the cell. For example, MeCP2 has been shown to 
be linked to histone methylation (Fuks et al 2002); MeCP2 associates with histone 
methyltransferase activity in vivo to methylate H3 K9 (Fuks et al 2002.) This clearly shows that 
DNA methylation can recruit factors which remodel chromatin into a form refractory to 
transcription (Fuks et al 2002.)
1.4. DNA methylation and transcriptional silencing.
A large body o f evidence connects DNA methylation and transcriptional silencing (Curradi et al
2002.) Experiments performed with Xenopus oocytes and microinjected methylated templates 
show that methylation o f DNA inhibits transcription (Kass et al 1993, Kass et al 1997, Keshet et al 
1985.) Conversely, genes which have been methylated and silenced in cultured cell lines can be 
reactivated by treatment with the demethylating agent 5-azacytidine (Jones 1985.)
How does methylation of DNA cause gene silencing? It has been proposed that methylation of 
DNA causes steric blocking, preventing access of transcription factors (Eden and Cedar 1994.) 
However, the bulk o f methylation-induced silencing does not appear to be this simple. The 
currently accepted model for the majority o f methylation-induced silencing is that methylated 
DNA recruits proteins (the methyl CpG binding domain proteins); these proteins then recruit other 
factors such as histone deacetylases (Hdacs) which can remodel the chromatin into a form 
refractory to transcription (Jones et al 1998, Nan et al 1998) Transcriptionally active euchromatin 
is less condensed than the densely-packed and transcriptionally-inactive heterochromatin
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(Jenuvvein and Allis 2001.) In accordance with this model, the histones assembled on methylated 
DNA are less acetylated than those on an unmethylated template and methylated transfected genes 
can be reactivated by treatment with Trichostatin A (Curradi et al 2002, Hseih et al 1994.) A 
distinctive chromatin structure, which is insensitive to nuclease digestion (a mark of repressive 
chromatin) is formed on methylated DNA (Keshet et al 1996, Curradi et al 2002) Methylation and 
histone remodelling are thought to act together: naturally hypermethylated genes can only be 
reactivated by Trichostatin A after they have been demethylated with 5-azacytidine (Cameron et al 
1999.)
1.4.1. Reading and writing the methylation marks: methyl CpG binding domain proteins 
and DNA methyltransferases.
The pattern o f methylation within the genome carries an extra ‘layer’ of information over and 
above the primary nucleotide sequence. The marks themselves are laid down by a family of DNA 
methyltransferase proteins (Dnmts) and interpreted by a family of proteins capable o f recognising 
methylated DNA; the Methyl-CpG-Binding Domain (Mbd) proteins.
1.4.2. DNA methyltransferases.
The DNA methyltransferases (DnmLv) are responsible for introducing methylation into the DNA. 
There are several members of the Dnmt family in mammals, each with its own specificity and 
function. All the Dnmts contain ten highly conserved motifs which make up a 500 amino acid 
catalytic domain catalytic domain (Cheng et al 1995.)
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1.4.3. Dnmtl .
Dnmtl was the first mammalian Dnmt to be identified, and is responsible for so-called 
maintenance methylation, i.e replenishing the symmetrical methylation marks on DNA which has 
been replicated and is thus hemi-methylated (Bestor 1992.) Dnmtl has a higher affinity for 
hemimethylated DNA in vivo, up to 40-fold higher than for unmethylated DNA (Fatemi et al 
2001) and is thought to be targeted to replication foci by Pena (Chuang et al 1997) where it can 
methylate DNA immediately after replication. Dnmtl is a large protein o f 184kDa, which has a
large multi-functional N-terminal domain which contains a nuclear localisation sequence, a
2+replication foci targeting domain and a cysteine-rich Zn binding domain (Hermann et al 2004.) 
Dnmtl appears to be essential for development; the D nm tl'1' mouse exhibits embryonic lethality; 
the embryos are stunted and have delayed development and reduced methylation levels (Li et al 
1992.) Interestingly, Dnmtl null ES cells are viable, and contain low levels o f methylation and a 
methyltransferase activity, which led to speculation that there may be another Dnmt activity in ES 
cells (Lei et al 1996.)
Dnmtl does not function in isolation and many proteins have been reported to bind Dnmtl 
through its N-terminal domain (Hermann et al 2004.) Dnmtl is implicated in cell cycle regulation 
through interactions with Pena, and Rb, as well as several other proteins (Hermann et al 2004.) 
Dnmtl also interacts directly with histone modifying activities such as the histone 
methyltransferase Suv39Hl (Fuks et al 2003) the histone deacetylases Hdacl and Hdac2 
(Rountree et al 2000, Robertson et al 2000) and also with methyl CpG binding proteins Mbd2, 
Mbd3 and MeCP2 (Tatematsu et al 2000, Kimura et al 2003) and the de novo methyltransferases 
Dnmt3a and Dnmt3b (Kim et al 2002.) These diverse associations show that Dnmtl is not only
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maintaining the methylation marks, but is actively involved in methylation-dependent silencing at 
different levels, and provides a possible feedback link between the proteins which create and 
maintain the methylation and those which read and act upon it.
1.4.4. Dnmt2
The Dnmt2 gene is conserved among eukaryotes, even in those which show no detectable 
methylation (such as S. pombe) (Hermann et al 2004.) The enzyme does not have the large N- 
terminal regulatory domain and is therefore more like bacterial methyltranseferases (Hermann et al 
2004.) Dnmt2 was thought for a long time to have no catalytic activity, but has recently been 
shown to have a weak methyltransferase activity in vivo and in vitro (Hermann et al 2003.) Dnmt2 
is ubiquitously expressed at low levels in most human and mouse tissue and in mouse ES cells 
(Okano et al 1998) and ES cells null for Dnmt2 are viable and show normal levels o f methylation 
at endogenous sequences (Okano et al 1998.) The biological function of Dnmt2 in mammals is not 
yet known, although a Dnmt2-like protein has been shown to mediate DNA methylation in 
Drosophila (Kunert et al 2003.)
1.4.5. Dnmt3a, Dnmt3b and Dnmt3l
Dnmt3a and Dnmt3b are de novo methyltransferases, i.e. they methylate previously unmethylated 
templates, and are therefore involved in laying down the methylation patterns in the developing 
embryo (Kaneda et al 2004.) Dnmt3a knockout mice were bom appeared to be normal at birth. 
However, most homozygous mutant mice became runted and died at about 4 weeks o f age. In 
contrast, no viable Dnmt3b~' mice were recovered at birth (Okano et al 1999.) A recent conditional 
deletion o f Dnmt3a has shown that it may have roles in genomic imprinting, as males carrying the
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conditional allele show defective spermatogenesis and lack o f methylation at some paternally 
imprinted loci (Kaneda et al 2004.) The two genes are highly similar (Hermann et al 2004) and 
each can partially compensate for the loss the other, as shown by a double mouse knockout 
(Dnmt3a' '  Dnmt3b ' ') which has a more severe phenotype than the individual deletions (Okano et 
al 1999.) The fact that patients with the disorder ICF (immunodeficiency, centromeric instability, 
facial abnormalities) (who have mutations in DNMT3b) are affected despite having normal 
DNMT3a levels, however, shows that the two proteins cannot fully compensate for the loss of the 
other, as do the individual mouse knockouts (Hermann et al 2004.) Dnmt3a and Dnmt3b also exist 
as multiple, differently spliced isoforms, allowing a greater diversity of function (Hermann et al 
2004.)
A third member of the Dnmt3 family, Dnmt3L, has been shown to interact with Dnmt3a and 
Dnmt3b and although it has no catalytic activity itself, it has been shown to act as a stimulatory 
factor in methylation (Chedin et al 2002) and also as a transcription repressor that recruits Hdac 
activity (Deplus et al 2002.) Dnmt3a and Dnmt3L have also been shown to be essential for the 
establishment o f imprinting in the oocyte (Hata et al 2002.)
Despite the recent advances in this field, it is still not fully understood how the complex patterns 
of methylation are established during development (Herman et al 2004.) It is not known how some 
regions escape the global methylation which occurs in embryogenesis or how chromosomes are 
marked to ‘remember’ which regions to methylate or leave unmethylated. The answers to these 
questions are important, not just for basic research, but for their implications in human disease, 
development, and in processes such as cloning, in which defective imprinting is a major hurdle.
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1.4.6. Establishment and Maintenance of Methylation Marks.
The patterns and overall level of methylation within the genome varies over the life cycle o f an 
organism, with two ‘waves’ o f demethylation and epigenetic reprogramming occurring, one as the 
germ cells develop, and one when the egg is fertilised and begins to develop into an embryo (Reik 
et al 2001.) In the developing mouse embryo, between 10.5 and 12.5 days post coitum, the 
primordial germ cells (PGCs) which will become the progenitors of future gametes, migrate, and 
enter the germinal ridge, which will form gonadal tissue (Reik et al 2001.) During this time their 
sex-specific methylation marks are erased (Reik et al 2001.) During subsequent gametogenesis, 
methylation levels rise as sex-specific marks are re-established, until methylation levels are high in 
fully mature gametes (Reik et al 2001.) Initiation o f de novo methylation in sperm occurs around 
14.5 days post coitum and continues postnatally in diploid gametocytes before they undergo 
meiosis (Reik et al 2001.) In females, de novo methylation occurs in oocytes which are arrested in 
the diplotene stage o f meiosis (Reik et al 2001.) (See fig 1.5.)
The second wave of reprogramming is initiated at fertilisation; both egg and sperm carry sex- 
specific methylation marks and these must be ‘reset’ to allow for correct development o f the 
embryo (Mayer et al 2000.) There is a marked asymmetry between the way maternal and paternal 
pronuclei undergo demethylation; the paternal genome undergoes a rapid ‘active’ demethylation 
within 4 hours of fertilisation, in which methylation is stripped off in an active process by an as yet 
unidentified demethylase, in the absence o f transcription or translation (Reik et al 2001.)
By contrast, the maternal genome appears to undergo a slower, ‘passive’ demethylation. The 
methylation marks are effectively diluted out as there is no primary de novo methylase (D nm tl) at 
this stage, so when strands are replicated, no de novo methylation of the hemimethylated daughter 
product occurs (Reik et al 2001.)
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Fi s i .  6. Levels o f  Methylation in the Germ line and Developing Embryo 
(Adopted from Reik et aI 2001.)
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Fie 1.6. Levels o f methylation in the maternal and paternally-derived genomes through the life cycle 
of the mouse.
Maternal levels are represented by a pink line, paternal levels by a blue line. The dashed lines indicate 
imprinted genes (top) which are not de methylated at fertilisation, and unmethylated sequences, which are 
not methylated (bottom.) Note the two waves o f demethylation and re-methylation. effectively resetting' 
the imprint marks as they pass through the germ line, and the asymmetry between the rates o f 
demethylation for the maternal and paternally-derived genomes. (Reik et al 2001.)
Around the fifth cell division, de novo methylation is initiated (Reik et al 2001.) At this point, 
the first two cell lineages emerge; the inner cell mass (ICM) and the trophoectoderm (TE); the 
ICM becomes highly methylated and gives rise to adult tissues, whilst the TE becomes
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hypomethylated and gives rise to the extraembryonic tissues (Reik et al 2001.) The PGCs arise 
from the ICM and migrate to the germinal ridge and the cycle begins anew (Reik et al 2001.)
1.4.7. How are the sex-specific m ethylation marks reset correctly?
Despite the almost global demethylation, each cycle sees sex-specific methylation marks reset 
on the correct parts of the genome; how does this occur? Is there a residual mark left on the DNA 
which directs the methylation machinery? This question, and a possible mechanism of action, is far 
from resolved, but it does seem that some sequences are fully or partially protected from 
demethylation at various times (Reik et al 2001.) During the wave o f demethylation which occurs 
in PGCs, some repetitive sequences such as intracistemal-A particles (IAPs) seem to retain their 
methylation (Reik et al 2001.) However, at this stage, using bisulfite genomic sequencing to 
examine methylation patterns, Hajkova et al have found that some imprinted genes, such as Peg3, 
Litl, Snrpn and H19 are demethylated between 10.5 and 13.5 days gestation in the mouse 
(Hajokova et al 2002.) How imprinted genes are identified and ‘re-imprinted’ remains unknown.
During the pre-implantation wave o f demethylation, imprinted genes appear to retain their 
gamete-derived methylation patterns, presumably to allow the asymmetric monoallelic expression 
patters necessary for embryonic development (Reik et al 2001.)
Recent work by Bourc’his and Bestor has shown that Dnmt3L (DNA methyl transferase 3-like 
protein) may aid in the de novo methylation o f dispersed repeated sequences in the male germ cells 
(Bourc’his and Bestor 2004.) Dnmt3L does not have the catalytic motifs of the other Dnmt family 
members, but it is related structurally to the other Dnmts (Hata et al 2002.) Male mice which lack 
Dnmt3L are viable but produce no sperm and are thus sterile (Hata et al 2002.) Female mice are 
fertile, but their heterozygous offspring die before mid-gestation due to the biallelic expression of 
genes which are normally silenced on the maternal allele (Hata et al 2002, Bourc’his and Bestor
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2004.) In early germ cells, the loss o f Dnmt3L caused meiotic failure, due to non-homologous 
synapsis (Bourc’his and Bestor 2004, Hata et al 2002.)
1.5. Readine the methylation marks: methyl binding domain proteins.
The methyl CpG binding domain (MBD) proteins ‘read’ and interpret the methylation marks on 
DNA, and thus are critical mediators o f many epigenetic processes. At the present time, the MBD 
family consists o f M bdl, Mbd2, Mbd3, Mbd4 and MeCP2. Another methyl binding protein, Kaiso, 
has also been characterised (Daniel and Reynolds 1999, Prokhortchouk et al 2001.) Although it 
binds CpGs in a different manner, it acts as a transcriptional repressor and so can be considered a 
member o f the MBD family (Prokhortchouk et al 2001.)
Sequence alignments of MBD family members reveal an intron in a conserved position in all 
members o f the family (with the exception o f the recently discovered Kaiso), indicating that they 
are evolutionarily related, and defined two subgroups; the MBDs of MeCP2 and Mbd4 being 
similar to each other, while the MBDs o f M bdl, 2 and 3 are more similar to each other than those 
of MeCP2 and Mbd4 (Ballestar and Wolffe 2001, Hendrich and Tweedie 2003.) The structure of 
the methyl binding domain itself has been solved by NMR (Okhi et al 1999, Wakefield et al 
1999.) The domain contains around 70 residues and forms a wedge shaped a /p  structure, in which 
four antiparallel p strands form one face o f the wedge (see fig 1.7) (Ohki et al 1999.) The longest 
two strands are thought to interact with the major groove, where the methyl group would be 
located (Wakefield et al 1999, Ohki et al 1999.)
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F jsM L  Structure o f  the methyl CpG binding domain as it binds to methylated PISA.
Fie 1.7. The methyl-CpO binding domain.
The domain contains around 70 residues and forms a wedge-shaped a  (5 structure. In which four antiparallel (5
strands form one side o f  the wedge. The longest two strands are thought to interact with the major groove, where
the methyl group would he located. (Wakefield et a! 1999.)
Mbdl, Mbd2 and MeCP2 have been demonstrated to repress transcription from methylated 
promoters in vitro and in vivo, via the association of their transcription repression domain (TRD) 
with a co-repressor complex (Nan and Bird 1999.) Mbd4, on the other hand, is a thymine
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glycosylase and is not associated with transcriptional repression (Hendrich et al 1999.) It is 
thought that Mbd4 may play a part in limiting the mutagenicity of methylcytosine (which readily 
undergoes deamination) (Hendrich et al 1999, Bellacosa 2001, Petronzelli 2000.) MeCP2 is a 
transcriptional repressor; mutations in human MECP2 cause Rett syndrome, a neurodevelopmental 
syndrome which affects mainly females and is a major cause of mental retardation (Hagberg et al 
1985, Amir et al 1999.)
1.5.1. M b d l.
Mbdl is the largest member o f the MBD family (Wade et al 2001.) It is not essential for 
development (i.e. M bdl'7* null mice survive) but M bdl'7' adults have defects in adult neurogenesis 
and hippocampal function and have an elevated rate o f aneuploidy in neurons (Zhao et al 2003.) 
Mbdl contains a TRD at the C-terminal end (Wade 2001.) Yeast 2-hybrid screening has revealed 
that Mbdl interacts with the Suv39Hl histone methyltransferase (Fujita et al 2003) and p i 50, a 
subunit o f chromatin assembly factor 1 (Reese et al 2003.) Mbdl has also been shown to interact 
with the methylpurine-DNA glycosylase (Mpg) which removes 3mA and 7mG from DNA by base 
excision repair (BER) (Watanabe et al 2003) providing an interesting link between transcriptional 
repression and DNA repair functions via an MBD protein. Watanabe et al proposed that an 
Mbdl/Mpg complex sits on the promoter; when challenged with the alkylating agent MMS, Mbdl 
dissociates, leaving Mpg to repair the damage. After repair, the complex reforms (Watanabe et al 
2003.)
Uniquely among the MBD family, Mbdl also contains three zinc-coordinating CXXC motifs 
(Reese et al 2003.) The third o f these domains, CXXC-3, undergoes alternative splicing in mouse 
and human and splice variants containing CXXC-3 are capable of DNA methylation independent
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transcriptional repression (Stancheva et al 2004, Reese et al 2003.) Mbdl localises to CpG sites in 
vivo via the CXXC-3 domain (Stancheva et al 2004.) Only the MBD is required for binding to 
methylated DNA and the CXXC-3 motif can bind to unmethylated DNA (Jorgenson et al 2004.) 
Several mechanisms may account for this; firstly that the dual binding capacity o f Mbdl may 
allow it to target CpGs regardless o f their methylation state; secondly, the different isoforms may 
confer a degree o f flexibility, allowing tissue specific gene regulation, and thirdly that Mbdl may 
use both domains at once to allow binding to sites which have both methylated and unmethylated 
CpGs (Jorgenson et al 2004.) Clearly, the role o f Mbdl in gene expression is more complex than 
originally thought.
1.5.2. Mbd2.
Mbd2 is the methyl-binding component o f the Mecpl complex, which represses transcription 
from densely methylated genes (Ng et al 1999, Feng and Zhang 2001.) Mecpl also contains 
Hdacl, Hdac2 and RbAp46/48 proteins which allow Mbd2 to target histone deactylase/chromatin 
remodelling activity to methylated templates (Feng and Zhang 2001.) Mbd2 can also associate 
with Mbd3, which is part of the Mi2/NuRD co-repressor complex. Mbd2 and Mbd3 can form a 
complex with Dnmtl on hemimethylated DNA at replication foci which may help to retain the 
repressive state after replication (Feng et al 2002.) Mbd2 can also act synergistically with other 
proteins; for example, the recently identified M izf protein interacts with Mbd2 and acts as a 
transcriptional repressor in an HDAC-dependent manner (Sekimata et al 2001.)
Mbd2 null {M b d l')  mice have been created and are found to be viable and fertile, with normal 
imprinting patterns and methylation levels (Flendrich et al 2001.) The knockout is not entirely 
benign, however, as these mice have a number o f problems in carrying and delivering offspring,
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and show impaired nurturing behaviour (Hendrich et al 2001.) Significantly reduced repression of 
exogenous methylated promoters was also seen in cells cultured from M bd2" mice, (which cannot 
form a normal MeCPl complex) which were capable of being rescued by re-introduction of Mbd2. 
It is not known what the effects of this reduced silencing would be in vivo, although it is interesting 
to speculate that the consequences o f ‘leaky’ repression could include a predisposition to neuronal 
defects (Hendrich et al 2001, Carter and Segal 2001.)
It appears that the activity and function o f Mbd2 is highly dependent on its various binding 
partners. For example, one binding partner, the GTP-ase Mbd2in is capable of binding to Mbd2 
and reactivating Mbd2-repressed promoters without altering their methylation status (Lembo et al
2003.)
Perhaps the most exciting recent developments surrounding Mbd2, however, have been clear 
evidence that the gene plays a role in tumourigenesis. A paper by Sansom et al used the ApcMm 
mouse crossed onto Mbd2 heterozygous or null backgrounds to show that Mbd2 deficiency 
strongly suppresses intestinal tumourigenesis in the mouse (Sansom et al 2003c.) The Ape 
mouse is strongly predisposed to intestinal tumourigenesis, and is used as a mouse model of the 
human intestinal cancer syndrome FAP (Familial Adenomatous Polyposis.) When the Mbd2 gene 
is deleted on an ApcM,n background, mice live significantly longer and have a greatly reduced 
tumour burden (Sansom et al 2003c.) Mbd2 has also been shown to have a protective role in 
bladder carcinoma (Zhu et al 2004.) Mbd2 may also be involved in other tumourigenic 
phenotypes; the human p 14 promoter lies within a CpG island which shows abberant methylation 
in colon carcinomas and Mbd2 also binds to the 5’ regulatory ends of the p i6 and p 14 tumour 
suppressor genes in human cancer cell lines, contributing to their transcriptional repression. 
(Magdinier et al 2001, Zhu et al 2004.) Since Mbd2 null mice appear both viable and fertile,
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MBD2 inhibitors could potentially be a productive avenue to explore for therapeutic purposes. 
Although work is at an early stage, MBD2 antisense inhibitors have been used to suppress 
tumourigenesis o f human cancer cell lines in vitro and in vivo, providing valuable proof-of- 
principle (Campbell et al 2004, Zhu et al 2004.)
1.5.3. Is Mbd2 a dem ethylase?
Mbd2 has been described as being a demethylase (Battacharya 1999) although other groups 
have disputed this (Ng et al 1999, Hendrich et al 2001, Santos et al 2002.) If reduced methylation 
inhibits intestinal tumourigenesis in the A pcUm mouse, then the loss of Mbd2 would be expected to 
increase the amount of methylation, thus increasing tumour formation, whereas it in fact reduces it 
(Sansom et al 2003c.) This argues that Mbd2 is not a demethylase in the mouse.
1.5.4. Mbd3.
Mbd3 is highly similar to Mbd2 all along its length, (Hendrich and Bird 1998) and is a 
component o f the Mi2/Nurd chromatin remodelling complex (Zhang et al 1999.) The binding 
properties o f Mbd3 appear to vary between species; murine Mbd3 does not bind methylated DNA 
(Hendrich and Bird 1998, Saito and Ishikawa 2002) whereas Xenopus Mbd3 binds strongly to 
methylated DNA (Wade et al 1999) with a similar affinity to the isolated MBD domain from 
MeCP2 (Wade et al 1999.) Intriguingly, Xenopus also produces a long form of Mbd3 via 
alternative splicing, xMbd31f, which has an extra 20 aa inserted into the MBD and is thus 
incapable of binding methylated DNA (Wade et al 1999.)
Because Mbd2 and Mbd3 are similar in sequence, it had been suggested that they may have a 
number o f redundant functions in vivo. Studies by Hendrich et al on M bd3f mice show that Mbd3
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is absolutely required for embryonic development (Hendrich et al 2001.) Mbd3 A blastocysts were 
detected, but no normal embryos were present past the implantation stage, with embryos being 
severely abnormal and in the process o f being reabsorbed by 8.5 dpc (Hendrich et al 2001.) These 
studies show conclusively that Mbd2 and Mbd3 are not functionally redundant in vivo (Hendrich et 
al 2001.) The vital nature of Mbd3 to the developmental process has also been reiterated in the 
Xenopus system. xMbd3 was found to be highly expressed in the nascent eye regions, in the brain 
and the branchial arches of Xenopus embryos (Iwano et al 2004.) Injection of xMbd3 antisense 
morpholino oligonucleotides caused severe defects in eye and brain formation, and o v er- 
expression o f xMbd3 and xM bd3lf (which cannot bind methylated DNA) also caused a similar 
phenotype in a dominant negative manner (Iwano et al 2004.)
In 2002, two novel genes were identified on human chromosome 19 that are 30-42% identical to 
human MBD3 and MBD2 but which lack the MBD itself (Jiang et al 2002.) These genes were 
named MBD3L1 and MBD3L2 (Jiang et al 2002.) Neither protein was found to be capable of 
binding methylated DNA (Jiang et al 2002.) Mouse orthologues of both proteins were identified 
(although at only 31% and 36% identical, one may be somewhat sceptical that they are true 
orthologues) and characterised and MBBD3L expression was found only weakly in normal human 
tissue and stronger expression was found only in abnormal tissues such as germ cell tumours, the 
human ovarian teratocarcinoma cell line PA1 and the mouse embryonal carcinoma cell line P I9 
(Jiang et al 2002.)
Expression patterns of MBD3L1 were examined, and MBD3L1 was found to be localised in the 
nucleus, in large foci, and was capable o f a degree o f transcriptional repression which was 
independent of HDAC activity (Jiang et al 2002.) Interestingly, the expression o f M bd3ll was 
extremely tissue-specific; occurring at significant quantities only in mouse testis at stages VII-XI 
of mouse spermatogenesis (Jiang et al 2002.) Surprisingly, Jiang et al did not make a connection
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between the expression of M bd3ll (which has similarity to a methyl CpG binding protein but does 
not bind methylated DNA) in the process o f spermatogenesis, when methyl marks are being altered 
in the male gamete
1.5.5. Mbd4.
Mbd4 contains a methyl CpG binding domain (Hendrich and Bird 1998) but unlike many other 
members of the MBD family, it does not appear to be involved in transcriptional repression 
(Bellacosa 2001.) Instead, Mbd4 functions to maintain the integrity of the genome, and has roles in 
base excision repair (BER) mismatch repair (MMR) and the cell cycle response to DNA damage 
(Parsons 2003.) Mbd4"  mice have been created and are viable and fertile with no apparent 
increase in tumour susceptibility (Wong et al 2002, Millar et al 2002.)
Mbd4 has two functional domains; the MBD, which directs binding to hemi- or fully- 
methylated DNA, and a C-terminal domain which acts as a thymine DNA glysosylase to remove 
T or U from mismatched CpG sites in vitro (Hendrich et al 1999, Petronzelli et al 2000) The 
CpG dinucleotide is hypermutable, with G»T and G«U mismatches being formed by the 
hydrolytic deamination o f 5 methyl-cytosine and cytosine to thymine and uracil. These 
deamination events are frequent, occurring at a rate of 2-300 per cell per day and if left 
unrepaired would form G*C and A*T transition mutations at the next round of DNA replication 
(Bellacosa 2001, Hendrich et al 1999.) By preventing these mutations, Mbd4 may act as a 
caretaker o f genomic fidelity at hypermutable CpG sites. Such mutations are known to 
contribute to tumourigenesis; nearly 50% of somatic P53 mutations in colorectal cancers arise at 
‘hotspots’ where cytosines in CpGs are deaminated to form transition mutations (Schmutte et al 
1995, Petronzelli et al 2000.) Loss o f functional Mbd4 may accelerate the formation of
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transition mutations and therefore Mbd4 can be considered to have tumour suppressor activity. 
The thymine glycosylase activity o f Mbd4 has been shown to reduce the mutability o f 5mC in 
vivo, as the frequency o f mutation o f 5mC in a mouse transgene is significantly increased in 
\ ib d 4 "  mice (Millar et al 2002, Wong et al 2002.) Mbd4 is also capable o f repairing other 
lesions, albeit with a lower specificity than for T or U mismatches. Mbd4 can remove 5- 
flurouracil (5-FU) from 5-FU base pairs (Petronzelli et al 2000.) Mbd4 can also remove 
thymidine from 0 6  methylguanine«T base pairs (Cortellino et al 2003.) This indicates that 
Mbd4 may play an important role in vivo in reducing mutation damage and thus might be 
expected to play a role in cancer prevention.
The MBD4 gene has been shown to be mutated in a number of mismatch-repair dependent 
tumours (Riccio et al 1999, Bader et al 1999, Bader et al 2000.) Moreover, deficiency o f Mbd4
K lin  * •has been shown to accelerate tumourigenesis on an Ape background in transgenic mice 
(Millar et al 2002.) The tumours formed in these mice showed an increase in the number o f 
mutations at CpG sites in the Ape allele. This effect was not fully penetrant, which implied that 
Mbd4 may be doing more in vivo than just initiating repair of T*G mismatches (Sansom et al 
2003a, Millar et al 2002.)
In addition to a role in base excision repair, Mbd4 has been shown to interact with M lhl, a key 
component of the mismatch repair (MMR) pathway (Bellacosa et al 1999.) During the major 
pathway o f post-replicative MMR, Mlhl  and Pms2 form heterodimers which interact with 
Msh2/Msh6 heterodimers bound to mismatched bases (Jiricny 1998.) Mbd4 was found to 
interact with Mlhl  and also with Msh2 -  components o f the mammalian mismatch repair 
(MMR) system, in yeast 2-hybrid screens, prompting speculation that it may itself be a part of 
the MMR machinery (Bellacosa 2001.) However, other co-immuoprecipitation-based studies
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have shown that Mbd4 does not interact with Msh6 or Pms2, which argues that Mbd4 is not part 
o f the MMR machinery as it is understood (Sansom et al 2004b.)
Many sporadic colorectal tumours and those arising in HNPCC (Hereditary non-polyposis 
colorectal cancer) patients are characterised by MSI (microsatellite instability) and are unable to 
repair slippage-induced insertion/deletion loops (IDLs) at simple repetitive sequences (Riccio et 
al 1999.) Bellacosa et al showed that the Mbd4 gene contains 4 such sequences (Bellacosa 
2001.) Bellacosa and Bader detected Mbd4 mutations in approximately 20-25% of human 
colorectal and gastric carcinomas (Bellacosa 2001, Bader et al 1999.) Virtually all o f these 
mutations were in a poly(A)(io) tract in the central portion o f the gene, resulting in frameshifts 
which produce a truncated protein with no C-terminal domain and no catalytic ability (Bader et 
al 1999.)
Sansom et al have crossed Mbd4 deficient (M b d f ') mice to mice lacking MMR and have 
shown that in the context o f MMR deficiency, the additional loss of Mbd4 does not accelerate 
spontaneous mutation frequency (as measured at the endogenous Dlb-lb locus) or alter tumour 
onset, tumour spectrum or levels of MSI (Sansom et al 2004.) This suggests that Mbd4 does not 
affect MMR-dependent tumourigenesis (Sansom et al 2004.) Mice doubly null for Mbd4 and Mlhl 
show no increase in apoptosis when exposed to 5FU or temozolamide, implying that Mbd4 and 
Mlhl lie on the same pathway and that MMR-dependent apoptosis may be mediated through 
Mbd4.
Mbd4 also has a key role in mediating the apoptotic response to DNA damage (Sansom et al 
2003a.) Sansom et al have characterised this response, and showed that mice null for Mbd4 show 
a significantly reduced apoptotic response to a range o f DNA-damaging agents such as 5-FU, 
temozolamide, y-irradiation and cisplatin (Sansom et al 2003a.) Mice deficient in MMR have
-35 -
previously been shown to have a similarly reduced response to DNA damaging agents (Toft et al 
1999, Sansom et al 2001, Sansom and Clarke 2002) and so Sansom et al postulate that the 
interaction between Mbd4 and MMR is associated with the normal damage response, and that the 
response to DNA damage is somehow mediated through Mbd4 (Sansom et al 2003a.)
1.5.6. Kaiso.
Kaiso is a newly discovered member of the Methyl CpG binding domain protein family 
(Prokhortchouk et al 2001.) Kaiso belongs to the BTB/POZ (broad complex, tramtrack, brie a 
brae/ pox virus zinc finger) family o f proteins and unlike other methyl CpG binding domain 
proteins, it does not contain a classical MBD, but instead binds CpG dinucleotides through a zinc 
finger motif (Prokhortchouk et al 2001.) Kaiso recognises and binds to sequences which contain 
at least two methyl CpG dinucleotides and is capable of repressing transcription from methylated 
templates in a methylation-dependent manner (Prokhortchouk et al 2001.) Kaiso was first 
identified as a binding partner o f the pi 20 catenin, p l2 0 ctn (Daniel and Reynolds 1999.) p 120ctn is 
an armadillo repeat protein and a component o f the E-cadherin-catenin cell adhesion complex 
(Daniel and Reynolds 1999.) It binds p l2 0 ctn at a distinct juxtamembrane site that has been 
implicated in the regulation of cell adhesion and motility (Daniel and Reynolds 1999.) This raises 
the possibility that Kaiso provides a link between cell-surface signalling and methylation- 
dependent gene regulation. p l20ctn and Kaiso are also associated in the nucleus, where it is 
thought that p l2 ( f ,n may negatively regulate Kaiso-mediated transcriptional repression (Ruzov et 
al 2004, Kim et al 2004.)
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Kaiso has been shown to be a methyl CpG-specific repressor; Prokhortchouk et al showed that 
ectopic expression of Kaiso in Mbd2' fibroblasts was capable of restoring repression of a 
methylated construct (Prokhortchouk et al 2001, Kim et al 2004.)
A Xenopus homologue o f Kaiso, xKaiso, has been studied in vivo proving that in Xenopus, 
xKaiso is essential for development (Ruzov et al 2004.) Xenopus embryos are an excellent model 
in which to study the mid-blastula-transition (MBT) the point where the zygote’s own genome, 
previously repressed, begins to be transcribed (Ruzov et al 2004.) The mechanisms whereby 
zygotic genes are repressed pre-MBT are still unknown, but a recent paper by Ruzov et al suggests 
that xKaiso may be responsible (Ruzov et al 2004.) An xKaiso knockdown recapitulates the 
phenotype of an xD nmtl knockdown: the embryos exhibit premature activation o f gene expression, 
apoptosis and ultimately, developmental arrest (Ruzov et al 2004.) Excessive expression o f xKaiso 
did not appear to have any negative effects on development (Ruzov et al 2004.) As well as the 
initiation o f zygotic transcription, the MBT is associated with the slowing of cell division, and the 
beginning o f cell migration. Ruzov et al note that loss o f cell adhesion is seen with both xDnmtl 
and xKaiso knockdowns (Ruzov et al 2004.)
Although Kaiso is clearly vital for development in Xenopus, the same is not true for mice; 
Kasio " mice have been generated and viable, fertile and appear healthy (Clarke AR, personal 
communication 2004.) This indicates that either the primary roles of the protein are different in the 
two species, or that mammals have another activity which can compensate for the loss o f Kaiso.
1.6. M ECP2 and Rett Syndrome.
The importance o f the MBD family o f proteins is underlined by the effects of mutations in one 
member o f the family; MECP2, which cause the human disorder, Rett syndrome (RTT OMIM#
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312750, Neul and Zogbhi 2004.) This thesis will examine the consequences of removal of 
MeCP2 in the intestine and mammary gland to attempt to shed light on the complex etiology of 
this syndrome.
Rett syndrome is a complex neurodevelopmental syndrome which affects an estimated 1 in 
10,000 to 22,000 live births (Hagberg 1985, Miyamoto et al 1997.) Most affected patients are 
female, although there are rare male cases (Coleman 1990, Clayton-Smith et al 2000, Topcu et al 
2002 .)
Rett syndrome was first described in 1966 by Andreas Rett, an Austrian physician who noticed 
two girls with a strikingly similar phenotype in his waiting room (Rett 1966.) The condition was 
not widely recognised, however, until 1983, when Hagberg et al described 35 girls with similar 
symptoms (Hagberg et al 1983.) A classic Rett patient will develop apparently normally for the 
first 6 to 18 months o f life, and then undergo a rapid period of regression, losing acquired speech 
and motor skills and acquiring a range o f  symptoms which define the syndrome (Hagberg et al 
1983.) This regression has been characterised as comprising four stages (Hagberg and Witt- 
Engerstrom 1986.) In the first stage o f classical Rett syndrome (stage I) the normal acquisition of 
new learned skills stops. Head growth decelerates, leading to microcephaly. Indeed, one of the 
earliest clinical signs of Rett syndrome is a marked deceleration of growth, with 85 to 94% of girls 
showing growth deceleration across all measurements (Motil et al 1994.) Affected girls become 
emotionally withdrawn and avoid eye contact, classic signs of autism (Neul and Zoghbi 2004.)
In the second stage, which generally lasts from around 1 to 4 years of age) affected girls lose 
skills they have learned, such as any speech they may have developed, and the ability to use the 
hands purposefully (Neul and Zoghbi 2004.) In stage II, apraxia and breathing irregularities 
develop, along with the stereotypical ‘hand-washing’ movements which are so characteristic of 
Rett syndrome (Neul and Zoghbi 2004.) During stage II, around half o f girls also develop seizures
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(Neul and Zoghbi 2004.) During stage III (generally 4-7 years) most acquired skills are lost and 
there is a period o f stabilisation (Neul and Zoghbi 2004.) Epileptic seizures become more common 
(Neul and Zoghbi 2004.)
Stage IV is considered to be from ages 5-15 and onwards; during this time, seizure frequency 
commonly decreases, but motor impairment and deterioration continues (Zoghbi et al 2002.) Many 
girls develop scoliosis which can leave them wheelchair-bound (Hageber and Witt-Engerstrom 
1996.)
The life expectancy of Rett patients is decreased, and although many do live well into 
adulthood (Zoghbi et al 2002) there is an elevated incidence of sudden death of 1.2% per year 
(Kerr et al 1997) which is thought to be attributable to cardiac and breathing abnormalities, such as 
the long, uncorrected QT intervals suffered by patients (Sekul et al 1994, Guideri et al 1999.)
Because the mechanism of action o f MECP2 is still unknown, treatment for Rett patients is based 
around the alleviation of symptoms to improve quality o f life, rather than an attempt to reverse the 
primary (unknown) causes; physical, occupational and music therapies are used to improve general 
well-being (Christodolou et al 2003.) L-camitine is also used, as Rett patients have lowered 
carnitine and very long chain fatty acid levels (Christodolou et al 2003.) A ketogenic diet can be 
used (to suppress seizures) along with opiate agonists to help with breathing disturbances, seizures 
and stereotyped involuntary movements (Christodolou et al 2003.)
1.6.1. M utations in Methyl CpG Binding Protein 2 (MECP2) cause Rett syndrome.
The actual cause o f Rett syndrome was unknown until 1999, when Amir et al identified 
mutations in MECP2 as being responsible (Amir et al 1999.) Although the almost total lack of 
affected males suggested an X-linked disorder which was lethal to the male foetus, conventional
-39 -
linkage analysis was hampered by the paucity o f familial cases o f Rett. A small number o f familial 
cases were found, however, which allowed the target region to be narrowed down. Transcripts in 
this region were studied, and eventually, in 1999, Amir et al found mutations in human MECP2 to 
be responsible for Rett syndrome (Amir et al 1999.) The case for MECP2 as the causative 
mutation was further strengthened by the discovery o f MECP2 mutations in 80% of sporadic Rett 
cases (Neul and Zoghbi 2004.) The other 20% may well be mutations which lie outside the 
sequenced portions, in as-yet unknown control elements (Neul and Zoghbi 2004.)
1.6.2. Rett syndrom e is phenotvpicallv diverse.
Rett syndrome is not tightly defined by a set o f clinical criteria, nor by a single type of mutation. 
Instead, a range of MECP2 mutations have been found in Rett patients which lead to a wide 
spectrum of symptoms (Hagberg and Skjeldal 1994.) In the most severe female forms o f Rett, the 
so called ‘congenital forms’ the normal period o f development is absent (Hagberg and Skjeldal 
1994) and girls often have infantile spasms and congenital hypotonia (Neul and Zoghbi 2004, 
Hagberg 1995) whereas in the milder ‘form fruste’ (‘worn down’) form, motor functions and 
speech may be preserved and patients do not have seizures (Zapella et al 1998, Hagberg et al 
1995.) Diagnosis is reached clinically by using a set of criteria similar to that shown in table 1 
below. As is clear from table 1, the phenotypic range of Rett syndrome is extremely broad. 
(Zoghbi et al 2002.)
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Table 1. Phenotypic Variation in Rett syndrome. (Females)
(From Young and Zoghbi 2002.)
Phenotype
Classic RTT Mild RTT variants Severe RTT variants
Genotypes N ull/severe inactivating H ypom orphic alleles Null alleles or severe
alleles. Balanced XC1 (late truncations) with 
balanced
XC1 or null alleles with  
favourable XCI.
inactivation, possibly  
with skew ed XCI.
Age at onset 6-18  months Later onset Congenital
Head/body size Sm all head and body M ay have sm all head/ body Small head/body
Seizures Y es N o Y es. Early onset
Speech L oss o f  speech Speech  preserved N o speech
Motor function M otor deficiencies U sually  ambulatory Hypotonia, motor deficiencies
Hand use Stereotypical hand use Retain hand use —
Social interactions A utistic features variable —
Intelligence M ental retardation M ild /no retardation Severe mental retardation
Spinal curvature S co lio sis and/or kyphosis Rarely seen Scoliosis and/kyphosis
Respiration Breathing dysfunction Rarely seen Breathing dysfunction
1.6.3. Genotype/Phenotype correlation in Rett syndrome.
The correlation o f genotype to phenotype is complex and still at an early stage, and is further 
complicated by the fact that MECP2 is carried on the X chromosome, so that skewed X- 
inactivation may contribute to severity (Neul and Zoghbi 2004.) However, some 
genotype/phenotype correlation has been done, albeit with somewhat contradictory results. Two 
studies have found that the phenotypes associated with truncating mutations are more severe than 
those associated with missense mutations (Cheadle et al 2000 and Monros et al 2001.) However,
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other studies have failed to find such a link (Young and Zoghbi 2004, Amir et al 2000, Bienenue et 
al 2000, Huppke et al 2000, Guinti et al 2001, Yamada et al 2001 Chae et al 2002.) Other work 
appears to show a correlation between mutations affecting the NLS and phenotype, (Huppke et al 
2002.) Huppke et al found four relationships between severity and mutation; mutations affecting 
the NLS were more severe than those not affecting it, mutations in the CTD were less severe than 
other types of mutation, truncations were found to be more severe than missense mutations (unless 
they occurred in the CTD) and missense mutations in the TRD and MBD were equivalent (Zoghbi 
et al 2004, Huppke et al 2002.)
The relationship between individual mutations and phenotype has been the subject of a study by 
Leonard et al, who studied the R133C mutation. In vitro models suggested that the R133C variant 
has a relatively normal functioning, and indeed, patients with R133C were less likely to have 
severe symptoms relating to speech, hand movements and ability to walk (Leonard et al 1999.) 
Clearly, a great deal more research is needed in this area to correlate individual mutations with 
specific phenotypes. The Edinburgh-based database www.MeCP2.org.uk is collecting detailed 
information provided by parents and carers on MECP2 mutations and their associated symptoms. 
The RetBASE database http://MeCP2.chw.edu.au also collects information from clinical sources 
such as paediatricians and laboratories that test for mutations in MECP2.
Correlation o f genotype to phenotype is complicated by the fact that MECP2 lies on the X- 
chromosome. Because MECP2 is X-linked, and MECP2 is subject to X chromosome inactivation 
(XCI) affected females are a mosaic o f wild-type and mutant cells (Neul and Zoghbi 2004.) If the 
X-inactivation patterns are skewed, the severity o f the disease can be modulated (Neul and Zoghbi 
2004.) Whilst studying a mouse model o f Rett syndrome in which the MECP2 protein is truncated 
at amino acid 308 (Mecp2m/X) which results in a hypomorphic allele similar to a mutation found 
in Rett patients, Young and Zoghbi noted that there was much more phenotypic variation in the
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symptoms of the female mice than would have been expected (Young and Zogbhi 2004.) They 
used this mouse model to study XCI patterns in the brain and found that XCI patterns were in fact 
non-random, with the wild type allele being favoured (Young and Zogbhi 2004.) This suggests that 
there is a survival advantage for the wild-type neurons, or a differentiation defect in mutant 
neuronal precursors (Young and Zogbhi 2004.) Interestingly, no females were found in which the 
mutant allele was favoured, which favours the non-random survival theory over stochastic XCI 
skewing (Young and Zogbhi 2004.) How relevant is this to the human form of the disease? Mice 
with the Mecp2308A mutation show a much greater phenotypic variability than humans with a 
comparable mutation, which implies that directed skewed XCI may be less important in humans 
(Neul and Zoghbi 2004.) The majority o f human Rett patients show balanced XCI in brain tissue 
(Shabazian 2002) but examples o f non-random XCI have been found (Ranieri et al 2003) Most 
interestingly, skewed XCI which favours the expression of the wild-type allele has been found in 
an asymptomatic carrier of a classic Rett mutation (Siranni et al 1998) and in patients who have 
much milder symptoms than would be expected due to favourable XCI (Wan et al 1999, 
Bienvenue et al 2000, Ishii et al 2001, Zapella et al 2001, Huppke et al 2002) This raises the 
intriguing possibility that females with mild mental retardation of unknown cause could in fact be 
carrying MECP2 mutations and that the spectrum of the disease may be much wider than was 
previously thought.
-43 -
1.6.4. Several neurodevelopm ental syndrom es have considerable phenotypic and genetic 
overlap.
There are a number o f syndromes with considerable clinical overlap in which diagnosis may 
well be down to the (subjective) diagnosis o f a clinician rather than the genotype o f the individual. 
Several syndromes, such as RTT, Angelman and other autism-spectrum disorders may share 
common mechanistic pathways (Zoghbi et al 2003.) The autistic spectrum of disorders shows a 
complex etiology (Samaco et al 2005.) A genetic component is highly likely, since autism exhibits 
a high degree of heritablility in families (Volkmar et al 2003) but there are probably multiple gene 
loci involved, as well as a considerable degree o f environmental influence (Samaco et al 2005, 
Volkmar et al 2003.)
Angelman syndrome (AS, OMIM #105830) is an imprinted disorder which can be caused by 
deficiency o f maternal chromosome 15q 11 -q 13, methylation defects or mutations in the maternal 
copy o f UBE3A, which encodes the ubiquitin ligase UBE3A/E6-AP (Zoghbi et al 2003.) 
Angelman syndrome and RTT have a degree o f phenotypic overlap (Zoghbi et al 2003) as both 
present with a high frequency o f autistic traits, developmental delay, seizures, stereotypic 
behaviours and language impairment (Zoghbi et al 2003.) One study has suggested that up to 8% 
of patients who show an Angelmann-like phenotype but have no mutations or abnormalities in 
chromosome 15, may have mutations in MECP2 (Watson et al 2001) and MECP2 mutations have 
also been reported in patients diagnosed primarily with autism (Lam et al 2000, Beyer et al 2002.) 
The 15q 11 -q 13 duplications have also been found in ~1 % of autism case (Schroer et al 1998.) This 
suggests that the boundaries that clinicians draw between these syndromes are not necessarily set 
in stone, and hint at a common pathology for several disorders.
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One study has shown that epigenetic overlap between RTT and Angelman syndrome can occur 
because MECP2 deficiency actually causes reduced expression of UBE3A, the gene which is often 
mutated in Angelman syndrome, and GABARB3, which encodes the p-subunit of the GABAa 
receptor and is another gene associated with autism (Samaco et al 2005, Cook et al 1998, 
Buxbaum et al 2002.) Samaco et al also found reduced UBE3A and GABARB3 expression in 
samples of autistic brain, consistent with another report (Veenstra-VanderWeele et al 1999.) 
Indeed they go as far as to posit the GABAa receptor genes as potential candidate genes for autism, 
either as direct mutations, or as indirectly affected genes. There is enough evidence to make this 
an attractive theory: several studies have demonstrated linkage to the GABAa receptor family 
(Samaco et al 2005, Cook et al 1998, Buxbaum et al 2002, Nurmi et al 2003.) Autoradiography 
has shown reduced GABAa binding in autistic brain (Blatt et al 2001) and elevated circulating 
GABAa levels have been found in autistic children (Moreno-Fuenmayor et al 1996, Dhossche et al 
2002, Aldred et al 2003.) Perhaps other primary lesions act upstream of an eventual GABAa 
effect?
One recent paper has opened up debate on the subject of phenotypic overlap by finding that one 
severe variant o f RTT, the Hanefield variant, which presents with early onset of seizures, is 
associated with mutations, not in MECP2 but in the cyclin dependent kinase-like 5, CDKL5/STK9 
(Scala et al 2005.) The Hanefield variant o f RTT has considerable phenotypic overlap with another 
syndrome, West syndrome, also called Infantile Spasm Syndrome X-linked (ISSX OMIM 
#308350.) ISSX causes infantile spasms, hypsarrhythmia and severe to profound mental 
retardation (Cook et al 1998.) Some families with ISSX have been found to have mutations in the 
aristaless related homeobox gene ARX  (Cook et al 1998, Buxbaum et al 2002.)
-45 -
Mutations in ARX  have been documented to cause several forms of epilepsy, inclding infantile 
seizures, myoclonic seizures and peripheral dystonia, as well as syndromic and nonsyndromic X- 
lined mental retardation (Cook et al 1998, Buxbaum et al 2002.) The CDKL5/STK9 gene has also 
been found to be involved in ISSX (Scala et al 2005.) Scala et al reasoned that the phenotypic 
overlap seen between the early-onset o f seizures from of RTT and ISSX warranted screening two 
early-onset RTT cases for ISSX-causing CDKL5/STK9 mutations (Scala et al 2005.) These 
patients were found to have no point mutations or re-arrangements in the MECP2 gene (including 
the exon 1 region) but both had mutations in various parts o f the CDKL5/STK9 gene, leading to 
non-functional protein being expressed (Scala et al 2005.) Scala et al then extended their analysis 
to 19 classic RTT and 15 PSV cases, and found no mutations in CDKL5/STK9, implying that these 
mutations are responsible for a rare subset o f severe, early-onset RTT of the type described by 
Hanefield (Scala et al 2005.) This version o f RTT is extremely rare, and Scala et al acknowledge 
that only a few cases have ever been described (Zoghbi et al 2003, Mount et al 2003) and so it may 
well be a distinct syndrome, or a variant o f ISSX.
1.6.5. Rett Syndrom e in Males.
Because Rett syndrome is an X-linked disorder, it was initially assumed that it was an 
exclusively female disease and that Rett syndrome would be universally lethal to the male foetus. 
However, rare male cases are found (Wan et al 1999, Villard et al 2000, Hoffbuhr et al 2001, 
Geerdink et al 2002, Zeev et al 2002) which tend to fall into 3 categories; boys with the classical 
Rett syndrome, boys with severe encephalopathy and boys with les severe neurological phenotypes 
(Neul and Zogbhi 2004.)
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Boys who have classical Rett syndrome mutations tend to be bom with severe encephalopathy 
and die within one or two years o f age (Wan et al 1999, Villard et al 2000, Hoffbuhr et al 2001, 
Geerdink et al 2002 Zeev et al 2002.) The fact that these mutations are also found in viable female 
children (Zeev et al 2002) shows both the effects of mosaicism in the body and the hazard of 
unmasking alleles on the X-chromosome. In a male with an XY karyotype, all cells carry the 
mutant allele, which accounts for the massively increased severity of the phenotype in males; 
unlike females they have no mosaicism to ameliorate the effects of the mutant allele and so the 
male MeCP2 allele is functionally haploid. However, in males with Klinefelter’s syndrome, who 
are genetically XXY but phenotypically male, the extra X can be inactivated, leading to classical 
Rett mosaicism and viability (Zoghbi et al 2003.)
Some males are also found who have acquired an MeCP2 mutation early in development, 
leading to somatic mosaicism (Clayton-smith et al 2000, Armstrong et al 2001, Topcu et al 2002.) 
Other rare events can also cause Rett syndrome, such as a case of a male with a translocation o f the 
SRY (sex-determining region Y) carrying part of the Y chromosome onto a paternal X 
chromosome with an MeCP2 mutation, leading to a phenotypically male but karyotypically female 
(XX) subject (Zoghbi et al 2003, Neul and Zogbhi 2004.) There are even cases o f MeCP2 
mutations with none o f these mitigating factors; Ravn et al reported a boy who has no apparent 
mosaicism or karyotypic abnormalities, but who has classic Rett syndrome caused by a mutation 
within the TRD (Ravn et al 2003.)
One exciting development in the field is the discovery of boys who carry MECP2 mutations but 
do not appear to be severely disabled or have classic Rett syndrome. These boys were found by 
examining families with X-linked mental retardation and boys who show features of Angelmann 
syndrome, mental retardation or other neurodevelopmental abnormalities (Meloni et al,2000, 
Couvert et al 2001, Dotti et al 2002, Klauck et al 2002, Kleefstra et al 2002, Winnepenninckx et al
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2002, Ynemtra et al 2002, Imessaoudee et al 2001, Cohen et al 2002.) The mutations found in 
these boys are never picked up in girls, possibly because in the heterozygous form their phenotypic 
effects are so mild that they may well escape detection, even though they may well exist (Neul and 
Zogbhi 2004.)
The spectrum of symptoms caused by MECP2 mutations is therefore much wider than was 
previously thought, although almost all include mental retardation o f some kind which reinforces 
the idea that MeCP2 has some critical role to play in the developing brain (Neul and Zogbhi 2004.) 
The actual mechanisms o f that role, however, are far from clear.
1.6.6. M ouse models o f Rett syndrome.
Mouse models o f Rett syndrome have been generated by targeting the Mecp2 allele. Guy et al 
created an Mecp2 null mouse by creating a conditional ‘floxed’ allele of Mecp2 and using a 
ubiquitous Cre recombinase (the so-called ‘deleter’ Cre) to create mice in which Mecp2 is floxed 
out in the early embryo (Guy et al 2001.) Mice develop to birth in a normal fashion, indicating that 
MeCP2 is not absolutely required for viability (Guy et al 2001.) After birth, these mice develop 
normally until around 3-8 weeks of age, when they develop tremors and breathing irregularities, as 
well as other abnormalities such as misalignment o f the jaw (Guy et al 2001.) The mice tend to 
die at around 54 days.
Mecp2 null mice were also generated by other groups, who also observed a short period of 
normal development followed by the onset o f tremors at around 5 weeks o f age and death at 
around 10 weeks (Chen et al 2001.) The reason for the disparities in lifespan may be due to the 
exact targeting o f the allele or background effects. Chen et al found that the brains of their null
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mice were grossly normal, although they did report smaller, and more closely packed neurons, 
closely mirroring findings in human Rett patients (Chen et al 2001.)
Both Guy et al and Chen et al also used a neural and glial cell precursor specific Cre (nestin 
fused) to remove Mecp2 from the neuronal and glial populations. Mice produced in this way are 
reported to recapitulate the phenotype o f whole-body null mice, and from this, both groups 
concluded that Rett syndrome was a purely nervous-system-confined disorder (Guy et al 2001, 
Chen et al 2001.)
MeCP2 is expressed in most bodily tissues, however (D’Esposito et al 1996), and so it may be 
expected that it plays a role, albeit perhaps a subtle one, in other tissues of the body. If Mecp2 is 
deleted in neural progenitor cells, mice develop a Rett-like phenotype by 3-8 weeks of age and die 
at 6-10 weeks of age (Chen et al 2001, Guy et al 2001) however, when Mecp2 is deleted in post­
mitotic neurons, using a Cam-kinase linked Cre, a similar phenotype occurs, but much delayed 
(Chen et al 2001.) This indicates that Mecp2 plays a role in maintenance and maturation o f 
neurons, rather than their initial formation (Neul and Zogbhi 2004.)
The constitutive (whole-body) null mice are analogous to male cases of Rett syndrome in that 
they have no functioning MeCP2, unlike the mosaicism seen in most human female cases. In order 
to more closely recreate a human mutation, Shabazian et al created a mouse with a stop codon 
after codon 308 (Shabazian et al 2002.) The resulting MeCP2 protein contains the MBD, the TRD 
and the NLS but removes the C terminal domain (Shabazian et al 2002.) The male mice carrying 
this mutation appear normal until around 6 weeks of age, when they develop a mild tremor 
(Shabazian et al 2002.) The tremor becomes worse as the mice age, and at around 5 months o f age, 
mice develop kyphosis, mimicking the scoliosis seen in human patients (Shabazian et al 2002.)
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Some but not all mice develop seizures, and all exhibit anxiety, abnormal social behaviour and 
decreased grooming (Shabazian et al 2002.) Again, these mice develop forepaw stereotypies; 
many mice also lived to a year or more (Shabazian et al 2002.)
What have these mouse models shown us about the molecular complexities of Rett syndrome? 
They show that Rett syndrome can be modelled in mice, which opens up a range of promising 
avenues o f research. Transcriptome analysis o f the truncation mutant provided no significant gene 
changes, although histone H3 was found to be hyperacetylated, indicating abnormal chromatin 
structure (Shabazian et al 2002.) This implies that the normal processes linking methylation and 
chromatin remodelling may be disrupted.
1.6.7. Conditional alleles o f Mecp2.
When modelling a human disease in the mouse, the advantages of using conditional alleles are 
clear; many genes, if knocked out constitutively, cause either embryonic lethality, or morbidity 
(such as the constitutive model of RTT.) Using a conditional allele, however, the problem of 
embryonic lethality can be circumvented, as mice can be bom and develop with functioning copies 
of the gene. The gene may be switched on or removed in a specific tissue at a defined point in the 
life cycle, allowing the effect of removal in a specific tissue to be distinguished from the effects o f 
whole-body loss (Baranda and Dymecki 2004.)
Cre (Causes recombination) recombinase is a site specific recombinase of the integrase family, 
isolated from bacteriophage PI (Sauer and Henderson 1988.) Cre catalyses site-specific 
recombination between defined 34bp ‘Lox P ’ (locus % of crossover PI) sites (Baranda and 
Dymecki 2004.) If a gene is placed between two Lox P sites and exposed to Cre, then the gene will
- 50 -
be excised or ‘floxed out’ (Baranda and Dymecki 2004.) The Cre-Lox system can be used to create 
tissue-specific conditional deletions of an allele, overcoming the problem of embryonic lethality or 
developmental defects (Baranda and Dymecki 2004.) Mice carrying the Cre recombinase under the 
control of an inducible, tissue-specific promoter are crossed with mice carrying the gene o f interest 
that has been flanked by Lox P sites (Baranda and Dymecki 2004.) When the mice are given the 
appropriate inducer, the Cre is expressed in a spatially defined manner and the gene o f interest is 
floxed out only in a specific tissue (fig 1.8) (Baranda and Dymecki 2004.)
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Fig 1.8a. The conditional allele o f  Mecp2.
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Fig 1.8a. Conditional allele o f  Mecp2.
The conditional allele o f Mecp2 was created by Guy et al using Cre-Lox technology. Exons 3 and 4 
were replaced with the same exons flanked by LoxP sites. When crossed to a line carrying an inducible 
Cre recombinase, the resulting progeny can be used to conditionally delete the gene in a specific 
tissue.
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Fie 1.8b. Usine Cre Lox technology to conditionally delete Mecp2.
CytP450 Cre recombinas<
MeCP2
Cre catalyses LoxP site crossover and 
recombination
Recombination between LoxP sites 
deletes’ gene
Fig 1.8b. Cre-Lox Technology.
Two mouse lines, one carrying the tissue-specific inducible Cre recombinase and one carrying the floxed  
allele, are bred to create a line carying both transgenes. When this mouse is exposed to the inducer (in this 
case, P-napthoflavone) the Cre is induced and recombination occurs between the LoxP sites, removing the 
gene
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1.6.8. Elevated levels o f MeCP2 also cause a progressive neurological disorder.
A therapeutic approach to Rett syndrome might take the form of introducing the protein during 
an appropriate developmental window, in order to try to alleviate the effects o f endogenous 
MECP2 loss or malfunction. Dose levels may well be absolutely crucial; recent work by Collins et 
al and Luikenhuis et al shows that slight over-expression of Mecp2 in the mouse can have 
damaging effects (Collins et al 2004, Luikenhius et al 2004.) Collins et al over-expressed wild- 
type human MECP2 in transgenic mice to create levels around twice that of wild-type. At around 
10 weeks o f age, mice actually showed enhanced synaptic plasticity in the hippocampus, 
accompanied by enhanced motor and contextual learning. At 20 weeks of age, however, mice 
developed seizures, aggressiveness (shown by increased propensity to bite) kyphosis and 
hypoactivity (freezing.) The severity and onset o f this phenotype depended largely on the levels o f 
expression of the MECP2 construct (Collins et al 2004.) Mice which had the highest expression 
levels developed more severe symptoms sooner than lower-expressing lines (Collins et al 2004.) 
Interestingly, mice which survived for a year appeared to live normal lifespans (Collins et al 
2004.)
Collins et al also crossed their transgenic line onto the Mecp2 null mouse generated by Guy et 
al and observed that human MECP2 can completely rescue the Rett-like phenotype o f these mice 
(Collins et al 2004.) This argues that the effects seen in their mildly overexpressing mice are 
indeed due solely to the fact that MECP2 is being overexpressed, not the presence o f human 
MECP2 in a murine environment (Collins et al 2004.)
Luikenhuis et al have also created mice in which Mecp2 is under the control o f a neuron- 
specific promoter (Tau) and found that 2 to 4-fold over-expression of Mecp2 in postmitotic 
neurons lead to severe motor dysfunction, including side-to-side swaying, tremors and ataxia
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(Luikenhius et al 2004.) They also found that the Rett phenotype was rescued when a transgenic 
construct was used to express MeCP2 in Mecp2 mutant mice, with rescued mice showing no 
obvious signs o f any Rett symptoms (Luikenhius et al 2004.) Both studies show that MECP2 
levels must be tightly regulated in vivo, and raise the interesting possibility that some human cases 
of Rett syndrome may in fact be due to overexpression of MECP2. Increased MECP2 levels have 
in fact been recorded in a single case o f autism and a case of pervasive developmental disorder as 
well as a case o f the preserved speech variant of Rett (Arani et al 2004, Samaco et al 2004.)
1.6.9. Neuropathological difference in the Rett syndrome brain.
Rett syndrome is considered to be a neurodevelopmental disorder, rather than a 
neurodegenerative disorder (Shabazian and Zoghbi 2002.) Postmortem analysis of Rett syndrome 
brains reveals that they weigh 14%-34% less than normal (Jellinger and Seitelberger 1986) a 
difference which persists even when the smaller size of Rett patients is accounted for (Armstrong 
et al 1999.)
Studies of cerebral blood flow show that Rett patients have an infantile blood flow pattern 
(Nielsen et al 1990) and in vivo MRI scans reveal a reduction in the volume o f both grey and 
white matter in the Rett syndrome brain (Reiss et al 1993), with the average brain weight being 
around 950g, around that of a one-year-old child. However, no atrophy or degeneration is visible 
(Armstrong 1992, Armstrong et al 2003), indicating that the brain has failed to develop properly, 
rather than having developed and degenerated. The effects of Rett syndrome on the brain appear 
to vary with region; reduced neuron size has been reported in the hippocampus-entorrhinal cortex 
and in the speech-related cortex (areas 40, 45 and 22) (Baumann et al 1995, Belichenko 2001.) 
Post-mortem studies of RTT brains reveal smaller cortexes and cerebellums, accompanied by
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decreased cell size, packing density and synapse formation (Armstrong et al 1999.) Reduced levels 
of nerve growth factors, along with neurotransmitters and their receptors have been reported 
(Armstrong et al 1999.)
If lack of functional MECP2 does result in incorrect execution of the brain’s developmental 
plan, then the effects are by no means seen in all brain regions. The dendrites o f the superior 
temporal and occipital neurons do not show the reduction in dendritic branching seen in the limbic, 
frontal and motor neurons, for example (Armstrong et al 1995.) Also, the neuroendocrine system 
appears to mature as normal, with no difference in the age of menarche between Rett patients and 
normal controls (Engerstrom et al 1992.)
One significant difference between Rett and normal brains occurs in the process o f elaboration 
and pruning o f neuronal synapses which occurs during the early postnatal period (see fig 1.9) 
(Johnston et al 2003) with the density o f synapses being decreased in the Rett syndrome brain 
(Belichenko et al 1994.) These data suggest that Rett syndrome may be caused by alterations in 
dendritic organisation and problems at the synapse. This possibility will be discussed in greater 
detail later in the light of various experimental data.
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1.6.10. Rett Syndrome Causes Defects in Synaptic Elaboration and Pruning.
Fie /. 9. Synaptic pruning in Rett and normal brain.
Normal
c_089►»
C / 1
O
o
Z
Rett
10Birth 2
Age (years)
F/g 1.9. Synaptic elaboration and pruning in the RTT brain.
In the normal brain, the number o f synapses increases from birth until around 2 years o f age; after 
this point, synaptic pruning takes place to ensure the correct connections between neurons, in effect 
fine tuning' the connections within the brain. In the Rett brain, this process appears to be radically 
altered, with no elaboration or pruning occurring. The consequences o f this are unknown, but it is 
logical to assume that incorrect or inefficient neuronal connectivity would result; could this alteration 
in brain architecture be partly responsible for the symptoms o f RTT?
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1.6.11. MeCP2 and neurogenesis -  narrow ing down the phenotype.
Could Rett syndrome be a disease o f abnormal synapse function or development? Patients 
with Rett syndrome have a high incidence of seizures, hyperkinetic movements and abnormal 
breathing patterns which would suggest a defect in excitatory synapse function (Jarrar et al 2003.) 
A role for Rett syndrome in neuronal maturation and synaptic development has also been reported 
in other studies and MECP2 has been located to the postsynaptic compartment (Aber et al 2003) 
There have been several clues that MECP2 might somehow be involved in the process of 
neurogenesis, and more specifically, neuronal maturation. Developmental studies have shown that 
the levels of MeCP2 in the rodent brain are correlated with neuronal maturation and synaptognesis 
(Mullaney et al 2004, Shabazian et al 2002, Akbarian et al 2001 Coy et al 1999) with structures 
that develop sooner, such as the brain stem, becoming MeCP2 positive before later developing 
structures such as the hippocampus and cerebral cortex. In cell cultures, MeCP2 levels also 
correlate with increasing maturity (Jung et al 2003.) This hints that MeCP2 may be involved in 
neuronal maturation. However, microarray studies show little or no changes in the mouse CNS in 
response to the loss o f Mecp2 (Tudor et al 2002, Matarazzo et al 2004)
Others have used the olfactory system as a model for the developing nervous system; as 
olfactory neurons (ORNs) mature, they travel up through the epithelium which allows the ageing 
of neurons based on position and the expression of stage-specific markers (Matazzaro et al 2004) 
The olfactory epithelium can also be accessed via biopsy in humans, and so provides a valuable 
opportunity to examine human tissue. The olfactory epithelia of Rett patients had fewer 
terminally-differentiated ORNs and far more immature neurons, supporting the theory that MECP2 
is needed for neuronal maturation. Studies on the mouse olfactory system have already shown 
changes in the olfactory proteome (Matarazzo and Ronnet 2004) and so this system was examined
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to determine whether loss of MeCP2 in the mouse lead to changes in the neurodevelopmental 
program of olfactory neurons (Matarazzo and Ronnet 2004.) Lack of MeCP2 resulted in delays in 
the terminal differentiation of developing neurons and also their glomerular organisation 
(Matarazzo and Ronnet 2004.) This correlates with post-mortem examinations of Rett brains, 
which have smaller, more densely-packed neurons with reduced dendritic arborisation (Zoghbi et 
al 2003, Armstrong et al 2003.) If Mecp2 is deleted in neural progenitor cells, mice develop a Rett- 
like phenotype by 3-8 weeks o f age and die at 6-10 weeks of age (Chen et al 2001, Guy et al 
2001.) However, when Mecp2 is deleted in post-mitotic neurons, using a Cam-kinase linked Cre, a 
similar phenotype occurs, but much delayed (Chen et al 2001.)
1.7. M ECP2 -  A member o f the M ethyl Binding Domain Family.
MECP2 is an abundant chromosomal protein (Nan et al 1999) located at Xq28 in humans and is 
a member of the MBD family (Ballestar and Wolffe 2001.) The protein is rich in basic amino acids 
and has several potential phosphorylation sites (Lewis et al 1992.) MeCP2 contains four functional 
domains; an 85 amino acid methyl CpG binding domain (MBD) similar in structure to those found 
in other MBD proteins, a 104 amino acid transcriptional repressor domain (TRD), a nuclear 
localisation signal (NLS) and a C-terminal portion which mediates binding to the nucleosome core 
(Nan et al 1999.) The methyl binding domain (MBD) (Nan et al 1996) contains around 70 residues 
and forms a wedge shaped a /p  structure, in which four antiparallel p strands form one face o f the 
wedge (Okhi et al 1999.) The longest two strands are thought to interact with the major groove, 
where the methyl group would be located (Okhi et al 1999, Wakefield et al 1999) (See fig 1.7.)
MeCP2 is localised to the CpG-rich heterochromatic pericentromic regions o f mouse 
chromosomes (Nan et al 1999.) This localisation can be disrupted, becoming diffuse in mouse 
embryonic stem (ES) cells lacking Dnmtl (Nan et al 1996) which have lower levels of
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methylation; this implies that binding o f MeCP2 to chromatin appears to be dependent on the 
presence o f methylated DNA (Nan and Bird 2001.)
1.7.1. M ECP2A and MECP2B: alternative splicing of MECP2.
MECP2 was originally thought to be a 3-exon gene, and was later found to have an extra, 
upstream non-coding exon (exon 1) (Reichwald et al 2000.) It was also known that the MECP2 
transcript had two different polyadenylation sites which gave rise to two mRNA variants with 
different 3’UTRs o f 2kb and 10 kb (Coy et al 1999.) However, two recent simultaneous reports 
have been published, by Kriaucionis et al and Mnatzakanian et al, which show that Mecp2 
undergoes alternative splicing to form two distinct isoforms with different N-termini (fig 1.10.) 
(Kriaucionis et al 2004, Mnatzakanian et al 2004.)
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Fig 1.10. Alternative splicing generates two iso forms o f  MECP2.
MECP2
MECP2A
(MECP20)
MECP2B
(MECP2a)
Fie I .10. The exonAntron structure o f  MECP2.
Mecp2 undergoes alternative splicing to form  2 distinct isoforms;MECP2A and MECP2B. 
Shaded regions indicate protein coding.
(from Kriaucionis et al 2004 and Mnatzakanian et al 2004.)
A search of EST databases showed that MECP2 sequences grouped into those containing, and 
those without, the second exon (Kriaucionis et al 2004.) (Perhaps rather confusingly, Kriaucionis 
et al called their new transcript MECP2a, whereas Mnatzakanian et al called theirs MECP2B 
(Kriaucionis et al 2004, Mnatzakanian et al 2004.) The A/B notation will be used herein. Exon 2
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normally contains the ATG START site, but if exon 1 is included, it contains an ATG which can 
act as the START site for an ORF of 501aa in mice and 498aa in humans (Kriaucionis et al 2004.)
Alignment o f the two iso forms shows that Mecp2B is more closely related to ancestral forms of 
Mecp2 such as those found in X.leavis and D.rario (Kriaucionis et a 20041) Kriaucionis et al also 
examined the relative abundances o f the two transcripts in vivo and found that MECP2B is more 
abundant in most tissues, being at least 10-fold more abundant in mouse brain extracts, and the 
proportion o f Mecp2B appears to increase during neuronal maturation (Kriaucionis et al 2004.) As 
well as being less abundant, Mecp2A appears to be inefficiently translated in vivo. A short 39aa 
ORF in the 3’UTR of Mecp2A could potentially interfere with translation. In the mouse, the short 
ORF starts from the same codon that initiates translation o f the Mecp2B form, but in the Mecp2A 
form, the ORF terminates due to alternative splicing 55nt upstream of the ‘proper’ translation start 
site. Characterisation o f the two isoforms revealed no differences in cellular localisation 
(Kriaucionis et al 2004.)
The realisation that exon 1 does contain coding sequences could have major implications for 
Rett patient screening. Exon 1 has previously been excluded from many screening programs 
(which could explain why not all clinically diagnosed Rett patients have defined MECP2 
mutations.) (Kriaucionis et al 2004.) However, because MECP2B is the more abundant iso form, 
mutations in exon 1 could potentially remove over 90% of total MECP2 from the cell (Kriaucionis 
et al 2004.) Exon 1 contains repeated GCC and GCA codons which may be susceptible to 
expansion such as that seen in the FMR2 gene, causing FRAXE mental retardation (OMIM 
#309548) (Kriaucionis et al 2004.) The finding o f the MECP2A isoforms may also explain why 
no exon 2 mutations are found in Rett patients; they may have such a mild effect that the MECP2B 
isoform can compensate for them (Stancheva et al 2003.)
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A key question which remains unanswered is whether the two isoforms differ in function; for 
example, the MECP2B N-terminus contains a potential phosphorylation site which is absent from 
the MECP2A isoform, which could lead to functional differences (Kriaucionis et al 2004.) On the 
other hand, human MECP2A was able to rescue MeCP2 deficiency in Xenopus embryos, which 
argues against large functional differences, although one also could argue that it may well not 
rescue human cells (Kriaucionis et al 2004.)
1.7.2. MECP2 -  Function in vivo.
Despite intensive effort by many groups around the world, the mechanism of action o f MECP2 
is still unknown. Very few target genes for MECP2 have been identified and the theory that 
MECP2 is somehow responsible for neuronal maturation has been strengthened, but in many ways, 
we are still far from identifying the precise molecular pathways which lead to such a devastating 
neurological phenotype, much less being at a stage of being able to offer therapy for Rett patients.
It was widely presumed that loss o f MECP2 would lead to significant changes in a small number 
of genes that could be linked to the phenotype. Studies by Nan et al have showed that MeCP2 can 
repress transcription in vitro from methylated promoters, but not non-methylated promoters (Nan 
et al 1997.) Nan et al also found that MeCP2 appears to bind the Sin3A repressor complex, which 
acts to remodel chromatin into a state refractory to transcription via the recruitment of histone 
deacetylases (Hdacs) (fig 1.11) which deacteylate histone tails (Nan et al 1998.)
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Fis 1.11. M eCP2 and Transcriptional Repression.
Deacetylated 
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Fig 1.11. Mecp2 binds to methylated CpG dinucleotides (yellow circles) and recruits the Sin3A complex, 
made up o f  RbAp46. RbAp48, Sin3A. Sap 18 and Sap30. which then recruits Hdacl and Hdac2. The Hdacs 
deacetylate histone tails remodelling the chromatin into a form refractory to transcription.
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Indeed, the transcriptional repression induced by MeCP2 in vitro can be relieved by Trichostatin 
A, a HDAC inhibitor (Nan et al 1999.) This evidence, and the fact that MeCP2 binds to a single 
symmetrically methylated CpG pair, which are widespread in the genome, lead Nan et al to 
hypothesise that MeCP2 is a global transcriptional repressor in vivo (Nan et al 1997.) As such, 
mutations in MeCP2 were expected to cause significant changes in the transcriptional profile
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of the cell, which would lead to the symptoms of Rett syndrome. However, the lack of large 
transcriptional differences in the absence o f MeCP2 implies that MeCP2 may be acting in a 
different, more subtle manner (Tudor et al 2002)
1.7.3. M ECP2 links DNA methvlation to histone methvlation.
The inhibition o f HDAC activity, using drugs such as Trichostatin A only partially relieves 
MeCP2-mediated transcriptional repression, indicating that other mechanisms of repression by 
MeCP2 exist (Fuks et al 2002.) Post-translational histone methylation is an important mechanism 
in the setting of chromatin structure and regulation of gene expression (Fuks et al 2002, 
Kouzarides 2002.) Methylation of lysine 9 o f histone H3 (H3 K9) is associated with gene silencing 
(Kouzarides 2002.) Recent work by Fuks et al has shown that MeCP2 associates with histone 
methyltransferase activity in vitro and in vivo (Fuks et al 2002.)
The MeCP2 associated methylation activity was found to be specific for H3 K9 methylation of 
the HI gene. Fuks et al propose that MeCP2 forms a link between DNA methylation and histone 
methylation, to reinforce their repressive activities (Fuks et al 2002.) Deacetylation o f H3K9 is 
necessary for methylation o f the residue (Rea et al 2000) and so MeCP2 may first mediate 
deacetylation, then methylation o f H3 K9 which may in turn attract proteins such as HP1 (Fuks et 
al 2002) setting up a self-reinforcing cycle o f repression.
For such a vital process, the lack o f significant transcriptional differences seen in the absence of 
MeCP2 suggests that other factors may be able to partially compensate for the loss of MeCP2; 
perhaps the activity is mediated by a large protein complex which can use overlapping protein 
activities to make up for the loss o f MeCP2.
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1.7.4. Is MeCP2 Really a Global T ranscrip tional Repressor?
In vivo, it is thought that MeCP2 may exist as part of a larger chromatin-remodelling complex; 
proteins which have been reported to bind mammalian MeCP2 include Dnmtl, Co-Rest, Suv39Hl 
and c-Ski (Kimura and Shiota 2003, Kokura et al 2001, Lunyak et al 2002.) MeCP2 has been 
shown to interact with the Sin3A/Hdac (Nan et al 1998) chromatin remodelling complex, which 
remodels chromatin into a form refractory to transcription. In X.leavis, xMeCP2 was found to 
partially co-fractionate with Sin3A and transcriptional repression by MeCP2 can be partially 
alleviated by the Hdac inhibitor Trichostatin A (TSA) (Jones 1998.) However, native MeCP2 has 
recently been purified from rat brain and found to not bind stably to the Sin3A complex, or indeed 
any other proteins in nuclear extracts (Klose and Bird 2004.) Size exclusion chromatography of 
MeCP2 revealed that its apparent molecular weight was 400 to 500kDa, much higher than the 
predicted weight based on the amino acid sequence (52.4 to 53 kDa, depending on the species) 
(Klose and Bird 2004.) This finding could result from MeCP2 existing in vivo as a larger complex, 
as a protein with an unusual shape, or as a homo-multimer (Klose and Bird 2004.)
Klose and Bird used a combined size exclusion chromatography and sucrose gradient 
sedimentation to determine that MeCP2 appears to behave like an elongated monomer of 
approximately 6.15nm (Klose and Bird 2004.) O f course, these studies are carried out in vitro, and 
the properties o f purified MeCP2 may well be different from MeCP2 which is interacting with 
DNA in a nucleoprotein context. Further work is needed to ascertain binding partners in vivo and 
to find out exactly what MeCP2 is interacting with in the cell.
The survival of Mecp2 >y and Mecp2 l mice (Guy et al 2001, Chen et al 2001) and the lack of 
major developmental abnormalities in RTT patients demonstrates that MeCP2 is not absolutely
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required for execution of the developmental process. However, the creation of mice null for 
MeCP2 confirmed that loss of the protein is necessary and sufficient for the development o f Rett- 
like symptoms. Clearly, whilst not essential for viability, MeCP2 is an important part of at least 
some stage o f the brain’s developmental program.
With the advent of microarray technology, the transcriptome of a cell can be easily examined, 
and huge amounts of data generated in a way that was unthinkable only a few years ago. Since 
MeCP2 is thought to be a global transcriptional repressor, microarray analysis of cells with and 
lacking MeCP2 would be expected to reveal widespread and significant changes in the 
transcriptome. However, transcriptome analysis o f Mecp2'A brains showed very few differences, 
although computer programs were able to pick out wild type and mutant samples from their 
expression profiles (Tudor et al 2002.) Whatever the effects of removing MeCP2 in the brain, they 
clearly do not cause a lasting large alteration in the transcriptional activity of one or two specific 
genes, (which would allow the function o f those genes, and thus the mechanisms behind Rett 
pathology, to be elucidated.) This may be due to the window of MeCP2 action being limited; the 
degenerative period in Rett is relatively short compared to lifespan and it may well be that analysis 
o f brain tissue at one particular time point in the disease progression will yield larger 
transcriptional differences. It could also be that removal of MeCP2 results in a subtle 
transcriptional alteration which neurons may be very sensitive to; it has been suggested that 
MeCP2 damps down the inherent ‘noise’ in the system, o f ‘leaky’ transcripts which neurons might 
be very sensitive to; this observation lead to the proposal that neurons may be more sensitive to 
transcriptional ‘noise’ (Carter and Segal 2001.) However, if neurons per se are more sensitive to 
spurious transcripts, this does not explain the differences seen in various brain regions; why would 
some brain regions, containing similar neuron types, react so differently? This is an intriguing 
idea; spurious transcription may be toxic to the cell at a threshold level determined by cell type, or
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perhaps cell position. Experiments which have examined the transcriptome of the MeCP2 null 
brain (Tudor et al 2002) and found no significant changes warrant an examination of the role of 
MeCP2 as a global transcriptional repressor.
1.7.5. M eCP2 Directly regulates Bdnf and jtHairv2a.
Despite initial microarray studies finding no significant changes in the MeCP2 null 
transcriptome, more recently, groups using different methodologies have found two genes to be 
controlled directly by MeCP2; B dnf in the mouse, and xHairy2a in the frog (Chen et al 2003, 
Vetter 2003, Stancheva et al 2004, Martinowich et al 2003.)
1.7.6. MeCP2 and Bdnf.
B dnf (brain derived neurotrophic factor) was the first gene found in the mouse to be regulated by 
MeCP2. Bdnf is synthesised in response to neuronal activity, and is thought to be involved in 
changing short-lived neuronal stimuli into more lasting alterations in the brain -  a process thought 
to be at the root o f memory and learning (West et al 2000.) Bdnf therefore plays a vital role in 
neuronal plasticity, learning and memory (West et al 2000.)
The Bdnf locus is controlled in a complex manner, with at least four transcriptional start sites 
that produce a range o f mRNA products (Timmusk et al 1994.) In the rat the Bdnf exon III 
promoter (the equivalent promoter in the mouse is the Bdnf exon IV promoter) is activated in 
response to the wave of calcium that floods into the cell on depolarisation
When calcium is absent, the promoter is inactive, but when depolarisation leads to calcium 
uptake, the promoter is activated around 100-fold (Chen et al 2003, Tao et al 2002.)
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In 2003, two groups independently discovered the link between Bdnf and MeCP2; 
Martinowich et al created Bdnf promoters with reduced methylation levels which they then 
transfected into cultured neurons (Martinowich et al 2003.) Upon depolarisation, reduced levels of 
transcription were seen in templates with lower methylation levels (Chen et al 2003, Martinowich 
et al 2003.) They then directly analysed the levels of methylation in cultured neuronal cells and 
found that there was a difference in methylation density at the exon IV promoter before and after 
depolarisation (Chen et al 2003, Martinowich et al 2003.) This implies that altered methylation 
states may be at least in part responsible for controlling Bdnf promoter IV. Martinowich et al went 
on to examine the proteins which associated with the Bdnf locus using chromatin 
immuoprecipitation (Martinowich et al 2003.)
These experiments showed that MeCP2 was associated with the locus in the absence of 
depolarisation; when depolarisation occurred, MeCP2 was largely lost from the locus (Chen et al 
2003, Martinowich et al 2003.) Martinowich et al also reported a major redistribution of MeCP2 
within the cell in response to depolarisation, becoming more punctate (Martinowich et al 2003.) 
MeCP2 was only lost from specific loci, as an imprinted gene, Rasgrfl, did not lose associated 
MeCP2 (Martinowich et al 2003.) This implies that depolarisation incurs both global and specific 
changes in MeCP2 distribution. Martinowich et al found that the CRE binding protein Creb was 
also associated with a CRE element in the B dnf promoter and that on depolarisation, Creb had a 
higher affinity for the promoter (Martinowich et al 2003.) They predict that this creates a 
transcriptional activation complex (see fig 1.12) and that this acts in concert with the loss o f the 
Hdacs to remodel chromatin into a more permissive form (Martinowich et al 2003.)
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Fie 1.12. Possible mechanism o f  action o f M e C Y l  at B d n f promoter IV  in the mouse.
Hdacl
Sin3A
MeCP2
Transcription blocked
Silencing complex'7
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D slI  .12. Possible mechanism o f action o f M e C V l  at Bdnf promoter IV in the mouse.
Transcriptional
activation complex? 
P
Transcription activated.
In the resting cell (A) the promoter is highly methylated (black circles) and MeCP2 is bound to the 
promoter. CREB binds with lower affinity fo r  the CRE element. MeCP2 recruits Sin3A and Hdacs and 
remodels the chromatin into a repressive state. Upon depolarisation (B) the promoter loses some 
methylation (yellow circles.) MeCP2 is phosphorylated and has lower affinity for the promoter. Creb 
becomes phosphorylated and becomes tightly bound to the CRE, possibly assembling a transcriptional 
activation complex. In the presence o f this, and in the absence o f  the \1ecp2-recruited Hdacs, the 
chromatin is remodelled into a permissive state. (Adaptedfrom Matinowich el al 2001.)
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Chen et al also found that depolarisation of neurons leads to the dissociation o f MeCP2 from 
the Bdnf exon III promoter (Chen et al 2001.) In neuronal cultures from Mecp2 mutant mice, Bdnf 
transcripts were upregulated by around two-fold when stimulation was absent, therefore loss of 
MECP2 lead to a small decrease in basal transcription from the exon IV promoter (Chen et al 
2001.) Chen et al also looked at the effects of the depolarisation on MeCP2 itself. When 
depolarisation occurred, a novel form of phosphorylated MeCP2 accumulated in the cells 30 to 60 
minutes after depolarisation. DNA binding assays revealed that this phosphorylated form was 
unable to bind to a methylated template probe (Chen et al 2001.) This raises the intriguing 
possibility that Bdnf may be controlled by MeCP2 using a mixture of phosphorylation and 
methylation changes which may alter the chromatin environment to allow assembly of 
transcription complexes (Chen et al 2001, Martinowich et al 2001.) It shows how the association 
of MeCP2 with DNA is not static, as might be assumed from its ubiquitous presence on the 
chromosome, but fluid and dynamic, which represent a shift in our thinking on how MeCP2 
interacts with DNA in vivo (Chen et al 2001, Martinowich et al 2001.) It does not tell us how, 
where or by what MeCP2 is phosphorylated, or how the levels of methylation change, however, so 
there must be more protein players in the MeCP2/&/«/story.
It is also noteworthy that the loss o f MeCP2 does not lead to the same 100-fold increase in Bdnf 
transcription that occurs on depolarisation, as only a 2 fold-change is seen (Chen et al 2001.) This 
also indicates that there may well be more proteins involved in the MeCP2-mediated repression 
mechanism.
The Xenopus transcriptional repressor, xHairy2a has also been found to be a target gene for 
MeCP2 (Stancheva et al 2003) and MeCP2 appears to have a similar mode of action at the 
xHairy2a promoter; MeCP2 appears to be bound to the methylated upstream flank of the promoter
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and leaves the promoter upon activation o f the gene (Stancheva et al 2003, Klose and Bird . 
Hairy2a is a transcriptional repressor which represses the expression of pro-neuronal genes in the 
non-neuronal cells which surround developing neurons (Klose and Bird 2003, Stancheva et al
2004.) A deficiency o f Xenopus MeCP2 leads to inappropriate activation of the xHairy2a gene, 
with severe consequences for the embryonic nervous system i.e abnormal patterning of primary 
neurons during neuronal differentiation (Stancheva et al 2003.)
1.7.7. Is Rett syndrome a disorder o f altered imprinting?
Although there is in vivo evidence that MeCP2 binds upstream of the differentially methylated 
region upstream of H19 (Drewell et al 2002) most researchers have rejected the idea that Rett 
syndrome is a disorder of altered imprinting. A number o f imprinted genes such as H19, Igf2, 
Snrpn, Ipw and Ndn have been examined (Balmer et al 2002) and normal imprinting patterns 
found in Rett patients. Recent work however, claims that Rett syndrome could be due to alterations 
in imprinting patterns (Horike et al 2005.) Horike et al examined whether MeCP2 was involved in 
repressing only one allele of an imprinted pair. They sequenced 100 MeCP2 binding sites 
identified by ChIP and found that several were contained in the imprinted cluster on mouse 
chromosome 6 that contains the Dlx5 and Dlx6 genes (Horike et al 2005.) Dlx5 is a member of the 
Distal-less homeobox gene family and play roles in several developmental processes, including 
limb formation and neurogenesis (Panganiban et al 2002.)
In humans, DLX5 is maternally expressed; in mice however, this imprinting is ‘relaxed’ and 
there is biallelic expression, although expression from the maternal allele is higher (Horike et al
2005.) (This is an important caveat o f this work -  it is not clear how a fully imprinted and a
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relaxed imprinting state compare in vivo.) Horike et al found that the CpG island of Dlx5 is, 
surprisingly, normally unmethylated and the MeCP2 binding sequence 52kb from the 3’ end is not 
differentially methylated (Horike et al 2005.) In wild type mice, this region is enriched in histone 
H3 methylated at lysine 9 and is associated with a higher order loop characteristic of silenced 
chromatin (Horike et al 2005.) In the absence o f MeCP2, this region still somehow loses its ability 
to bind H dacl and becomes enriched in acetylated histone H3, losing the loop (Horike et al 2005.) 
This implies that these distinct loop structures may be induced by the presence of MeCP2 and may 
control longer-term transcriptional activity via a mechanism which is dependent on histone 
methylation rather than DNA methylation (Pescucci et al 2005) (Horike et al 2005.)
1.8. Aims and Objectives
1.8.1. Examining the role o f MBD proteins in the murine intestine.
The methyl binding domain proteins ‘read’ and act upon the methylation marks created on DNA 
(Hendrich and Tweedie 2003.) The importance o f these proteins is demonstrated by the effects of 
their removal on various systems; removal of MECP2 in the human causes Rett syndrome, which 
can be modelled in the mouse (Guy et al 2001, Chen et al 2001.) Removal of Mbd2 reduces 
intestinal tumourigenesis whilst Mbd4 appears to regulate the apoptotic response to a variety of 
DNA damaging agents (Sansom et al 2003a, Sansom et al 2004.) This demonstrates that MBD 
proteins are involved in a wide range of cellular processes.
This project will use a combined transgenic and biochemical approach to further characterise the 
roles o f MeCP2 and Mbd4 in the murine intestine and the removal of MeCP2 in the mammary 
gland. A conditional allele of Mecp2, combined with an intestinal-specific or mammary-specific
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Cre-recombinase will allow removal o f MeCP2 only in the intestine or mammary gland, in order to 
study the effects of removal of the gene in a non-neuronal setting.
Studying the consequences of MeCP2 removal in a system other than the nervous system may 
be informative; changes in the proliferation, migration or differentiation in the intestine may be 
more easily scored than behavioural changes which occur as a result o f MeCP2 removal in the 
brain or nervous system. In such a system as the intestine, it may be simpler to dissect out specific 
molecular pathways for the action o f MeCP2 which may in turn shed light on the the mechanisms 
underlying Rett syndrome pathology.
Constitutive null alleles of Mbd4 and M lhl will be used to investigate the role of Mbd4 and 
Mlhl in apoptotic signalling in response to Fas ligand and anoikis, and the interaction of Mbd4 
with the MMR system. These experiments will be designed to shed light on the roles of MBD 
proteins in the intestine and mammary gland, and provide insights into the elusive mechanism of 
action of MECP2 in Rett syndrome.
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Chapter 2. Materials and Methods.
2.1. Immunohistochemistry/stains.
• All procedures use sections obtained from formalin-fixed, paraffin-embedded 
samples, at a thickness of 5- 10pm
• Sections must not be allowed to dry out at any point in the procedure.
• Xylene and ethanol clearing/ dehydration steps must be carried out in a fume
hood.
• Incubations are carried out in a humidified slide box, at room temperature unless 
otherwise stated.
2.1.1 H&E (Haematoxvlin and Eosin) staining
Clearing.
• Wash slides 2 x 10 mins in xylene
• Wash 2 x 5  mins in 100% ethanol
• Wash 1 x 5 mins in 95% ethanol
• Wash 1 x 5 mins in 75% ethanol
• Wash in tap water lx 2 mins.
• Immerse slides in haematoxylin for 1 min
• Rinse in tap water (with a continuous flow-through) for 5 mins
• Immerse in eosin for 30 seconds
• Rinse in tap water for 5 mins
Dehydration
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• Wash slides 1 x 5 mins in 75% ethanol
• Wash 1 x 5 mins in 95% ethanol
• Wash 2 x 5  mins in 100% ethanol
• Wash 2 x 10 mins in xylene
• Mount in DPX (Distrene plasticiser and xylene) (Sigma) Place the coverslip on a flat 
surface and apply a small amount o f DPX, making sure there are no bubbles. Pick up the 
slide and gently place it, section side down, onto the coated coverslip. Turn the assembly 
over and gently press down on the coverslip with a blunt pencil until the DPX spreads 
out to cover the whole section and the whole o f the underneath of the coverslip.
• Leave on a level surface to dry for 48 hours.
2.1.2. GIP (Gastrointestinal polypeptide) staining.
Use Dako kit # K4006 or K4007 and GIP antibody (Monosan)
Clearing.
• Wash slides in 2 x 10 mins in xylene
• Wash 2 x 5  mins in 100% ethanol
• Wash 1 x 5 mins in 95% ethanol
• Wash 1 x 5 mins in 75% ethanol
Antigen retrieval
• Immerse the slides in preheated 1 x citrate buffer (Sigma) at 99°C for 20 mins -  preheat 
the buffer by placing the slide container in a cool water bath and bringing the container 
and buffer up to 99°C. Do not place a cold slide container/glass slides into hot 
buffer/water bath as they are likely to shatter.
• Remove the slide container from the water bath using gloves, and allow to cool to room 
temperature for 'A hour.
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Peroxidase block
• Draw around the section with a DAKO immunohistochemistry pen, to leave a 
hydrophobic line around the section -  this keeps the liquid on the section and prevents it 
from drying out.
• Apply enough peroxidase block from bottle 1 (supplied with kit) to cover the section.
• Incubate in a humidified chamber for 4-6 mins.
• Gently rinse the section with buffer (1 xPBS -  phosphate buffered saline (Sigma))
• Immerse the sections in buffer
Primary antibody
• Tap off the excess buffer
• Apply the primary antibody (diluted 1:400 in buffer.) Use just enough to cover each 
section.
• Incubate for 50 mins at room temp.
• Rinse with buffer.
•  Tap off excess buffer - do not allow the sections to dry out.
• Apply enough labelled polymer from bottle 2 (supplied with kit) to cover the section.
• Incubate for 30 mins
• Rinse with buffer.
Substrate chromogen.
• Add one drop of bottle 3b to one ml o f bottle 3a, (supplied with kit) mix and use 
immediately.
• Apply enough o f the mixture to just cover each section.
• Incubate for 5-10 mins
• Rinse gently with buffer.
Counterstain.
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• Immerse the slides in Haematoxylin for 30 sec to 1 min.
• Rinse the slides in distilled water
• Dip each slide 10 times into a bath o f 37mM ammonia
• Rinse the slides in deionised water for 10 mins
• Dehydrate and clear (by immersion in increasing concentrations of ethanol followed by
xylene) and mount in DPX (as in protocol 2.1.1.)
GIP positive cells appear dark brown, background appears blue/brown.
2.1.3.Grimelius (Enteroendocrine cell stain.)
Solutions needed:
1. Silver staining solution (100 ml aceteate buffer pH 5.6, 87ml distilled water,
3ml 1% silver nitrate solution.)
2. Reducing solution (2.5g hydrated sodium sulphite, lg hydroquinone, 50ml distilled 
water.)
3. Acetate buffer (4.8ml 0.2M acetic acid, 45.2 ml 0.2Msodium acetate, 50ml distilled
water.)
*AII solutions must be made up in glass containers only, which must be thoroughly rinsed 
with distilled water. Contact with plastic w ill result in the stain failing.*
De-waxing and Rehvdration.
• Wash the slides for 2 x 10 mins in xylene
• Wash 2 x 5  mins in 100% ethanol
• Wash 1 x 5 mins in 95% ethanol
• Wash 1 x 5 mins in 75% ethanol
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• Wash the slides for 5 mins in tap water.
• Incubate for 3 hours at 65°C in silver nitrate solution -  bring the container with the slides
and silver nitrate solution up to 65°C in a water bath, do not place a cold container into a
hot water bath or the container and slides may shatter.
•  Remove the container carefully using heatproof gloves.
• Drain the silver solution from the slides
• Treat with freshly prepared reducing solution for 1 min at 45°C.
• Repeat steps 4 and 5 until the desired effect is achieved (typically 3-5 repeats.)
• Dehydrate, clear and mount in DPX, as in protocol 2.1.1.
• Enteoendocrine cells will appear black with black granules, the background appears 
yellow/brown.
2.1.4. Alcian Blue.
Solutions needed:
1. Alcian blue pH 2.5 (2g alcian blue (or as needed) 100ml 0.5% acetic acid.)
2. 0.1%  nuclear fast red (O.lg nuclear fast red, 2.5g ammonium sulphate, 100ml distilled 
water.)
Method.
• Wash 2 x 1 0  mins in xylene
• Wash 2 x 5  mins in 100% ethanol
• Wash 1 x 5 mins in 95% ethanol
• Wash 1 x 5 mins in 75% ethanol
• Wash (and transport if necessary) in tap water.
• Stain in alcian blue solution for 5 mins
• Wash well in tap water for 5 mins
• Counterstain in 0.1% nuclear fast red for 5 min
• Wash well in tap water
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• Dehyrate, clear and mount in DPX.
• Mucins appear bright blue, nuclei appear red. Background appears red/pink.
2.1.5.Alkaline phosphatase.
• Alklaline phosphatase staining for the villus was carried out on paraffin sections of
intestine, using Dako kit #K0699, according to the supplied instructions.
(http://www.dakocytomation.co.uk/prod_downloadpackageinsert.pdf?objectid= 10060800 
1)
2.1.6. BrdU (Brom odeoxvuridine staining)
• Wash the slides for 2 x 10 mins in xylene
• Wash 2 x 5  mins in 100% ethanol
• Wash 1 x 5 mins in 95% ethanol
• Wash 1 x 5 mins in 75% ethanol
• Wash for 5 mins in tap water.
• Add 5ml of antigen unmasking solution (DAKO to 500mls of DDW
• Place in the microwave and microwave on full power for 3 x 5 mins for antigen
unmasking. Shake the container carefully between 5 minute incubations to
remove bubbles.
• Allow the slides and unmasking solution to cool for 30 mins.
• Place the slides in 5m HC1 for 10 mins.
• Remove the slides and wash for 2 x 5 mins in PBS.
• Draw around the section with a DAKO pen.
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• Block non-specific staining by incubating in PBS/BSA (Bovine serum album 1%) 
for 20 mins.
• Apply a 1:50 dilution o f BrdU antibody (MCA2060 Serotec) in 1 % BSA/PBS.
• Incubate for 1 hour.
• Wash the slides 3 x 5  mins in PBS.
• Develop in Dab chromogen (Sigma) (2 drops of bottle A from the Dab kit to 1 ml
of bottle B from the kit) for 5-8 mins until a dark brown colour develops
• Wash the slides for 5 mins in PBS
• Counterstain with a 30 second immersion in haematoxylin.
• Wash for 5 mins in tap water
• Dehydrate and mount in DPX as in protocol 2.1.1.
• BrdU positive cells appear dark brown/black, background appears blue.
2.2. Genotvping.
2.2.1. DNA Purification: Puregene method
• Take a small (3-5mm) section o f mouse tail tip from the dead animal (or use
appropriate anaesthetic to take a sample from a live animal.)
• Add 500pl of cell lysis solution (Gentra) and lOpl of proteinase K 20mg/ml to each
tube containing mouse tail and shake overnight at 37oC
• Allow the tubes to cool to room temp
• Add 200pl of protein precipitation solution (Gentra) to each tube. Vortex and then 
spin in microfuge at 13,000rpm for 5 mins
• Remove the supernatant into clean tube containing 500pl of isopropanol.
• Vortex and spin at 13,000 rpm for 5 mins
• Pour off the supernatant and leave the tubes upside down to dry overnight.
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• Add 500pl o f nuclease-free water to each sample.
• Vortex gently for 2 seconds and leave at 37°C shaking overnight to resuspend the 
DNA.
• Use 2pl o f the resulting DNA suspension in the following PCR protocols.
2.2.2. Mecp2 PCR.
Prim ers p5 (forward) 5’ G GT AAA GAC CCA TGT GAC CC 3’ 
p7 (reverse) 5’ GGC TTG CCA CAT GAC AA 3’
For one reaction....
• 5pl 10 x Buffer (Sigma)
• 3|il 25mM MgCb (Sigma)
• Ipl lOmM DNTP mix
• lfil o f each primer
• 2pl RedTaq (Sigma)
• 35pl distilled H 20
• 2pl DNA.
PCR Cycle.
95°C for 3 mins 
95°C for 30 sec 
56°C for 1 min 
72°C for 1 min . 
72°C for 5 mins 
END
x 30
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The PCR products are then run on 2% agarose gel containing ethidium bromide (4pl per 100ml 
gel) and bands visualised under UV light. Bands appear around 416 bp (wild type) and 470 bp 
(floxed allele)
2.2.3. Ble-Cre PCR.
Primers. Big forward; CTTCTGGGGTCTACCAGGA 
Big reverse: TCGTGCTTCTGAGCTCTGCA
For one reaction...
• 5pl 10 x Buffer (Sigma)
• 3jil 25mM MgCh (Sigma)
• lpl 10 mM DNTP mix (Sigma)
• lpl o f each primer
• 2pl RedTaq (Sigma)
• 35pl distilled H2O
• 2pl DNA.
PCR Cycle.
95°C for 3 mins
95°C for 30 sec
55°C for 1 min
72°C for 1 min
72°C for 5 mins
END
x 30
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The PCR products are then run on 2% agarose gel containing ethidium bromide (4pl per 100ml 
gel) and bands visualised under UV light.
2.2.4. Ah-Cre PCR
Primers: P l=  TGACCGTACACCAAAATTTG 
P2= ATTGCCCCTGTTTCACTATG
For one reaction..
5pl 10 x Buffer (Sigma)
3(0.1 25mM MgCb (Sigma)
1 fol 10 mM DNTP mix (Sigma) 
1 pi o f each primer 
2pl RedTaq (Sigma)
35(ol distilled H2O 
2jol DNA.
PCR program.
94°C for 2 mins 
94°C for 1 min 
55°C for 1 min 
72°C for 1 min ■ 
72°C for 5 mins 
END
x 35
Run the PCR products on a 2% agarose gel containing ethidium bromide. The AH-cre appears as 
a band just below lkb.
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2.2.5. Mbd4 PCR
Primers: P 1: CGT GTG GAT GGG AAA GAG TT 
P2: GGA AGT CAG AGC TGC AAA C 
For one reaction...
• 35.25 \i\ distilled H2O
• 5 |il Buffer
• 1 Ml dNTPs
• 1 pi Primers (x4)
• 2 .5 (J.I Mg
• 0.25fil Taq
• 2 Ml DNA
• PCR Program:
• 94°C for 2 mins
• 45 sec 94°C M
• 45 sec 65°C
• 1 min 72°C -------
• 5 min 72°C
• The PCR products are the run on a 4%  agarose gel. Product: wt = 322 bp. KO 
(knockout) = 469 bp
2.2.6. M lhl PCR
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Primers P I : GAC AGC ACC AGA CCA AGC TA
P2: AGG ACT GTC TAA GGC AGC A
For 1 reaction....
• 5pl lOx PCR buffer
• 2pl of MgC12
• 1 pi P 1 (40 pmols per reaction)
• 1 pi P2 (40pmol per reactiom)
• 1 pi P3 (40pmol per reaction)
• 4 pi dNTPS (undiluted)
• 0.25 pi o f TaQ polymerase
• 393pl of distilled H2O
PCR protocol.
• 94°C 1 min
• 94°c 1 min *
• 60°C 1 min
• 72 °C for 1 min-------
• 72°C for 5 mins
• Run the PCR products on a 2% agarose gel, the wild type band = 258bp, mutant 
band = 198bp
2.2.7. ADcn°x PCR
Primers:
• Apc-P3 GTTCTGTATCATGGAAAGATAGGTGGTC
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• Apc-P4 CACTCAAAACGCTTTTGAGGGTTGATTC
Reaction x 1 5pl lOx Buffer
2.5pl 50mM MgCl2 
lpl lOmM dNTP MIX 
lfil both primers (lOpmol/pl; lOpM) 
0.25pl Taq 
37.25pl distilled H20  
2pl DNA
PCR Cycle 95°C 3 minutes 
95°C 30 secs <+ 
60°C 30 secs
72°C 1 min -----
72°C 5 mins
• The products are run on a 2% agarose gel. The wild type band appears at 296bp 
and the floxed allele at 314 bp.
2.2.8. LacZ (Rosa26R) PCR.
Primers:
• LacZl TACCACAGCGGATGGTTCGG
• LacZ2 GTGGTGGTTATGCCGATCGC
Reaction x 1 5pl lOx Buffer
■ 2.5pl 50mM MgCl2
■ Ipl lOmM dNTP MIX
■ lpl both primers (40pmol/pl; 40pM)
■ 0.25pl Taq
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37.25pl dH20  
2pl DNA
PCR Cycle 95°C 3 minutes 
95°C 30 secs +  
55°C 30 secs 
72°C 40 secs _  
72°C 5 mins
x 35.
Run the PCR product on a 2% agarose gel, a band will appear at 351 bp if the 
allele is present.
2.3. LacZ Staining o f small intestinal wholem ounts.
• Immediately after killing the mouse, remove the intestinal tract and flush with ice- 
cold PBS.
• Flush the gut with X-gal fix (2% formaldehyde, 0.1%glutaraldehyde in PBS kept 
on ice)
• Cut the gut into 7cm sections
• Pin down on wax plate with the mesenteric line uppermost, trim off any excess 
mesentery.
• Pin down the other end o f the gut so that it is stretched slightly. Begin opening the 
gut and pin out.
• Fix in 10% formalin for 1 hr.
• Wash with PBS
• Demucify by incubation in DTT demucifying solution for 30 mins.
• Flood the plate and pipette off the excess mucus.
• Add approx. 40 mis X-gal stain (1ml o f solution A to 100ml solution B.)
• Solution A = 2% X-gal in DMF (Promega)
• Solution B= O.lg MgCl, 0.48g K ferricyanide, 0.64g K ferrocyanide in 500mls
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PBS.
• Incubate overnight in the dark at room temperature with gentle agitation.
• Fix with formalin or X-gal fix.
2.3.1. DTT Demucifving Solution.
• 1 vol glycerol (5mls)
• 1 vol 0.1M Tris pH 8.2 (5 mis)
• 2 vols 100% ethanol (lOmls)
• 6 vols saline (30ml)
• 170mgs DTT per 50 mis solution.
2.3.2. Wax Plates.
• Melt Ralwax (BDH# 36154) in a pyrex beaker over a bunsen flame. Once melted add
0.1 vols of paraffin oil. Pour into plates and allow to cool.
2.3.3. M ammary W holemounts.
• Remove the entire mammary gland from the mouse
• Place on a glass slide and gently flatten the gland as much as possible.
• Place the slide into freshly made up 2% paraformaldehyde and leave for at least 2 hours,
and preferably overnight.
• Remove the gland from the slide and rinse in PBS and then distilled water (at least 5 
mins)
• Place the gland in carmine red overnight, ( lg  carmine red dye (Sigma) +2.5g potassium 
alum in 500ml distilled water.)
• Dehydrate the gland as follows;
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• 15 mins in 75% ethanol
• 15 mins in 95% ethanol
• 2x 15 mins in 100% ethanol
• Clear the gland in benzyl benzoate overnight
• Mount the gland on a glass slide by placing it on the slide, coveing it in a minimal 
amount o f DPX and placing a coverslip over it.
• Photograph immediately.
2.3.4. 2% Paraformaldehyde.
• Makes 500ml.
• Dissolve lg o f paraformaldehyde (Sigma) in 500ml distilled water.
• Gently heat (on a hot plate set to around 50°C) and stir and add NaOH dropwise until the
solution is clear.
• Use immediately or freeze aliquots and store at -20°C)
2.4. Scoring Apoptosis.
Apoptosis was scored in H&E stained paraffin sections. Apoptotic cells can be identified by 
their distinctive morphology. Apoptotic cells are rounded and stain redder than surrounding 
cells, and are often surrounded by a lighter ‘halo’. Chromatin can be seen to be condensed within 
the cell, and there may be membrane blebbing.
2.5. Preparation o f M urine Colonic / Small Intestinal Crypts.
• Immediately after culling the mouse, remove whole colon/small intestine.
• Flush through with water and open up the intestine along the long axis.
- 90 -
• Rinse in HANKS balanced salt solution (HBSS, Sigma) at room temp.
• Shake gently in 10ml o f 2mM EDTA (pH8) in HBSS for 20 mins at 37°C.
• Discard the supernatant.
• Vortex the remaining material for around 20 seconds in 10ml HBSS and transfer the 
supernatant containing complete crypts (and some single cells) into a 15ml tube
• Repeat the vortexing until the supernatant is almost clear.
• Allow the crypts to settle out for 5 mins at room temperature
• Pipette (using a glass pipette) some of the crypts into 5 small microfuge tubes.
• Label the tubes with the appropriate timepoints.
• Spin the tubes at 500rpm for two minutes.
• Discard the supernatant and wash the pellet twice with Dulbecco’s-MEM (DMEM, 
Sigma)
• Add 1ml DMEM and resuspend the by gently inverting the tubes a few times and 
incubate at 37°C in 5%C02.
2.5.1. Short-Term Culture o f Colonic Crypts.
• Transfer the isolated crypts to culture dishes (inserts coated with 1% heat-denatured BSA 
overnight at 4°C or collagen)
• Incubate at 37°C, 5% CO2 for the time needed.
• Take the tubes at the relevant timepoints, spin down gently and replace the supernatant
with 10% formalin.
• Resuspend the crypts by gently inverting the tube.
• Spin down (3 mins at 500rpm) and replace the supernatant with fresh formalin.
• Embed in paraffin, section and stain with H&E.
2.6. Cell Culture.
2.6.1. Preparation o f murine em bryonic kidney cells.
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Solutions needed: 15ml PBS + 37.5mg trypsin +37.5pg collagenase A, (Sigma) filter sterilised. 
PBS, filter sterilised.
DMEM +5% FBS (Foetal bovine serum) (Sigma)
DMEM +5% FBS +0.1 g gentamicin. (Sigma)
♦All solutions are 0.2|im filter sterilised.*
• Cull pregnant female at day E 19.
• Remove embryos and kill by decapitation after immersion in ice-cold PBS.
• Remove kidneys and process each one separately.
• Dip each kidney briefly in 70% ethanol and then wash/transport in PBS.
• Place into 5ml of PBS +trypsin/collagen solution.
• Mechanically disrupt the kidney, mince finely using crossed sterile scalpel blades.
• Shake or stir gently for 30 mins at 37°C.
• Add 5 ml o f the DMEM+5%FBS solution and gently mix by pipetting.
• Allow the clumps to settle.
• Take off the supernatant and spin for 5 mins at 500rpm.
• Resuspend the pellet in DMEM/FBS/gentamicin
• Incubate at 37°C in 5%CC>2
• Check, feed and wash as necessary.
2.6.2. To trvpsinise the cells (for passaging)
Solutions needed.
■ Sterile PBS
■ PBS+0.05% trypsin+0.053mM EDTA
■ 47.5 ml DMEM + 2.5mls FBS + 2.5mg gentamicin
All solutions are warmed to 37°C
■ Aspirate the medium and discard it.
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■ Wash cells gently with PBS, aspirate and discard.
■ Repeat.
■ Add enough lxtrypsin/EDTA solution to cover the cells, then gently rock the culture 
vessel 4-5 times to coat the monolayer
■ Watch the cells until around 75% have rounded up and detached.
■ Resuspend the cells in culture medium
■ Centrifuge at 500rpm for 4 mins.
■ Resuspend in medium and transfer to a new culture dish.
2.7. RNA extraction and preparation for Affvmetrix Microarrav.
2.7.1. RNA Extraction From Intestinal Tissue.
Reagents.
• RNeasy mini-kit Qiagen cat no. 74104
• TRIzol reagent Invitrogen cat no. 15596-018
• Superscript Double-stranded cDNA synthesis kit (custom) (10 reactions) Invitrogen cat 
no. 11917-010
• T7(dT24) prim er. GENSET Custom Primer. HPLC-purified supplied by Helena 
Biosciences.
• Sequence: 5’-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT24)- 
3’
• Phase Lock Gel (light) tubes. Helena Biosciences Cat. No. 0032-007961
• Enzo BioArray High Yield Transcript Labelling kit supplied by Affymetrix (10 reactions) 
cat no. 900182
• Trizma base. Sigma cat no. T1503
• Magnesium Acetate . Sigma cat no. M2545
• Potassium acetate. Sigma cat no. P5708
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• 7.5M Ammonium acetate. Sigma cat no. A2708
• P-mercaptoethanol . Sigma cat no. M3148
• 0.5M EDTA Sigma cat. No. E7889
• Phenol/chloroform/IAA. Ambion cat no. 9730
• Glycogen (5mg/ml) Ambion cat no. 9510
• 1Kb plus DNA ladder Invitrogen cat no. 10787-018
• 0.24-9.5Kb RNA ladder Invitrogen cat no. 15620-010
• RNA century size markers Ambion cat no. 7140
• RNAlater Sigma cat no. R0901
2.7.2. Fragmentation buffer
(5X) fragmentation buffer: (200mM  Tris-acetate, pH 8.1, 500mM KOAc, 150mM  
M gOAc)
The fragmentation buffer is made using RNase-free reagents. Tris-containing solutions 
should NOT be treated with DEPC. However, once d ^ O  has been DEPC treated and 
autoclaved, it can be used for making Tris solutions.
Buffer: 4ml 1M Tris acetate pH.l (Trizma base, pH adjusted with glacial acetic acid.)
0.64g magnesium acetate 
0.98g potassium acetate 
DEPC treated dH20 to 20 ml.
2.7.3. Obtaining RNA from Tissue Samples.
• Dissect out the tissue o f interest to a maximum thickness in one direction of 5mm. (For 
the intestinal MeCP2 array, the very top 3cm of the proximal small intestine was used.)
• Transfer immediately to cold RNA later™ (Sigma cat no. R0901) to inactivate 
endogenous RNase activity.
• Tissue stored in RNA later™ can keep for 1 day at 37°C, 1 week at 25°C, 1 month at 
4°C and can be archived indefinitely at -20°C.
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To process the tissue:
• Pour off the RNA later™ and note the wet weight of the tissue.
•  Add 1ml cold Trizol reagent (Gibco cat no. 15596-018) per lOOmg tissue.
• Homogenise the tissue.
• Clean the homogeniser before first use, between each use and after final use with a 15 
second pulse in 5ml 4M NaOH followed by a 15 second pulse in 5ml H20 for 15 sec, 
then a 15 second pulse in 5 ml 75% ethanol (all solutions made with nuclease-free 
water)
• Aliquot 1 ml samples into clean, labelled RNase-free centrifuge tubes. Keep on ice.
• Centrifuge for 10 mins at max speed in a bench-top centrifuge at 4°C.
• Take off the supernatant (avoid the surface layer of fat) and transfer to new, labelled, 
sterile RNase-free tubes.
• Add 200p.l chloroform, shake for 5-10 mins, then chill for 5-10 mins.
• Centrifuge samples for 15mins at max. speed (bench-top centrifuge at 4°C)
• Carefully remove the top aqueous layer which will contain the RNA and transfer to
new tubes. Avoid taking material from the interface, which will contain DNA.
Dispose o f the lower layer in phenol waste.
• To precipitate the RNA, add an equal volume of isopropanol, mix by inversion and 
leave for 10 mins at 4°C. Leaving the tubes for longer may maximise RNA yields.
• Centrifuge samples for 15 mins at max. speed (bench-top centrifuge at 4°C)
• Discard the supernatant and air-dry the pellet for 5-10 mins.
• Resuspend the RNA in 100jal (or more if needed) nuclease-free water.
• Determine the total yield o f RNA spectrophotometrically. 1 A260 unit = 40pg/ml of 
single-stranded RNA.
2.7.4. First Strand cDNA Synthesis.
• Place the following in a microfuge tube;
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lOjig (Xjil) total RNA in DEPC (Diethyl pyrocarbonate, Sigma)-treated 
water.
lfil T7 (dt24) primer (lOOpmol/pl)
Ypl DEPC-treated water
= 1 lpl total.
• Incubate at 65-70°C in a heated block for 10 mins.
• Place tubes on ice
• Prepare a master mix on ice. Quantities per reaction are;
4ja.l (5x) first strand buffer (thaw at 37°C then keep on ice)
2(0.1 (0.1M) DTT 
1 (0.1 dNTPs (lOmM)
=7(0.1 total per reaction.
• Add 7(0.1 mix to each tube.
• Incubate at 42°C for 2 mins
• Add 2(0.1 superscript II reverse transcriptase
• Incubate for 1 hr on a heated block at 42°C.
• Place the tubes on ice and proceed to the second strand synthesis or freeze on dry ice
and store at -80°C.
2.7.5. Second Strand Synthesis.
NB.Use EXACTLY 2U RNase H per reaction
• Place all the reaction tubes on ice. For each reaction use:
91 pi DEPC treated water 
30pl (5x) second strand buffer 
3(0.1 (lOmM) dNTPs 
lpl E.coli DNA ligase (lOU/pl)
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4pl E.coli DNA Pol I (lOU/pl)
1 pi E.coli RNase H (2 U/p.1)
=130pl per reaction total.
• Mix by vortexing briefly, centrifuge down briefly if necessary.
• Add 130|il o f master mix to each o f the first strand reaction tubes.
• Mix by pipetting, centrifuge down briefly if necessary.
• Incubate at 16°C for 2 hrs.
• Add 2pl T4 DNA polymerase.
• Incubate at 16°C for 5 mins.
• Place tubes on ice and proceed to ‘clean-up of double-stranded cDNA or freeze on
dry ice and store at -80°C.
2.7.5. Clean-Up o f Double-Stranded cDNA.
• Centrifuge phase-Iock tubes for 30 sec at maximum speed.
• Add an equal volume o f RT buffer saturated Phenol/chloroform/IAA to the cDNA
reaction («160pl)
• Vortex briefly to mix
• Place the mixture in a Phase-lock tube
• Centrifuge at maximum speed for 2 mins
• Transfer the upper (aqueous) phase to a new eppendorf tube.
• Add: 0.5 vols 7.5M Ammonium acetate (*80pl)
4pl glycogen
2.5 vols 100% ethanol (room temperature) («600pl)
• Mix by tapping the tube
• Centrifuge at maximum speed for 20 mins -  NO LONGER.
• Remove the supernatant, being careful not to disturb or discard the pellet.
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• Add 160pl cold 80% ethanol.
• Centrifuge at room temperature for 5 mins at maximum speed.
• Discard the supernatant.
• Repeat the cold 80% ethanol wash, removing all the ethanol carefully with a pipette.
• Allow the pellet to air-dry for 5-10 mins.
• Resuspend in 12pl o f DEPC-treated water.
• Proceed to ‘in-vitro transcription’ or freeze on dry ice and store at -80°C.
2.7.6. In Vitro Transcription.
• Use reagents from the Enzo Bio-array high yield transcript labelling kit.
• Once thawed, reagents should be kept at room temperature until the reaction is ready 
to be incubated to reduce the precipitation o f DTT.
• The reaction should be kept in an incubator/warm room to reduce condensation on the 
inside of the tube cap.
• Thaw all reagents and the dsDNA at room temperature.
• Prepare a master mix;
lOpl DEPC-treated water
4pl (lOx) HY reaction buffer
4p.l biotin-labelled ribonucleotides.
4pl DTT
4pl RNase inhibitor mix 
2pl T7 RNA polymerase.
= 28 pi total per reaction
• Add 28 pi of master mix to each o f the 12pl samples of cDNA.
• Mix by pipetting, spin briefly if necessary
• Incubate at 37°C for 5 hrs. Gently mix the reaction every hour and spin briefly if 
necessary to remove condensation.
• Proceed to ‘clean-up o f cRNA’ or freeze on dry ice and store at -80°C.
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2.7.7. Clean-Up of cRNA
• Do not touch the membrane o f the spin columns
• Centrifuge at 10,000 rpm.
• The capacity o f the RNeasy™ mini-column is lOOpg. If the expected yield is more 
than lOOpg, split the reaction and use 2 columns
• To the in vitro transcription reactions, add 60pl DEPC-treated water and 350 pi RLT 
buffer.
• Mix by pipetting
• Add 250pl (100%) ethanol.
• Apply to RNeasy™ mini-column, centrifuge for 15 sec.
• Empty collection tube.
• Add 500pl RPE buffer
• Spin at for 15 sec.
• Empty collection tube
• Add 500pl RPE buffer
• Spin for 2 mins
• Transfer spin column to a fresh collection tube
• Spin for 1 min
• Transfer spin column to a new collection tube.
• Elute cRNA by placing 50pl DEPC-treated water on the middle of the membrane and 
leave at room temperature for four minutes.
• Spin for 1 min
• Take the eluate and reapply to the same spin column
• Leave at room temperature for 4 mins
• Spin for 1 min.
• Determine the concentration o f the cRNA spectrophotometrically. Measure the 
absorbance o f an aliquot o f the eluate at 260nm and 280nm. The aliquot must be 
diluted in dLLO (not DEPC treated)
• Ensure the sample is diluted sufficiently to give a reading in the linear range for the 
spectrometer (usually in the range o f 0.1-0.4 absorbance units.) Calculate the
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concentration of RNA given that an A260 reading of 1 is equivalent to 40pg/ml of 
single-stranded RNA.
• The expected yield of cRNA starting from lOpg total RNA is 40jig to 1 lOpg.
• If you have less than 40pg of cRNA per reation then do not use the target as there is 
likely to be a problem with the cRNA preparation.
• The cRNA fragmentation procedure requires the RNA to be at a minimum 
concentration of 0.6pg/pl. if necessary the RNA can be concentrated by ethanol 
precipitation.
2.7.8. Ethanol Precipitation.
•  To the reactions add: 0.5 vols 7.5M ammonium acetate.
2.5 vols cold 100% ethanol
• Vortex to mix thoroughly.
• Precipitate at -20°C for 1 hour or overnight.
•  Centrifuge at full speed for 30 mins at 4°C.
•  Wash the pellet twice with 0.5ml cold 80% ethanol
• Air dry the pellet and resuspend in an appropriate volume of DEPC-treated water.
2.7.9. cRNA Fragmentation.
• Fragment 25pg of cRNA (20pg are needed for hybridisation and l-2pg for 
visualisation on a gel.)
• Do not change the ratio o f cRNA: fragmentation buffer.
• Prepare a mastermix; Xpl cRNA (25pg)
Ypl DEPC-treated water 
lOpl (5x) fragmentation buffer
= 50pl total.
• Incubate at 94°C in a heating block for EXACTLY 35 minutes
• Put tubes on ice.
• Run samples on a denaturing formaldehyde gel to check quality
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• Store at -80°C until hybridisation.
2.8. RNA Gel.
• Add 2.5g agarose to 150ml DEPC-treated water. Boil and cool.
• Work in a fume cupboard.
• Add; 6|il ethidium bromide
17.5mls lOx MOPS 
5mls (37%) formaldehyde
• mix well and allow to cool and set.
• Age the gel in lx  MOPS overnight, or for at least !4 hour.
2.8.1. Loading the Gel.
• Place lOpg RNA in a clean RNase-free tube and make up to 20pl with lx RNA 
loading buffer.
• Denature at 65°C for 15 mins.
•  Cool on ice.
• Load from ice, run alongside RNA markers, (Sigma) at lOOv for 1-2 hours. 
Photograph frequently as the ethidium bromide does not intercalate into fragmented 
cRNA with high efficiency.
2.8.2. lOx MOPS.
• lOx MOPS (makes 11)
41.8g MOPS (free acid, Sigma) 
pH to 7 with NaOH 
Add 16.6ml 3M NaOAc 
Add 20ml 0.5ml EDTA (pH8)
Make up to 11 with distilled water
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Autoclave.
2.8.3. C hecking the RNA Quality.
Ladder.
cRNA Fragmented
• 0.5-1 fig total RNA should show 2 bands with the upper band at roughly twice the
intensity o f the lower band.
• 500ng-1 pg cRNA should show a smear from 100bp-2kb with a brighter region from 
500bp-lkb.
• l-2pg cRNA should show a smear from 35bp-200bp.
• It is important to photograph the gel several times whilst it is running, as the fragmented 
cRNA does not intercalate ethidium bromide at the same efficiency as total RNA.
2.9. RNA extraction and preparation for RT-PCR
2.9.1. Obtaining RNA from Tissue Samples.
• Dissect out the tissue of interest to a maximum thickness in one direction of 5mm. 
(For the intestinal MeCP2 array, the very top 3cm of the proximal small intestine was 
used.)
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• Transfer immediately to cold RNA later™ (Sigma cat no. R0901) to inactivate 
endogenous RNase activity.
• Tissue stored in RNA later™ can keep for 1 day at 37°C, 1 week at 25°C, 1 month at 
4°C and can be archived indefinitely at -20°C.
To process the tissue:
• Pour off the RNA later™ and note the wet weight of the tissue.
• Add 1ml cold Trizol reagent (Gibco cat no. 15596-018) per lOOmg tissue.
• Homogenise the tissue.
• Clean the homogeniser before first use, between each use and after final use with a 15
second pulse in 5ml 4M NaOH followed by a 15 second pulse in 5ml H20 for 15 sec,
then a 15 second pulse in 5 ml 75% ethanol (all solutions made with nuclease-free 
water)
• Aliquot 1 ml samples into clean, labelled RNase-free centrifuge tubes. Keep on ice.
• Centrifuge for 10 mins at max speed in a bench-top centrifuge at 4°C.
• Take off the supernatant (avoid the surface layer o f fat) and transfer to new, labelled, 
sterile RNase-free tubes.
• Add 200pl chloroform, shake for 5-10 mins, then chill for 5-10 mins.
• Centrifuge samples for 15mins at max. speed (bench-top centrifuge at 4°C)
• Carefully remove the top aqueous layer which will contain the RNA and transfer to 
new tubes. Avoid taking material from the interface, which will contain DNA. 
Dispose o f the lower layer in phenol waste.
• To precipitate the RNA, add an equal volume of isopropanol, mix by inversion and 
leave for 10 mins at 4°C. Leaving the tubes for longer may maximise RNA yields.
• Centrifuge samples for 15 mins at max. speed (bench-top centrifuge at 4°C)
• Discard the supernatant and air-dry the pellet for 5-10 mins.
• Resuspend the RNA in lOOpl (or more if needed) nuclease-free water.
• Determine the total yield o f RNA spectrophotometrically. 1 A260 unit = 40pg/ml of 
single-stranded RNA.
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2.10. M aking cDNA from total cellular RNA.
• Make up lpg RNA in 9pl DEPC-treated water
• Heat to 70°C for 10 mins
• Heat to 42°C for 2 mins
• Add: 2pl random hexamer primers
2pl DTT 
4pl buffer 
lpl lOmM dNTPs 
1 pi DEPC-treated H2O.
• Add 1 pi Superscript reverse transcriptase to half the samples, and 1 pi DEPC-treated 
water to the other half.
• Heat to 42°C for 50mins-l hr.
• Heat to 70°C for 15 mins
• Store at -20°C until needed.
• Use 2pl of this cDNA in each PCR reaction.
2.11. Checking for genomic DNA contamination.
Run an Hprt PCR on each sample (+Reverse transcriptase and -  reverse transcriptase.) No 
bands should be seen in the absence of reverse transcriptase. The presence of a band indicates 
genomic DNA contamination and the sample should be re-prepared.
2.12. RT-PCR.
• For quantitative realtime RT-PC, the BioRad SYBR-green system was used.
• Each sample was run in duplicate.
• For each sample, use: 12.5pl SYBRgreen
8.5pl distilled water 
lp l each primer (lpM )
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2|il cDNA
• Place the samples in duplicate into a 96 well plate (or tube strips) and seal with clear optical 
quality caps or sealing film. With each run, run 4 ‘blank’ samples, in which the cDNA is 
replaced with water, to control for contamination.
• Genomic DNA contamination can be controlled for with a single run (to save sample.) A 
single run using p-actin primers on sample with/without reverse transcriptase will control for 
genomic DNA contamination.
2.12.1. RT-PCR primers
Hprt: PI: TGTTGTTGGATATGCCCTTG 
P2: TTGCGCTCATCTTAGGCTT
Glucagon: PI: GATTGCTTATTAATGCTGGTGT 
P2: TCTTCATTCATCTCATCAGGG
Cd44 PI: GTGGCAGAAGAAAAAGCTG 
P2: TTGTTCACCAAATGCACCAT
Mecp2 PI: ACCTCTAACCCTGCCTGGAT 
P2: AGGCCGTGCTAGCAAAGTAA
m46: PI: AGAAGCCACCAGCTAAACTG 
P2: TCCTGACAGCTTGATGCCAA
Gip P I : GCAAGATCCTGAGAGCCAAC 
P2: TTAGCATGGGATCGGAACTC
Pedgf: PI:ACCGTGACCCAGAACTTGAC 
P2:CACGGGTTTGCCAGTAATCT
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Wdnml PI: CGCAGTTTTGGAACTTGTGA 
P2: CAAGCATGGGGTCTGTAGGT
Igfbp3 PI: CAAAGCACAGACACCCAGAA 
P2: CTGCTTTCTGCCTTTGGAAG
IgfbplO PI: AGACCCGGATCTGTGAAGTG 
P2: TTCTGGTCTGCAGAGGTGT
Neuromedin PI: CCGAGGGACCAGAGACTACA 
P2: CATTGTCAGATTCCCTGGAT
P-Actin P I : TACAGCTTCACCACCACAGC 
P2: A AGG AAGGCTGG A A A AG AGC
Ccf-i PI: TATGTTCCAACCGAATGACA 
P2: GAGTCTCCTTTGCAGGCATC
Liprina  PI:TGATGTGGATGAGGATGAGC 
P2: GGTCACACGGGTCTCAATCT
Dlx5 PI: CAGAAGAGTCCCAAGCATCC 
P2: GAGCGCTTTGCCATAAGAAG
Dlx6 P1:CACAGCCCTTACCTCCAGTC 
P2: AGTCTGCTGAAAGCGATGGT
SSc2 PI: GCTCTCGATATGGCTGGGTA 
P2: TACCCGGACATCACCTTCTC
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Chapter 3: Investigating the Role of Mbd4 in the Intestine.
Mbd4 (also known as M edl) is unique in the MBD family in that it appears to play no role in 
transcriptional repression (Bellacosa 2001.) However, it is becoming clear that Mbd4 plays a 
vital role in maintaining genomic fidelity, suppressing tumourigenesis and mediating the 
apoptotic response to DNA damage (Sansom et al 2003a. Millar et al)
3.1. Apoptosis and the response to DNA damage.
DNA damage is caused by a wide variety o f agents, from environmental carcinogens such as 
PAHs in tobacco smoke (De Marini et al 2004) to endogenous damage caused by by-products of 
metabolism (Evans et al 2004.) Since damage to DNA would otherwise lead to damaging 
mutations, a number of mechanisms operate to detect and repair damage, such as base excision 
repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR) (Christmann et al
2003.)
Mbd4, a member o f the methyl CpG binding domain family, is involved in protecting DNA 
by acting as a G»T and G«U mismatch specific thymine or uracil glycolsylase (Bellacosa 2001, 
Petronzelli 2000.) Furthermore, Mbd4 acts preferentially on these mismatches when they are 
present in the context of methylated or unmethylated CpG sites (Bellacosa 2001, Petronzelli 
2000.) The CpG dinucleotide is hypermutable, with G»T and G»U mismatches being formed by 
the hydrolytic deamination of 5 methyl-cytosine and cytosine to thymine and uracil. These 
deamination events are frequent, occurring at a rate o f 2-300 per cell per day and if left 
unrepaired would form G*C and A«T transition mutations at the next round of DNA replication 
(Bellacosa 2001, Petronzelli 2000.) By preventing these mutations, Mbd4 may act as a caretaker
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of genomic fidelity at hypermutable CpG sites (Bellacosa et al 2001.) Such mutations are known 
to contribute to tumourigenesis; nearly 50% of somatic P53 mutations in colorectal cancers arise 
at ‘hotspots’ where cytosines in CpGs are deaminated to form transition mutations (Bellacosa 
2001, Petronzelli 2000.) Loss of functional Mbd4 may accelerate the formation of transition 
mutations and therefore Mbd4 can be considered to have tumour suppressor activity.
Mbd4 may also have a role in the MMR pathway of DNA repair. Having found that Mbd4 
interacted with Mlhl (a MutL homologue) in yeast 2-hybrid screens, Bellacosa proposed that 
Mbd4 is part of a multimeric protein complex involved in mismatch repair (Bellacosa 2001.) 
Initial characterisation o f Mbd4 supported this hypothesis. The protein is composed of three 
domains; an N-terminal methyl binding domain (MBD) a central region and a C-terminal 
catalytic domain with homology to bacterial DNA damage specific base excision repair 
glycoslyases / lyases (Bellacosa 2001, Petronzelli 2000.) During the major pathway of post- 
replicative MMR, Mlhl and Pms2 form heterodimers which interact with Msh2/Msh6 
heterodimers bound to mismatched bases (Jiricny et al 1998, Buermeyer et al 1999.) Mbd4 was 
found to interact with Mlhl (Bellacosa 2001) and also with Msh2 -  components o f the 
mammalian mismatch repair (MMR) system, in yeast 2-hybrid screens, prompting speculation 
that it may itself be a part of the MMR machinery. However, other co-immuoprecipitation-based 
studies have shown that Mbd4 does not interact with Msh6 or Pms2, which argues that Mbd4 is 
not part of the MMR machinery as it is currently understood (Sansom et al 2003b.)
3.1.1. Mismatch Repair
The mismatch repair system helps to maintain genomic stability by repairing insertion and 
deletion loops (IDLs), mismatched base pairs and heteroduplexes that can form during DNA
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replication and recombination (Jacob and Praz 2002.) Although the bacterial MMR system is 
well characterised, less is known about how MMR works in mammalian systems (Jacob and 
Praz 2002, Hart et al 2002.) In bacterial MMR (see fig 3.1) the MutS protein detects the 
mismatch and interacts with MutL, activating MutH, a single-strand endonuclease. MutH can 
recognise the newly synthesised strand that carries the mismatched base, due to the transient lack 
of methylation on the adenines of the palindromic sequence GATC (Jacob and Praz 2002.) Since 
both bases in the mismatch appear ‘wrong’ the lack of methylation marks the strand on which 
the endonuclease should act (Jacob and Praz 2002.) The endonuclease then excises a stretch of 
DNA up to l-2kb in length from between the hemi-methylated GATC sites. The tract is then 
resynthesised correctly by DNA Pol III and ligated by DNA ligase (Jacob and Praz 2002.)
Most of the key MMR components are highly conserved from prokaryotes to mammals and 
homologues have been found for most o f the bacterial genes involved (Jacob and Praz 2002.) 
However, to date, no mammalian MutH homologues have been found, and the methylation 
recognition system must be subtly different since mammalian DNA is methylated on cytosines 
in CpG dinucleotides, not adenines in GATC sequences (Jacob and Praz 2002.) Four 
homologues of MutL (Mlhl-Mlh3 and Pm sl) have been identified in yeast and mammals along 
with six homologues of MutS (Mshl-Msh6) in yeast and five in mammals, which have no Mshl 
(Jacob and Praz 2002.) Msh2 can form heterodimers with Msh6 (to form a MutSa complex) or 
with MSH3 to form a MutSp complex. The MutSa and MutSp complexes recognise the 
mismatch (Jacob and Praz 2002.)
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Fie 3.1. Mismatch repair.
From Jacob and Praz 2002.)
MutSa MutSp
a r " A
Mismatch
m t  \h h f»
MutL
MutH
= < x >
=00=
M u tH
=06=
Base m ispairor Ibp IDL l-4bp IDL
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Av'rV
i Incision by MutH
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Mshl ^  1 ^ -----------  I MshI
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\ Excision by ExoJ, RecJ.ExoVII, ExoX \E xcision, resynthesis and ligation
Resynthesis and ligation, 
^  Pot III. Iigase
—
A. In prokaryotic MMR. MutS detects the mismatch and interacts with MutL, activating MutH, a single-strand 
endonuclease. MutH can recognise the newly synthesised strand that carries the mismatched base, due to the 
transient lack o f methylation on the adenines o f  the palindromic sequence GATC. The unmethylated strand is 
acted upon. The endonuclease then excises a stretch o f  DNA up to l-2kb in length from betn>een the hemi- 
methylated GA TC sites and the tract is then resynthesised correctly by DNA Pot III and ligated by DNA Iigase 
(Jacob and Praz 2002.)
B. Several MutL homologue activities are present in eukaryotes, but the major mismatch repair activity is a 
heterodimer o f Mlhl and PmsI (MutLa) which interacts with MutSa and MutS/3. Once bound, the MutL a  
complex can interact with other factors to form  a complex involved in the processing o f the mismatch. In 
eukaryotes, MutSa (Msh2/Msh6) recognises base-base mismatches and Ibp IDLs and MutS/3 (Msh2/Msh3) 
recognises larger IDLs. Both then recruit Pms2/Mlhl. Later steps are less well characterised but may involve 
recruitment o f Exol (a 3 '-5' exonuclease) and Pena to excise, resynthesised and ligate the repair (Jacob and Praz 
2002.)
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3.1.2. Defective M M R and hum an disease.
HNPCC (Hereditary non-polyposis colorectal cancer) is thought to account for 2-4% of the 
colorectal cancer burden of the western world and results from a defective mismatch repair 
system (Jacob and Praz 2002.) HNPCC tumours are therefore characterised by microsatellite 
instability (Jacob and Praz 2002.) It is believed that mutations in the mismatch repair genes 
MSH2, PMS2, and MLH1 account for the majority of cases (Jacob and Praz 2002.) HNPCC 
accelerates tumour progression; benign adenomas form at the same rate as in the unaffected 
population, but once formed, the MMR deficiency causes mutations to accumulate at a much 
higher rate (Kinzler and Vogelstein 1996) causing progression to malignancy to accelerate (Jacob 
and Praz 2002.)
Many sporadic colorectal tumours and those arising in HNPCC patients are characterised by 
MSI (microsatellite instability) and are unable to repair slippage-induced insertion/deletion loops 
(IDLs) at simple repetitive sequences (Riccio et al 1999.) Bellacosa et al showed that the MBD4 
gene contains 4 such sequences (Riccio et al 1999, Bellacosa 2001.) MBD4 mutations have been 
detected in approximately 20-25% of human colorectal and gastric carcinomas (Bader et al 
1999.) Virtually all of these mutations were in a poly(A)(io> tract in the central portion of the 
gene, resulting in frameshifts which produce a truncated protein with no C-terminal domain and 
no catalytic ability (Bader et al 1999.) This suggests that MBD4 is a tumour suppressor, albeit 
perhaps not a major suppressor, in the human intestine. Interestingly, no studies have yet looked 
at possible epigenetic inactivations of MBD4 in human colorectal cancers.
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If Mbd4 is indeed such an important part of the DNA repair machinery, it would be expected 
that loss of Mbd4 would accelerate tumourigenesis. Mbd4 null mice have been generated and 
crossed to mice carrying the ApcMm mutation, which predisposes to multiple intestinal neoplasia 
(Sansom et al 2003a.) Mbd4''ApcM,n/+ mice showed a significant increase in intestinal tumour 
burden when compared with their Mbd4+/VApc M,n/+ littermates, further reinforcing the status of 
Mbd4 as a tumour suppressor gene (Sansom et al 2003a.)
Because Mbd4 plays a role in DNA repair, it might be possible that Mbd4 deficiency would 
lead to an increase in mutation rates. Sansom et al found no increase in mutation rates in 
Mbd4'/' mice using the Dlb-1 assay (Monroe et al 1995); however, using the BigBlue® assay 
(Millar et al 2002) a small but significant increase in mutation was noted (The Dlb-1 assay can 
be used to score mutation rates in the intestinal crypts (Millar et al 2002) while the BigBlue® 
reporter locus, c/7, is highly methylated and would respond to an increase in C->T transitions.)
Although the negative Dlbl result might at first argue that loss of Mbd4 does not increase the 
mutation rate, it is not a highly sensitive assay, and the increased rate of C-^T transitions along 
with the significantly increased tumour burden of the ApcMm/Mbd4'/' mouse equates to an 
increase in mutation as it represents a shift in the mutation type to a deamination-like event. Loss 
of Mbd4 activity may not greatly compromise cell viability, as mice possess another thymine 
glycosylase activity, Tdg which may partially compensate for its loss (Nedderman et al 1996.)
Mbd4 can also act to remove 5-Fluorouracil (5-FU) mismatches in the context of G*5-FU 
mismatches (Sansom et al 2003a.) 5-FU is a uracil analogue used as a chemotheraputic agent. 
This raises the possibility that Mbd4 may be involved in tumour resistance to 5-FU therapy 
(Sansom et al 2003a.)
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3.1.3. Mbd4 and Apoptosis.
The possible involvement of Mbd4 in the MMR system of DNA repair suggests a role in the 
signalling of apoptosis. Data presented by Sansom et al points to a role for Mbd4 in the 
mediation of the apoptotic response (Sansom et al 2003a.) Mbd4''' mice showed a significantly 
reduced apoptotic response after treatment with cisplatin, ionising radiation or the alkylating 
agent temozolamide, all o f which induce apoptosis in the intestinal epithelium via DNA damage 
(Sansom et al 2003a.) RNA damaging agents such as 5-FU (5-flurouracil), did not cause a 
differential response, implying that Mbd4 is needed to signal or mediate the apoptotic response 
following DNA damage but not the response to RNA damage (Sansom et al 2003a.)
Following on from this observation, this project will assess the response of Mbd4 deficient 
{Mbd4~'') mice to Fas ligand, which can trigger an apoptotic response via a cell-surface receptor, 
and the role of Mbd4 in anoikis (apoptosis driven by loss of cellular attachment.)
3.1.4. Apoptosis and anoikis.
Apoptosis is a regulated, programmed process that results in cellular ‘suicide’ (Brown and 
Attardi 2005.) Unlike necrosis, where the cell essentially ‘bursts’ and releases its contents into 
the surrounding tissue, an apoptotic cell is broken down in a highly regulated series of stages 
and is finally engulfed by other cells types (Brown and Attardi 2005.) Apoptosis plays a central 
role in growth and development; for example, in the developing human embryo, cells between 
the nascent fingers undergo apoptotic death to shape the embryonic hand (Hardy 1999.) 
Apoptotic death also serves to remove damaged cells which may otherwise carry dangerous 
genetic lesions (Brown and Attardi 2005.) Apoptosis is triggered by a variety o f cues, such as
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DNA damage, growth factor withdrawal or detachment from the matrix (Brown and Attardi 
2005.) The process of apoptosis is carried out via two central pathways; one which involves the 
activation of caspases and a second, mitochondrial pathway (Brown and Attardi 2005.) One 
such pathway, mediated by the death receptor, Fas, is shown in fig 3.2.)
One hallmark o f the cancer cell is reduced sensitivity to apoptotic signals, which increases 
their ability to proliferate uncontrollably. Loss o f sensitivity can be caused by mutations in 
genes encoding members of the apoptotic machinery, or by loss or mutations of proteins such 
as the cellular sentinel P53, which normally transduces cellular stress signals into growth arrest 
or apoptosis. Since the conditions encountered in a typical tumour (hypoxia etc ) are precisely 
those which would normally trigger apoptosis, a tumour may have higher rates of apoptosis 
than surrounding normal tissue, but it may also select for cells which can survive under these 
conditions (Hanahan and Weinberg 2000.)
3.1.5. Fas-Mediated Apoptosis.
Fas (also known as CD95 or APO-1) is one o f specialised subset of TNF receptors known as 
‘death receptors’ (Nagata 1999.) Interaction of Fas ligand (FasL) with its receptor induces 
apoptosis in Fas-bearing cells (Fig 3.2.) Upon ligand binding, the receptor trimerises (Nagata
1999.) The cytoplasmic regions o f the receptors contain ‘death domains’; trimerisation of the 
death domains recruits FADD, and adaptor molecule, to form the death-inducing signalling 
complex (DISC) (Nagata 1999.) FADD then recruits caspase 8, which auto activates and triggers 
a caspase cascade (Nagata 1999.) Caspases are the effectors of the apoptotic pathway and cleave 
a number o f cellular substrates leading to the functional and morphological consequences of 
apoptosis (Nagata 1999.)
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Fie 2.2. Apoptosis Triggered throush the Fas Receptor Pathway.
Adapted from Algeciras-Schimich et al 2002 and Joza et al 2002.)
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Caspase 3
□ □
CAD Caspase 9
ICAD
DNA cleavage, 
proteolysis o f  
lam inins, PAR P  
etc.
Fie 3.2. Fas-mediated apoptosis.
Interaction o f Fas ligand (FasL) with its receptor induces apoptosis in FasL-bearing cells. Upon ligand binding, 
the receptor trimerises. The cytoplasmic ‘death ’ domains trimerise and recruit FADD, anadaptor molecule, to 
form the death-inducing signalling complex (DISC.) FADD then recruits caspase 8, which auto-activates to trigger 
a caspase cascade that leads to apoptosis
3.1.6. Anoikis.
Since the default state of the cell is, effectively, apoptotic death, in a normal tissue, cells 
require a constant input of survival signals to remain alive. These signals can be both 
chemical (e.g. growth factors) and physical (attachment signals) (Hanahan and Weinberg
2000.) Cell death caused by loss o f attachment is called ‘anoikis’, from the Greek for ‘falling
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o ff  (Valentijn et al 2004.) Correct attachment signals ensure that the cell is in its proper 
place within the tissue microenvironment (Valentijn et al 2004.) One hallmark of a typical 
cancer cell is the loss of this requirement for positional information - this allows cells to 
escape their normal environment and spread (metastasise) throughout the body, hence anoikis 
is extremely relevant to the study of colorectal cancer (Hanahan and Weinberg 2000.)
In the intestine, epithelial cells form a layer overlying the endothelial ‘scaffold’ which 
supports the villus structures (Potten et al 1997.) There is considerable cross-talk between all 
elements o f the system to ensure correct positioning and migration of cells up the crypt-villus 
axis and to ensure that cells are removed from the system at the tips of the villi and shed into 
the lumen. The mechanisms underlying this communication are still unclear (Potten et al 
1997.)
The major mediators of the attachment-dependent survival signals are the integrins. 
Integrins are transmembrane cell surface receptors which are composed of heterodimers of 
various combinations of a  and p chains (Valentijn et al 2004.) At least 22 a /p  combinations 
are known, giving a large and diverse family of molecules which are capable of binding 
various different components of the extracellular matrix (ECM.) Since each component of 
the ECM is also capable of binding different integrins, the mechanisms of attachment and 
signalling are complex and not fully understood (Valentijn et al 2004.)
It has recently been shown that the Fas-mediated apoptotic pathway plays a role in 
triggering anoikis (Valentijn et al 2004, Grossman 2002.) It is thought that changes in cell 
shape caused by detachment may bring the Fas receptors into close enough proximity to 
trimerise and trigger the pathway (Valentijn et al 2004, Grossman 2002.) However, since 
cells can be rescued by addition of soluble matrix components, this may not be the major 
route o f Fas-mediated anoikis (Valentijn et al 2004.) Another theory is that detachment
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triggers upregulation o f components o f the Fas pathway; detatched endothelial cells have 
been shown to produce a 3-fold upregulation o f Fas receptor, a 1.5 fold upregulation of Fas 
ligand and a massive downregulation o f FLICE, an inhibitor of the pathway (Valentijn et al
2004.)
This project assesses the role o f Mbd4 in anoikis by examining how quickly wildtype 
Mbd4*l+ and Mbd4'~ null isolated intestinal epithelial crypts undergo detachment-mediated 
death. This project also assess the requirement for Mbd4 in the apoptotic response of the 
small and large intestine and the liver, by challenging mice with wild type or a null allele of 
Mbd4 with the pro-apoptotic Jo-2 Anti-Fas antibody, which acts in a similar manner to Fas 
ligand (FasL) and triggers the Fas-mediated apoptotic death pathway.
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3.2. Results
3.2.1. Mbd4 influences anoikis in isolated murine small intestinal crypts.
Anoikis is the term given to programmed cell death induced by a loss of detachment signals 
(Valentijn 2004.) Mbd4 has been shown to modulate the anoikis response to cell detachment 
(Screaton et al 2003.) Fadd is also reported to be localised to the nucleus in adherent cells lines 
(Screaton et al 2003) and adherence is seen to protect to some degree against Fas-ligand 
induced cell death. Taken together, these results imply a role for Mbd4 and Fadd in the 
modulation o f the anoikis response to cell detachment.
I first wanted to determine whether it was possible to isolate small intestinal crypts from 
the murine small intestine, to define the process of death occurring in wild-type crypt 
populations. Isolated small intestinal crypts were derived from wild-type mice and then 
observed at 0,1,2 and 3 hours from the time o f isolation. Once taken out of the in vivo 
environment, crypts are deprived of the normal attachment and survival signals they receive 
and, as would be expected, gradually undergo a mixture of apoptotic (stress-induced) and 
apoptotic (anoikis-induced) death.
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Fis 3.3. Anoikis in Isolated Murine Small Intestinal Crypts.
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Fis 3.3. Anoikis in isolated murine small intestinal crypts.
A.) Isolated crypts on a background of single-cell debris. B) Arrow = Apoptosis/anoikis occurring in a crypt 
cell C.) Cells are extruded from intact crypts, then undergo apoptosis/anoikis. D.) At 2 hours, many crypts 
are still intact. E.) By 3hours, most crypt structures have gone, leaving only single-cell debris. F.) Even at 3 
hours some cells remain viable and cel! division can still be seen occurring in the intact crypt.
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H&E stained section visually; an apoptotic cell is rounded, and tends to stain more pin 
its surrounding cells (fig 3.3b.) The chromatin in the nucleus is condensed and darkly 
while the membrane may be ‘blebbing.’
In contrast to the short-lived single-cell debris, those cells enclosed in crypt si 
survived a number o f hours. Even at 3 hours, cells were seen undergoing mitosis ( 
arrow) implying that they were still viable. Cell which did undergo apoptosis withir 
structure often appeared to be ‘squeezed out’ o f  the crypt (fig 3.3c arrow), althoi 
possible that this could also be a sign o f  membrane blebbing.
Given the ability to isolate murine small intestinal crypts, I next wanted to dc 
whether the presence or absence o f  Mbd4 would affect the rate o f anoikis in this assc 
matched 3 month old male and female Mbd4+/+ and Mbd4~f~ outbred mice segregating 1 
and C57/B16 genomes were culled and crypt preparations made from the small intestine 
crypt populations were examined at 0, 1 ,2  and 3 hours post-isolation for apoptosis. Re 
shown in fig 3.4.
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Fig 3.4. Loss o/r M bd4 reduces anoikis in isolated small intestinal crypts
100
Mbd4
Mbd4
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Time.
Fig 3.4. Loss o f  Mbd4 results in reduced anoikis in isolated murine small intestinal crypts.
At 2 and 3 hours, Mbd4" crypts undergo significantly less anoikis than Mbd4 /+ crypts (p= <0.005.) The 
difference is largest at 2 hours, when around 25% o f  Mbd4 " crypts have died compared to over 90% o f Mbd4+/+ 
crypts (p=0.0404.)
Fig 3.4 shows the differences in anoikis between the Mbd4+M and Mbd4'A crypts. At 0 and 1 
hours, no significant difference in the number of apoptotic cells is seen. At 2 hours, however, 
25% of cells in Mbd4 A crypts have died compared to over 90% of cells in Mbd4+/+ crypts, a 
significant difference (p=<0.005.) By 3 hours, the difference is still significant (p=0.0404) , 
although the difference is much smaller, with around 82% of cells in Mbd4'/' crypts having 
died compared to over 95% of cells in Mbd4+/+ crypts. This shows that there is a significant 
difference between the rate at which Mbd4'/_ and Mbd4+/+ crypts undergo detachment- 
mediated death, implying a role for Mbd4 in anoikis.
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3.2.2. The role of Mbd4 in Fas-mediated apoptosis.
Having shown that Mbd4 plays a role in detachment-mediated apoptosis (anoikis) I then 
wanted to investigate the possible role of Mbd4 in Fas ligand-mediated apoptosis. To do this, 
the livers, and small and large intestine o f Mbd4~/~ and Mbd4+/+ mice were exposed to Fas 
ligand to induce apoptosis and examined at 3, 6, 9 and 24 hours post exposure.
Age-matched, weight matched 3 month old male and female Mbd4'f' and Mbd4+/+ outbred 
mice segregating for S I29 and C57/B16 genomes were given a single injection of lOpg Anti- 
jo2  antibody, which mimics the action o f Fas ligand and left for 3, 6, 9 or 24 hours before 
being culled (n= 3 per timepoint.) Tissues were prepared and stained with H&E. Apoptosis 
was scored as a percentage o f cells in the liver and as the number of apoptotic cells per 50 half 
crypts. Results are shown in figs 3.5, 3.6 and 3.7.
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Fis 3.5. Apoptosis in the Small Intestine ofM b64-deficient Mice - 10 us Fas lisand.
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Fis 3.5. Apoptosis in the small intestine at 3, 6, 9 and 24 hours after administration o f Jo-2 anti-Fas.
Apoptosis peaks' at around 6 hours and there is a significant difference in levels of apoptosis between 
wild-type and Mbd4 deficient mice at the 6 hour time point (Mann Whitney 2 tailed test p=0.0048.) No other 
time points show a significant difference in levels o f  apoptosis between the two genotypes.
-  123-
Fig 3.6. Apoptosis is increased in the /arse intestine o f  Mbd4-deficient Mice - 10 us
Fas lisand.
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Fie 3.6. Apoptosis in the laree intestine at 3. 6. 9 and 24 hours after administration o f Jo-2 anti-Fas.
Apoptosis peaks ’ at around 6 hours and there is a significant difference in levels of apoptosis between 
wild-type and Mbd4 deficient mice at the 6 hour time point (Mann Whitney 2 tailed test p=0.0127.) Unlike 
the small intestine, the large intestine does show a small but significant difference at 24 hours (p=0.05)
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Fis 3 .7. Apoptosis in the Liver o f  M bdA-deficient Mice -10 u s  Fas lisand.
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Fis 3 .7. Apoptosis in the liver at 3, 6, 9 and 24 hours after administration o f Jo-2 anti-Fas.
Note how levels o f apoptosis are much higher than in the intestine. Apoptosis 'peaks ’ at around 6 
hours and there is a significant difference in levels o f  apoptosis between wild-type and Mbd4 deficient 
mice at the 6 hour time point (Mann Whitney 2 tailed test p = 0.0543.) No difference is observed at any 
other time point.
Figs 3.5, 3.6 and 3.7 show an increased apoptotic response in Mbd4' ~ mice compared to 
wild-type (Mbd4w+) mice following Fas ligand administration. Note how the shape of the 
response curve is identical in all three tissues tested (small and large intestine and liver) with 
a peak in apoptosis occurring at the six hour time point in all tissues. The difference in
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apoptosis at the six-hour time point is significant in all tissues (Mann-Whitney 2-tailed test, 
n=6, p=0.0048 (small intestine), p=0.0217 (large intestine) p=0.0543 (liver)) No other 
significant differences were found at the 3, 9 or 24-hour time points except in the large 
intestine, where a small but significant difference was seen (p=0.048.)
The similar shape o f the response curves shows that the timing of the response is similar in 
various tissues; what does differ is the scale o f the response in different tissues. In the small 
intestine, for example, the apoptotic index peaks at around 0.6 events per crypt (13.2% of 
crypt cells), whereas the response in the liver is more extreme, peaking at over 60% of cells. 
This had differing effects on the structural integrity of the tissues involved. The six-hour 
peak in the intestine had no discernible effect on the integrity of the gut, (i.e although 
apoptosis was present, no gross change in tissue architecture was seen) whereas the livers 
examined at the six and 24- hour time points showed reduced cell number and obvious 
widespread tissue damage.
The Fas ligand may be absorbed and reach the liver more efficiently than the gut, (so the 
liver is more affected by the fas-mediated apoptosis, and may also metabolise much of the 
Fas ligand, meaning that less is available to reach the intestine), or hepatocytes may be more 
susceptible to fas ligand-induced apoptosis than enterocytes.
From the above data, it can therefore be concluded that Mbd4 deficient mice have an 
increased apoptotic response to Fas when com pared with wild-type mice across a range 
of different tissue types.
3.2.3. Investigating the interaction between M lh l and Mbd4.
Since Mbd4 and Mlhl are known to interact, the effect of Mlhl on apoptosis and mitosis in 
the small intestinal crypt and the liver was examined. Fas ligand induces extensive apoptosis
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in both intestine and liver and so a range o f doses were used in an intital attempt to determine 
a dose which would allow accurate measurement of apoptosis and mitosis with minimal tissue 
damage.
Age-matched, weight matched 3 month-old M lh rf~ and M lhl+/+ mice were given 5pg, 8pg or 
lOpg o f anti-jo2 Fas ligand as an intraperitoneal injection and left for 6 hours (as the previous 
study showed that the maximal apoptotic response occurs at 6 hours) At 6 hours, animals were 
sacrificed, and their small intestines removed and prepared for H&E sections as previously 
described. Apoptosis and mitosis were scored visually. Results are shown in fig 3.8.
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F/g 3.8. Dose curve; small intestinal apoptosis for 5u2. 8uz and lOuz Fas lisand at 6 hours.
a.
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Fis 3.8. Dose curve o f apoptosis at different levels o f  Fas administration in M lhl and M lhl'' mice.
A T 5 fug Fas ligand, almost no apoptosis is seen, whereas at 10fig, tissue damage swaps the apoptotic 
signal. A significant difference in apoptosis between Mlhl * and M lh l" mice is seen at 8fig for 6 hours, ( 
p 0 038 Mann-Whitney) with loss o f  Mlh 1 causing a lowered apoptotic response to Fas ligand.
Fig 3.8 shows the apoptotic response at varying doses of Fas ligand. At the 5pg dose, 
almost no apoptotic response was observed, making this dose too low for useful apoptotic 
index studies. At lOjig, tissue damage swamped the apoptotic response (the apparent low 
numbers o f apoptoses observed in fig 3.8 at 10p.g is due to the large amount of tissue 
damage reducing cell number to an extent where apoptosis is not seen.) Since the 8pg 
dose produced a significant difference in apoptosis between the genotypes (p= 0.038 
Mann-Whitney) without causing tissue damage, the dose of 8pg Fas ligand was used in
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the subsequent experiment. A dose o f lOpg Fas ligand had been used in the previous 
experiment (on M b d f  mice) but the M lh lw+ and Mlhl ' mice appear to be unusually 
sensitive to Fas ligand, possibly due to differences in strain background between 
colonies.
I next wanted to explore the possible interaction between Mlhl status and apoptotic 
response, to determine whether Mlhl could influence apoptosis. 3 month-old age 
matched, weight matched male and female Mlhl* ' and M lhl"  mice (n=6) were given 
one injection of 8pg anti-jo2 Fas antibody and left for 3 or 6 hours. After 3 or 6 hours, 
animals were sacrificed and small intestines were removed and prepared as H&E stained 
sections as previously described. Apoptosis and mitosis were scored visually. Results are 
shown in fig 3.9.
Fis 3.9. Loss ofM lh 1 reduces the apoptotic response to Fas.
3 Hr 6 Hr
l ime
Fie 3.9. Loss o f  Mlh 1 reduces the apoptotic response to Fas at 6 hours.
At 6 hours, a significantly lower apoptotic response to Fas is seen in Mlhl" cells (p=0.0187 Mann- 
Whitney.) At 3 hours, a small but significant difference (p=0.0I9 Mann-Whitney) is seen.
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Fig 3.9 shows the lowered apoptotic response of M lhl'' cells to Fas ligand, scored as the 
number of apoptotic cells per crypt. A significant difference in apoptosis was seen at 6 
hours. This difference is significant (p=0.0187 Mann-Whitney) and large (approximately 
3-fold.) A smaller but still significant (p=0.0190) difference is seen at 3 hours.
Since Mlhl had affected the apoptotic response to Fas ligand, the mitotic response to 
Fas ligand was investigated using the same samples as the apoptosis experiment. Mitosis 
was scored visually as the number of mitotic figures per crypt. Results are shown in fig 
3.10 below.
Fie 3.10. Loss o f  M lhl increases the mitotic response to Fas lieand.
Fie 3.10. Loss o f  Mlh 1 increases the mitotic response to Fas lieand.
Loss o f  Mlh 1 leads to a significant difference in mitosis in response to Fas at both 3 hours (p= 0.0259) 
and 6 hours (p= 0.0304 Mann-Whitney.)
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Mlhl''' mice were found to have an increased mitotic response to Fas at both 3 and 6 
hours. Both the increases were significant (3 hours, p=0.05, 6 hours p=0.018.) The loss of 
Mlhl in the murine small intestine therefore, leads to a greater mitotic response to Fas, 
but a smaller apoptotic response. This implies that MLH1 is involved in both cell 
proliferation and apoptosis signalling.
Since the loss of Mbd4 increased the amount o f apoptosis seen in both the intestine and 
the liver at 6 hours after Fas ligand administration, I next wanted to determine whether 
the different (lower) apoptotic response to Fas ligand in the absence of Mlh2 was also 
seen in the liver. Liver samples were taken from the same mice as the Mlh 1/Fas ligand 
intestinal experiment and stained with H&E. Apoptosis was scored visually as a 
percentage of cells in the liver undergoing apoptosis. Results are shown in fig 3.11.
Fig 3.11. 8 ue  Fas induces extensive liver apoptosis at 6 hours.
Fig 3.11. 8fig Fas induces extensive apoptosis in the liver at 6 hours, but there is no difference between 
Mlhl' and Mlhl mice (p=0.885 Mann-Whitney.)
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Fas ligand did induce apoptosis in M lhl'A and M lh l+/+ mice, with lower levels being seen 
at 3 hours and higher levels at 6 hours. However, no difference was seen between genotypes 
(p=0.885 Mann-Whitney) and there was a high degree of variability within the sample. This 
could be due to background effects of the outbred colony.
3.2.4. Characterising the apoptotic response in Mbd4/Mlhl double null mice.
The above results indicate that both Mbd4 and Mlhl are mediating the apoptotic response 
to Fas ligand in the intestine. Therefore, in order to test if these genetic elements exist in the 
same pathway, the phenotype o f mice deficient for both Mlhl and Mbd4 was investigated. 
Examining the apoptotic response to Fas in mice doubly null for Mbd4 and Mlhl would be 
highly informative. It would be expected that the double null mouse would have an increased 
apoptotic response to Fas ligand, due to loss o f Mlhl and Mbd4 which would leave large 
amounts of free Fadd in the cell. It might also be expected that the lack of Mbd4 would be 
dominant to the Mlhl response.
Age and weight matched doubly null mice {Mlhl v* Mbd4 ~A)  were given 8pg Fas and 
sacrificed after 6 hours. Results are shown in fig 3.12.
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Fis 3.12. M lh l' M b d f f~ mice show hish variability in apoptosis rates: small intestine
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Fig 3.12. Administration o f Fas induces apoptosis in the small intestine. However, no significant 
differences are seen between any o f the genotypes.
Fig 3.12 shows the highly variable response to Fas in Mbd4/Mlhl double null mice. No 
significant differences were seen between any of the genotypes. This may be due to strain 
background effects of the double cross -  each strain was outbred segregating C57/B16 
and S I29 genomes. Repeating and refining this experiment with a more inbred strain 
might eliminate this variation and could lead to greater insight into the interactions 
between Mlhl, Mbd4 and apoptotic signalling.
M lh f  + 
+ Mlhl" 
M lhl+ + 
Mlhl"
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3.3. Discussion.
In this series of experiments, loss of Mbd4 is seen to increase the apoptotic response to Fas 
ligand, whereas loss of Mlhl is seen to decrease the apoptotic response and increase the 
mitotic response to Fas ligand. No investigation of the mitotic response to Mbd4 status was 
undertaken.
Why might lack o f Mbd4 increase the apoptotic response to Fas ligand? Indeed, exactly 
the opposite result would have been predicted from previous studies; Mbd4'A null mice show 
a significantly reduced apoptotic response after treatment with cisplatin, ionising radiation or 
the alkylating agent temozolamide, all o f which induce apoptosis in the intestinal epithelium 
via DNA damage (Sansom et al 2003a.) RNA damaging agents such as 5-FU, did not cause a 
differential response (Sansom et al 2003a) which implies that the reduced apoptotic response 
depends on the mode of damage, i.e. DNA-damaging agents induce an MBD4-dependent 
apoptotic response whereas RNA damaging agents do not (Sansom et al 2003a.) The nature 
of the signal is therefore likely to be an important determinant of the response; DNA damage 
can be viewed as an 'internal' signal, coming from within the cell. Fas ligand, on the other 
hand, is an 'external' signal, originating outside the cell and being transduced in a different 
manner (via the caspase cascade pictured in fig 3.2.)
New evidence from Screaton et al has shown that Fadd is primarily a nuclear protein, and 
is not based in the cytoplasm as previously thought (Screaton et al 2003.) They also show 
that Fadd interacts with Mbd4, suggesting a link between genome surveillance (the primary 
role of Mbd4) and apoptosis (Screaton et al 2003.) This suggests that Mbd4 and Fadd may 
act together to signal apoptosis, perhaps as pictured in fig 3.13.
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Fie 3.13. Putative Mechanism  o/~Fadd/Mbd4 Interaction.
a. Wild Type Cell.
Cell Lives
In a wild-type cell, Mbd4 sequesters 
Fadd in the nucleus, preventing it 
from shuttling to the cytoplasm to 
interact with the Fas receptor.
b. MBD4-Deficient Cell.
Caspase ---------- ► Apoptosis
\ \ \ cascade
In an M bd4-deficient cell, Fadd is allowed 
to shuttle between the nucleus and 
cytoplasm . When Fas ligand interacts 
with the receptor, Fadd can interact with 
the receptor and initiate the caspase 
cascade that triggers apoptosis.
Fie 3.13. A putative mechanism to explain the higher apoptotic response in Mbd4 deficient cells.
Fadd is capable o f shuttling between the nucleus and cytoplasm, and is held in the nucleus by Mbd4. 
Evidence suggests that Mbd4 and Fadd interact (Screaton et al 2003.) When Fas ligand interacts with the 
receptor, a wild type cell is less likely to undergo apoptosis; Fadd is prevented from leaving the nucleus 
and so cannot initiate the apoptotic process. When Mbd4 is removed however, nothing prevents Fadd from  
entering the cytoplasm and interacting with the receptor, hence the caspase cascade is triggered and the 
apoptotic machinery is set in motion.
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This implies that Mbd4 may sequester Fadd in the nucleus until an appropriate signal induces it 
to release Fadd providing further evidence that Md4 plays a role in modulating the apoptotic 
response (Screaton et al 2003.) Evidence suggests that Mbd4 and Fadd interact and that Fadd is 
capable of shuttling between the nucleus and cytoplasm, and is held in the nucleus by Mbd4 
(Screaton et al 2003.) Screaton et al also suggest that a fraction of cellular Fadd is exported from 
the nucleus (possibly by exportin 5) upon activation of the Fas receptor (Screaton et al 2003.) 
The model pictured in fig 3.13. might work as follows: In a wild-type cell, Mbd4 sequesters 
Fadd in the nucleus, preventing it from shuttling to the cytoplasm to interact with the Fas 
receptor. When Fas ligand interacts with the receptor, a wild type cell is less likely to undergo 
apoptosis; Fadd is prevented from leaving the nucleus and so cannot initiate the apoptotic 
process. When Mbd4 is removed however, nothing prevents Fadd from entering the cytoplasm 
and interacting with the receptor, hence the caspase cascade is triggered and the apoptotic 
machinery is set in motion.
The precise role of Mbd4 in apoptosis has still to be determined. In vivo, Mbd4~f~ liver and 
intestinal cells are more sensitive to Fas ligand-induced apoptosis, whereas MEF (Murine 
embryonic fibroblast) cells over expressing Mbd4 were less sensitive to Fas ligand-induced 
apoptosis (Screaton et al 2003.) Isolated small intestinal crypts are also less sensitive to anoikis. 
Perhaps the levels of free Mbd4 are critical to the nature of the response, but the data do show 
unequivocally that Mbd4 influences the apoptotic response.
3.3.1. Interaction between M lhl and Mbd4.
As well as playing a major role in removing common DNA lesions such as 06-MeG, MMR 
also modulates the response to a range of other DNA damaging agents such as 5-FU,
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topoisomerase inhibitors and cisplatin (Sansom et al 2003a, Cortellino et al 2003.) It is thought 
that repeated attempts by Mbd4 to repair a lesion may in some cases trigger a long patch repair 
requiring the MMR machinery, and that this may be recruited via the association of Mlhl with 
Mbd4 (Cortellino et al 2003.)
The interaction between MMR and Mbd4 is still largely unclear; loss of Mbd4 does not 
increase tumour onset, spectrum or MSI in MMR-deficient animals, showing that Mbd4 does 
not affect MMR-dependent tumorigenesis (Sansom et al 2004.) Intruigingly, however, MMR 
proteins have been found to be reduced in Mbd4-deficient cells, and this appears to be a post- 
translational effect; could they be unstable in the absence of Mbd4?
Mlhl has been found to be associated with Fadd (Screaton et al 2003.) Could Mbd4 be 
associated with Fadd and Mlhl in a large multi-protein complex that signals to the apoptotic 
pathway in response to a certain level of DNA damage, or Fas-mediated death? One putative 
model for such an interaction is shown in figure 3.14. If Mbd4, Fadd and Mlhl are 
complexed together, via death domain interaction, there could be competition between the 
three proteins such that they are held together in an unstable triumvirate, with the stability 
and strength of the interactions being determined by Mbd4. In the presence of Mlh 1, the 
Mbd4/Mlhl/Fadd complex is less stable, and there is more free Fadd in the cell. When the 
Fas receptor is activated, this Fadd can bind the receptor and activate the caspase cascade. 
This in turn would create double strand breaks in DNA which would be sensed further down 
the pathway by Mlhl and the cell would undergo apoptosis. In the absence of M lhl, the 
Mbd4/Fadd interaction would be strengthened, and less free Fadd would be available, 
reducing the chances of an activated Fas receptor being able to initiate an apoptotic cascade. 
The cell would be more likely to live.
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The increased apoptosis seen in Mbd4 "  mice implies that the Mlhl/Fadd combination is 
weaker than the whole complex (freeing more Fadd.) Conversely, the decreased apoptosis 
seen in M lh l"  mice implies that the Mbd4/Fadd complex is stronger than the whole complex, 
freeing less Fadd and resulting in lowered levels of apoptosis.
Investigation o f the binding strengths of these proteins in vitro and in vivo could provide 
evidence for or against this model. It would also be informative to use immunohistochemistry 
to attempt to localise Mbd4, Mlhl and Fadd in the cell as it is exposed to the Fas ligand 
signal; it might be expected that the proteins would shuttle in and out of the nucleus in 
response to the signal.
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Fig 3.14. A putative model for the interaction between Fadd, Mbd4 and M lhl in
response to Fas ligand.
A.
Mbd4
B. Mlhl +/+
Activation o f caspase cascade
Apoptosis
Caspases create double 
strand breaks sensed by 
Mlhl
C. Mlhl
Less activation o f caspase cascade
Cell Lives
\ =Fadd o  =Mhd4 O  =Mlhl —activated Fas receptor
Fie J. 14. A putative model for the interaction between Mbd4, M lhl and Fadd in death receptor signalling.
A. Fadd, Mbd4 and Mlhl are known to interact via death domains.
R In the presence of Mlhl, the Mbd4 Mlhl/Fadd complex is less stable, and there is more free Fadd in the cell. 
When the Fas receptor is activated, this Fadd can bind the receptor and activate the caspase cascade. This in 
turn creates double strand breaks in DNA which are sensedfurther down the pathway by Mlhl.
C. In the absence of Mlhl, the FaddMbd4 interaction is more stable. Less free Fadd is present, and so less Fadd 
is available to activate the caspase cascade which leads to apoptosis if  the Fas receptor is stimulated and so cell 
is more likely to survive.
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Chapter 4: Investigating the Role of MeCP2 in the
development and involution of the murine mammary gland,
4.1. Mammary growth and development in the mouse.
The mammary gland is unusual in that although the rudimentary gland is present at 
birth, most of the cellular growth and tissue architecture formation occurs during puberty, 
lactation and pregnancy. This makes the mammary gland an attractive model in which to 
study processes affecting growth and development (Hennighausen and Robertson 1998.)
The murine mammary gland consists of two main tissue components; the parenchyma and 
the stroma (Hennighausen and Robertson 1998.) The stroma is the adipose tissue which 
forms the mammary fat pad and the parenchyma is the network of branching ducts and 
alveoli which grows through the fat pad (Hennighausen and Robertson 1998.)
The primitive mammary gland forms during embryogenesis; in the female mouse, by 
embryonic day 11 (E ll)  Two raised ridges o f tissue (the mammary ridges) are visible on 
either side of the ventral midline (Hennighausen and Robertson 1998.) By day 12, cells 
within the ridges have concentrated to form two rows of five mammary buds (Hennighausen 
and Robertson 1998.) These buds proliferate and grow rapidly just before birth, to form the 
mammary cord, which opens into the nipple externally, and branches into the rudimentary 
gland internally (Hennighausen and Robertson 1998.) so that by birth, several ducts are 
present in the gland (Hennighausen and Robertson 1998) (Fig 4.1.)
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Fig 4.1. Growth and Development o f  the Mouse Mammary Gland.
i. (Adapted from  Henninghausen and Robinson 1998)
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(Taken from  http .//mammary, nih.gov/atlas/wholemounts/normal/index. html)
Fig 4. Li Stages in the development and growth o f the mouse mammary gland, showing the gene products 
required for each stage of development. ER^ oestrogen receptor, PRL=prolactin, PRLR prolactin receptor, 
PR progesterone receptor, CSF-1 = colony stimulating factor I.
Fig 4 I. ii. Wholemount analysis o f mammary gland growth in the mouse. A = newborn, B= 4 week virgin, C -  
6 week virgin, D - 10 week virgin, E = pregnancy day 9, F pregnancy day 16.
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During the first few weeks of life, the gland grows isometrically (i.e. it keeps pace with and 
does not exceed the growth of the animal and the mammary ducts grow and branch slowly 
(Hennighausen and Robinson 1998.) At the leading end of each duct is a structure called the 
terminal end bud (TEB.) TEBs are highly dynamic and proliferative structures and are made 
of up of two cell types; cap cells and body cells (Humphreys et al 1987, Daniel and 
Silberstein 1987.) Cap cells form a thin outer layer and interact with the surrounding stroma 
through a thin basal lamina, and around 6-10 layers of body cells form the interior o f the 
TEB (Humphreys et al 1987, Daniel and Silberstein 1987.) Cap cells are the precursors of 
myoepithelial cells in the mature gland, while body cells give rise to epithelial cell lineages 
(Humphreys et al 1987.)
At around four weeks of age, the mouse enters puberty, and the rate o f growth increases 
markedly, exceeding the rate of growth of the animal. The TEBs drive through the stroma, 
influenced by various growth factors and steroid hormones, principally oestrogen and EGF 
(epidermal growth factor), to create the branching pattern of ducts seen at this stage of 
development (Humphreys et al 1997, Cunha et al 1997.) During puberty, the ductal tree 
continues to grow until it has reached the periphery of the gland, whereupon the TEBs form 
terminal ductal structures with low mitotic activity (Humphreys et al 1987, Daniel and 
Silberstein 1987, Hennighausen and Robinson 1998.)
Between adolescence and pregnancy, the cells of the mammary gland are mitotically 
dormant and undifferentiated (Hennighausen and Robinson 1998.) However, during 
pregnancy, the gland must be remodelled to produce and secrete the milk that nourishes the 
young. To accomplish this, a huge amount of cellular growth is needed. Oestrogen, 
progesterone and other, placental hormones stimulate extensive branching of the ductal tree -  
the mammary epithelium expands to fill the stroma between the ducts and extensive lobulo-
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alveolar proliferation and differentiation occurs (Humphreys et al 1987, Daniel and 
Silberstein 1987, Hennighausen and Robinson 1998.) This proliferation extends into the early 
period of lactation, with about 20% of total mammary growth occurring during this time 
(Hennighausen and Robertson 1998.) When the young mice are weaned, the gland is 
remodelled once again to resemble the virgin-like state, in the process of involution 
(Hennighausen and Robertson 1998.) Various signals, including stasis of the milk in the 
ducts, trigger involution which occurs in two distinct phases; firstly, apoptosis of the 
secretory epithelial cells, then apoptotic degradation of the lobular alveolar structure and the 
mammary basement membrane, accompanied by degradation of the extracellular matrix. The 
epithelium is replaced by adipose tissue and the gland resembles that of a mature virgin 
female. The process of growth, lactation and involution repeats itself for each pregnancy 
(Hennighausen and Robertson 1998.)
The dynamic changes which occur in the mammary gland during development, pregnancy 
and involution are under tight genetic and hormonal control. Disruption of the fine control of 
mammary morphogenesis can manifest itself as alterations in the growth and structure of the 
gland, as well as altering the timing and manner of involution. This project will assess the 
role of MeCP2 in the developing mammary gland and the role of MeCP2 in remodelling the 
gland during involution.
4.2. Methyl Binding Proteins in the Developing Mammary Gland.
Levels of two MBD proteins; MECP2 and MBD2, have been measured in the human 
foetal mammary gland (Billard et al 2002) (see fig 4.2.) Levels of MECP2 RNA were found 
to increase gradually through gestation and reach adult levels at 31 weeks - around the same 
time as mammary morphogenesis is complete (33 weeks.) This suggests that MECP2 may
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play a role in the developing mammary gland (Billard et a l  2002.) Levels of MBD2 mRNA 
rise gradually through foetal mammary development, but remain lower at birth than in the 
adult tissue, which suggests that MBD2 does not play a role in mammary development 
(Billard et a l  2002.)
Fin 4.2. Levels o f  MECP2 and MBD2 RNA in the Developins Human Mammary 
Gland.
From (Billard et al 2002.)
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Fie 4.2. Levels ofMBD2 and MECP2 mRNA during mammary development in the mouse.
Levels o f MECP2 mRNA (brown line) in the mammary gland peak during mammary development, whereas 
levels o f Mbd2 mRNA (pink line) continue to rise after birth into adulthood. This suggests that MECP2, but 
not MBD2, might play a role in mammary growth and development.
4.3. Investigating the role of methyl CpG binding domain proteins in the mammary gland.
In order to investigate the role of MeCP2 in the developing gland, a line of mice carrying 
both a conditional, LoxP-flanked allele of Mecp2 and a mammary-specific Cre recombinase 
were generated by crossing Mecp2/]ox/flo* and Mecp2 wt/wl females onto a mouse line carrying
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the mammary-specific p-lactoglobulin Cre (Blg-Cre (Seibert et al 1998)) to form a line 
carrying various alleles of the two transgenes. Big is expressed during development at a 
lower level (7% Cre mediated deletion) and at a higher level during lactation (70-80% Cre- 
mediated deletion.) (Seibert et al 1998.) This means that the Cre-driven recombination and 
removal of MeCP2 will occur only in the mammary gland at a slightly lower level during 
development and at a high level during lactation. This will allow the analysis of the role of 
MeCP2 in the growth and development o f the murine mammary gland, and, if the mouse is 
mated and gives birth to young, the role of MeCP2 in lactation and involution of the 
mammary gland.
4.3.1. Investigating the role o f MeCP2 in the developing murine mammary gland.
Wholemount analysis of mammary glands from 4, 6, 8 and 10 week old Mecp2 +/+ 
BlgCre+ or M ecp2^ox/^ ox BlgCre+ virgin females were used to investigate the role of MeCP2 
in the developing gland. Carmine red stained wholemounts and H&E stained sections of 6, 8 
and 10 week old Mecp2 flox/flox BlgCre+ and Mecp2 +/+ BlgCre+ glands were examined for 
developmental criteria such as the extent o f penetration of the ductal system through the fat 
pad and the extent of branching of the ductal system. Results are shown in fig 4.3.
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Fis 4.3. Loss o f  Mecp2 does not alter the development o f  the mammary gland at 4
weeks.
Fis 4.3. Loss o f Mecp2 does not affect the srowth o f  the mammary eland.
A and B = Mecp2wi *'Blg-Cre . C and D = Mecp2^ox^ oxBlg-Cre . At 4 weeks o f age there is no visible 
difference between M ecpf^^ B lg-C re and MecpP2wl™Blg-Cre female mammary glands. Both wild type and 
\1ecp2 null glands contain similar epithelial trees with a similar degree of branching (arrows) which have 
extended into the fa t pad.
At 4 weeks o f age, no difference was seen between the mammary development of  
M e c p f^ B lg -C r e  and mice. The extent o f penetration of the epithelial
tree into the fat pad was similar, and no differences were seen in gross morphology (e.g the 
degree o f branching of the tree.)
20mm 20mm
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20mm 20mm
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Fis 4.4. Loss o f  MeCP2 does not alter the mature adult appearance o f  the virgin 
mammary' stand.
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Fin 4.4. Loss of Mecp 2 does not appear to affect the final appearance o f the murine mammary aland.
A,C= Mecp^,<aflox Blg-Cre* , B.D = Mecp2w> wt Blg-Cre' , both virgin glands are composed mainly o f  
adipose tissue, with the epithelial ductal tree running through it. A shows that very rare anomalous 
structures were seen (in two out of three Mecp2flnxflox Blg-Cre" mice.)
The mature adult appearance o f both Mecp2^ox/^ ox Blg-Cre+ and Mecp2w,/wl Blg-Cre+ 
mammary glands was largely similar, being composed mainly o f adipose tissue 
containing a small amount o f epithelial tissue (the epithelial ducts) running through the 
fat pad (fig 4.4d, arrow.) The loss o f MeCP2 does not appear to grossly affect the 
development o f the mammary gland; very occasional areas of slight abnormality were 
seen but these were not present in all mice examined. In the light of this result, no further 
developmental studies were carried out.
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4.4. Investigating the Role of MeCP2 in the Involution of the M amm ary Gland.
Preliminary investigation o f a multiparous Mecp2fIox*1ox Blg-Cre+ female mouse that 
had undergone several rounds o f  pregnancy, lactation and natural involution, appeared to 
imply that involution may be delayed in Mecp2*loxflox BLG-Cre+ females (Fig 4.5.)
Fis 4.5. Preliminary investisation o f  the involution o f  the Mecp2-nul! mammary 
sland.
Fig 4.5. A= multiparous Mecp2 flox flox Blg-Cre ' female mammary gland. 19 days after weaning o f last 
litter.
B Mecp2w> M/ Blg-Cre ' fully-involuted female mammary gland (21 days.) The wiId-type gland is fully 
involuted and mainly consists o f adipose tissue with only small amounts of residual epithelium. By contrast, 
the Mecp2-null gland contains thickened epithelium and milk remaining in the ductal structures (arrows.)
The Mecp2^oxflox Blg-Cre4 gland does not appear to have fully involuted, and still clearly 
showed thickened epithelial ductal structures which contained static milk remaining in the 
duct. The Mecp2wt/wt Blg-Cre+ gland, by contrast, is fully involuted and has remodelled to a
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The Mecp2 flox/flox Blg-Cre+ gland does not appear to have fully involuted, and still clearly 
showed thickened epithelial ductal structures which contained static milk remaining in the 
duct. The Mecp2wt/wl Blg-Cre+ gland, by contrast, is fully involuted and has remodelled to a 
virgin-like state; the majority of the epithelial tissue has been removed, with only small areas 
remaining and with adipose tissue dominating the gland. The apparent perturbation in 
involution implied that MeCP2 could play a role in the involution procees and that the 
apparent mammary phenotype of the Mecp2 flox/^ ox BLG-Cre+ mouse warranted further 
investigation.
In order to investigate the possible role of MeCP2 in the involution of the mammary 
gland, the glands of Mecp2 ^ox/^ ox Blg-Cre+ and Mecp2wt/wt Blg-Cre+ mice were observed at 
21 days post removal of pups. Involution is triggered by the removal of the litter which has 
been suckling normally for 10 days. 21 days is considered to be ‘full involution.’ This allows 
the final outcome of involution to be examined. If any changes were observed, further 
timepoints at 3, 6 and 10 days involution would be added.
3 Mecp2 Blg-Cre+ and 3 Mecp2wt/wt Blg-Cre+ 3 month old age matched female mice, 
segregating for C57/B16 and S I29 genomes were mated to Mecp2^ox/yBLG-Cre+ male mice. 
Male mice were removed from the mating cage when the first signs of pregnancy were 
visible and female mice were allowed to give birth and suckle young naturally for 10 days. 
Ideally, each female should suckle the same number of pups (6-8) and so a number of ‘foster 
mothers’ were used to foster excess pups and to provide pups to mothers whose litters were 
less than 6. After 10 days, the pups were removed from the experimental female to trigger the 
process of involution (pups were transferred to foster mothers for weaning.) Mice were then 
left for 21 days, culled and the mammary glands removed and prepared as H&E stained 
sections for analysis. Results are shown in Fig 4.6.
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Fie 4.6. 21 Day involution; loss o f  Mecp2 does not grossly affect the involution process.
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A.B.C Mecp2fhxfhx Blg-Cre '. D,E,F Mecp2w> wl Blg-Cre' m/ce. //<$£ stained slides show that most of 
the mammary gland has been remodelled in both Mecp2flnxfl,,x Blg-Cre '. D,E,F = Mecp2wl M/ Blg-Cre' mice 
by 21 days after removal ofpups. D.E and F (wild-type) show that most o f the epithelium has been replaced 
by adipose tissue Most Mecp2 deficient glands had the appearance of A, some showed small areas of 
remaining epithelium and milk remaining in the ducts (arrows,C.)
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In both genotypes, the gland had reverted to a virgin-like state, dominated by adipose tissue 
and with only small areas o f epithelium remaining. Very occasional small areas of epithelium 
were observed, but these were at a very low frequency and were observed in 2 o f 3 mice 
examined. Only 2 or 3 areas o f approximately 30-50pm were observed at a frequency of 2-3 
per gland. Although this could represent a mild phenotype occurring a low penetrance in the 
absence o f  Mecp2, the rare nature o f  these areas did not warrant frther investigation.
Fie 4 .7. Some abnormal areas are seen in Mecp2 -J e M m  (MeceiH^lBte-Cre)
mammary elands after 21-days involution.
Ductal structure Ductal structure with static milk Area o f  thickened epithelium
Fie 4 .7. Abnormalities seen in M eeol-deficient (M ecp2J1,,Xjflnx Blg-Cre ) mammary elands.
Very occasional areas o f not fully involuted gland were observed in 2 Mecp2 o^xfb,x Blg-Cre animals. 
However, these areas were not present in all animals and occurred at very low frequency.
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Chapter 5: Characterising the Phenotype of Loss of MeCP2 in 
the Murine Small Intestine,
5.1. MECP2 and R ett syndrom e.
Rett syndrome (OMIM #312750) is a neurodevelopmental disorder which mainly affects 
girls, caused by mutations in the methyl CpG binding protein 2 (MECP2) gene (Amir et al 
1999.) After a short (6-18 months) period o f normal development, patients enter a regressive 
phase, losing acquired speech and motor skills and developing a range of symptoms including 
autistic traits, scoliosis, and characteristic ‘hand wringing’ movements (Neul and Zoghbi 2004.)
The condition is considered to be purely confined to the nervous system and a mouse model 
of Rett (RTT) in which Mecp2 is conditionally deleted in the nervous system produces a 
virtually identical phenotype to a model with a whole body Mecp2 deletion (Chen et al 2001.)
The exact mechanisms whereby loss o f functional MECP2 causes the symptoms of RTT are 
not known, although the bulk o f current research suggests a fault in neuronal maturation, 
patterning and survival (Neul and Zoghbi 2004.) This places the primary mechanism of RTT 
pathology firmly within the CNS; however, patients with RTT can have a wide spectrum of 
symptoms, and frequently present with symptoms which are difficult to explain if RTT is 
exclusively CNS-based, such as bone abnormalities (Leonard et al 1995) and gastrointestinal 
problems (Motil et al 1999.) Despite these studies providing a sound rationale for examining the 
role of MeCP2 in non-nervous tissue, little research on the extra-CNS roles of MeCP2 has been 
carried out.
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5.1.1 Methyl C p G binding proteins and the intestine.
Other methyl CpG binding proteins have been found to have roles in the intestine, in 
modulating the tumourigenic response (Sansom et al 2003a,c, Millar et al 2002.) Loss of the 
methyl CpG binding domain protein, Mbd2 in an intestinal-tumour prone ApcM,n/+ background 
results in a significant reduction in tumour burden and mortality, even though the Mbd2 null 
(.Mbd2’/ ) allele alone does not produce a discernible phenotype in the intestine (Sansom et al 
2003c.) Mbd4 deficiency has been shown to accelerate tumourigenesis on an ApcM,n background 
(Millar et al 2002.) This shows that the MBD proteins have a potential role in the normal 
intestine; mouse models of RTT are available (Guy et al 2001) and this, along with the observed 
gastrointestinal problems seen in RTT patients, provides a further rationale for examining the 
role of MeCP2 in the murine intestine.
5.1.2. The small intestine as a model system; development of the gut.
The small intestine is an ideal model in which to study the growth, development and normal 
turnover of a system as it consists of a number of repeating basic units, the crypt-villus unit, 
which are well characterised and easy to study (Potten et al 1997.) Patterns of tissue 
organisation, cell proliferation, migration and apoptosis are all well-studied, and so if the loss of 
MeCP2 in the gut results in changes to any of these factors, they can be observed and quantified.
The development of the small intestine is also well characterised; the embryonic ectoderm 
forms the lining of the digestive tract and the liver, gall bladder and pancreas (Clatworthy et al 
2001.) These endodermal cells form only the lining of the digestive tube -  the musculature and 
connective tissue that surround it are derived from the lateral plate mesoderm (Clatworthy et al
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2001.) From embryonic day E l4.5 to E l8.5 the murine small intestine develops from a stratified 
epithelium into a simple columnar epithelium, accompanied by the formation of nascent villi in a 
proximal to distal progression (Clatworthy et al 2001.) At this stage of development there are no 
crypts, only villi separated by an intervillus epithelium that gives rise to the crypt structures after 
birth (Kaestner et al 1997.)
Crypts develop after birth (days 1-5) from the flat intervillus epithelium with mitotic cells 
segregating in these structures (Clatworthy et al 2001.) As the crypts elongate, they also 
undergo replication by bifurcating from the base (Clatworthy et al 2001.) The epithelium 
differentiates along the cephalo-caudal axis resulting in morphological differences along the 
length of the duodenum, ileum and colon (Clatworthy et al 2001.)
5.1.3. Normal structure o f the small intestinal epithelium.
The small intestine needs to maximise its internal surface area for optimal absorption of 
nutrients and water. This is achieved by the inner epithelium being folded and lined with millions 
of tiny projections (villi) and pits (crypts o f leiberkuhn) (fig 5.1.) The surface area is expanded 
even further by the presence of microvilli on the lumenal surface o f the cells which form the villi 
(Clatworthy et al 2001.)
The intestinal epithelium is a dynamic tissue with a large proportion of cycling cells. In the 
mouse, each one of the approximately 1.1 million crypts contains around 250 epithelial cells 
(Potten et al 1997.) A small number of stem cells are situated around position four in the crypt 
(i.e. the 4th cells from the base of the crypt.) Asymmetric division o f these cells forms two sub­
populations; cells which replenish the stem cell compartment and transit amplifying (TA) cells 
(Hermiston et al 1996.) There are about 150 TA cells per crypt, which cycle roughly once every 
24 hours (Hermiston et al 1996) forming the so-called proliferative or transit amplifying (TA)
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zone in the middle of the crypt (Potten et al 1997.) TA cells differentiate into one of four cell 
lineages (absorptive enterocytes, goblet cells, enteroendocrine cells and paneth cells) and 
migrate up the villi, with the exception of Paneth cells, which migrate down to the base of the 
crypts to complete their differentiation (Mills and Gordon 2001.) Recently, it has been proposed 
that the active multipotent stem cell divides to two different types of cell in the proliferative zone; 
a C0 lineage which forms the absorptive enterocytes, and an M0 lineage from which arises the 
secretory cells (paneth, goblet and enteroendocrine) (Bjerknes and Cheng 2001.)
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Fie 5.1. The structure o f  the small intestine: the crypl-villus unit.
C ells shed at villus tip
Enteroendocrine cell
V illus <
Goblet cell
Transit amplifying 
(TA) zoneCrypt •<
Stem cell
Paneth cell
Fin 5. /. The crypt-villus unit o f  the small intestine.
The crypt contains 22 cells along each side from base to villus junction, and the villus 
contains around 80 cells from  crypt junction to tip (Potten et al 1997.) Cells are 'born' in the 
crypt, originating from division o f  stem cells at position 4, proliferate in the transit 
amplifying (TA) zone, and then differentiate as they move up out of the crypt and along the 
villus. Paneth celts move down into the bases o f the crypts as they differentiate. Cells move 
up the villus and are lost by shedding or apoptosis at the tip (Potten et al 1997.)
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Cells migrate up the villus and are eventually sloughed off into the lumen of the gut (Potten et 
al 1997, Clatworthy et al 2001.) The effect of the rapidly cycling epithelium is to create a 
continuous flow o f new cells from the lower crypts to the tips of the villi; the question of whether 
cells at the tips o f the villi are mechanically sloughed off or undergo a form of apoptosis is still 
unresolved (Potten et al 1997, Clatworthy et al 2001.)
Paneth cells differ in their behaviour; they remain in the base of the crypt and have a longer 
life span then their epithelial counterparts, and are eventually removed by phagocytosis 
(Hermiston et al 1996.) Another cell lineage, the ‘M* or microfold lineage cells, are also found in 
the small intestine, but only in close proximity to the Peyer’s patches (Potten et al 2001.)
Each cell lineage performs a distinct function with the crypt-villus unit. Epithelial cells 
(absorptive enterocytes) possess a brush border of microvilli which increase the surface area 
available for absorption (Potten et al 2001) allowing rapid transport of ions and other molecules. 
Paneth cells are granular secretory epithelial cells (Potten et al 2001.) Paneth cells secrete large 
amounts o f proteins including lysozyme, TN F-a and cryptidins, which are thought to contribute 
to the antimicrobial defences o f the intestine (Potten et al 2001.) Enteroendocrine cells secrete 
neuropeptides, whereas goblet cells are flask-shaped and have no apical microvilli but instead 
produce and secrete the mucins that lubricate and protect the gut (Potten et al 2001.)
Rates of proliferation and loss must be tightly controlled; too little proliferation would 
compromise the absorptive ability o f the gut and decrease the integrity of the epithelial barrier, 
whereas too much proliferation would result in neoplasia. Any genetic, epigenetic or 
environmental disturbance to the fine balance o f proliferation, migration and shedding has the 
potential to modify tumourigenesis (Potten et al 1997.)
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5.2. Exam ining the consequences of loss of MeCP2 in the  murine intestine.
In order to characterise the effects o f loss o f functional MeCP2 on the murine small intestine, 
a conditional allele o f MeCP2 and an intestinal-specific Cre recombinase were used to remove 
MeCP2 only in the small intestinal epithelium. The conditional Mecp2 allele used was that 
created by Guy et al, and replaces exons 3 and 4 o f Mecp2  with the same exons flanked by LoxP 
sites (Guy et a l 2001, see fig 1.8a.) To delete the conditional Mecp2 allele only in the intestinal 
epithelium, an intestinal specific Cre recombinase driven by the CyplA  promoter (Ah-Cre) was 
used (Ireland et al 2004, Sansom et al 2004.) This Ah-Cre recombinase allows virtually 100% 
recombination in the small intestine using a regime o f four daily 80mg/kg injections of the (3- 
napthoflavone inducer (Sansom et al 2004.)
Age matched male Mecp2wt/yCre+ (wildtype, n=6) M ecp2^ox/yCre+ (n=6) and female Mecp2 
*LMtCre+ (n=6) and Mecp2 ^ ox/^ oxCre+ (n=6) mice were used on an outbred background 
segregating for 129 and C57/B16 genomes. Mice were given one daily injection of 80mg/kg p- 
napthoflavone each day at the same time (+/- 1 hour) for 4 consecutive days to induce the Cre 
recombinase and recombine out the conditional Mecp2 allele. At the appropriate time point, 
mice were killed by cervical dislocation and the small intestine was removed, prepared, 
sectioned and stained with haematoxylin and eosin and examined.
5.2.7. Mecp2 is removed from intestinal tissue after induction o f  the Cre recombinase.
In order to determine whether MeCP2 had been deleted in response to the P-napthoflavone 
inducer, mice carrying the Ah-Cre allele, the floxed Mecp2 allele and the Rosa26R reporter locus
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were subjected to the same injection regime as the experimental mice (the colony used for the 
main experiments does not carry the Rosa26R allele.) Results are shown in fig 5.2.
Fig 5.2. Removing Mecp2 in the murine intestine: LacZ reporter stain ins
Fin 5.2. LacZ reporter staining shows that recombination has taken place at high frequency in the small 
intestine.
The intestine has been opened longitudinally and sectioned, with the proximal end at the top right. 
Recombination causes a floxed STOP cassette in a LacZ reporter gene to be removed. The gene is then transcribed 
and can be assayed by treatment with X-gal. The blue colour corresponds with areas in which Mecp2 has been 
removed.
Induction of the Ah-Cre recombinase results in excision of a stop codon in the Rosa26R 
allele and the subsequent expression of a LacZ reporter gene. This allows staining with X-gal to 
reveal areas of recombination as blue (Soriano 1999.)
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5.2.1. Removin2 M eCP2 in the m urine intestine; quantitative real-tim e RT-PCR.
The LacZ reporter allele shows that the proximal intestine undergoes almost complete 
recombination after 4 injections o f (3-napthoflavone. The half-life of the MeCP2 protein is 
between 3 and 4 hours (Reichwald et al 2000) so after 7 days all the MeCP2 should be removed. 
Quantitative realtime RT-PCR was then used to examine the amount of Mecp2 RNA in intestinal 
tissues 7 days after the final injection. Fig 5.4 shows that Mecp2 mRNAlevels are greatly 
reduced (2.13-fold, p=<0.005 Mann Whitney.) Note that some Mecp2 activity remains; this is 
primarily due to the diverse cell population of the small intestine. Whole intestine is used to 
prepare RNA, but the recombination occurs only in the epithelium, which makes up a minority 
of the total cell types of the small intestine. Residual Mecp2 is most likely due to that present in 
endothelial and muscular lineages etc.
Fie 5.4. Quantitative real time PCR analysis o f  Mecp2 mRNA levels in Mecp2flox/}Cre+ 
mice after 4 injections o f  80me/ke napthoflavone.
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Fie 5.4. Mecp2 is removed in the small intestine.
Mecp2 is found to be significantly downregulated (2.13-fold, p=<0.005 Mann-Whitney) residual 
Mecp2 can be attributed to that remaining in non-epithelial tissues.
□ Mecp2 ‘ +Cre+
■ Mecp2 floxfloxCre
5.3. C haracterisation of the in testinal phenotype o f MeCP2-deficient mice.
Having shown that the recombination procedure removes MeCP2 from the small intestinal 
epithelium, I then proceeded to characterise the phenotype induced by loss of MeCP2. 3 month 
old age-matched male M ecp 'fOXjyCreJf and M ecp2+/yCre+ mice were induced and killed and their 
small intestines histologically examined 5, 7 and 9 days after the final injection of the p- 
napthoflavone inducer. The length o f villi and the size of crypts were quantified in order to 
detect and changes in intestinal morphometry. Villus length was counted in the proximal 5cm of 
the small intestine, as the number o f cells from the tip of the villus down one side to the 
crypt/villus boundary. Crypt size was counted as the number of cells from the base of the crypt 
up one side to the crypt villus boundary. The sizes o f the crypt and the villus have been well- 
defined in the mouse, with a normal crypt being 22 cells long and a normal villus being -80  cells 
long (Mahmood et al 1998.)
Upon removal of MeCP2 from the intestine, a phenotype appeared that was visible and 
stable five days after the final injection o f P-napthoflavone (fig 5.4.) Mice in which MeCP2 was 
removed developed intestinal villi that were on average 12.5% longer than the wild-type 
(p=<0.0001 Mann-Whitney, 100 viili/mouse counted.) No differences were seen in villus lengths 
between male M ecp2jlox/y Cre+ and female M ecp2flox/flox Cre+ mice, and the phenotype remained 
stable at 1 year post-injection (fig 5.4.)
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Fig 5.4. Villi become 12.5% longer when Mecp2 is removed from the murine small
intestine.
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Fie 5.4. Villi become longer in the absence o f  Mecp2.
Villi become 12.5% longer and the effect is stable, lasting at least 1 year.
Fig 5.5. Distribution o f  villus sizes as quantified by cell number. 
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Fie 5.5. Altered distribution o f  villus sizes in the absence o f  MECP2.
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The histogram shows how the distribution o f  variously-sized villi differs in MeCP2flox/y Cre+ and MeCP2 
^Cre mice. M eC P 2^ y show an altered distribution o f  villus sizes, with more larger villi being found.
5.4. Further characterisation  o f the M eCP2 deficient phenotype.
5.4.1. Crypt size rem ains constant in the absence o f MeCP2.
When MeCP2 is conditionally removed from the murine small intestine, an intestinal 
phenotype develops with villi becoming 12.5% longer as quantified by cell number (cell number 
is used as measuring the length o f the villus down the microscope is prone to errors induced by 
the preparation o f the section, which can distort tissues.) This phenotype is stable and persists for 
at least 1 year. This villus lengthening may be due to a number of factors, which may act alone 
or in concert; cellular proliferation and proliferation rates may have increased, the size of the 
crypt compartment may have increased, or cellular apoptosis rates may have decreased. In order 
to determine which factors are important in the villus-lengthening phenotype, a range of 
experiments examining proliferation, migration and apoptosis were carried out.
In order to determine if both the crypt and the villus compartments had expanded, the number 
of cells in the crypts o f  Mecp2/1ox/yCre+ and M ecp2+/yCre+ mice were counted (50 crypts/mouse). 
No significant differences were found between wild-type crypts and Mecp2 null crypts (p=0.387 
Mann-Whitney.) Results are shown in fig 5.6.
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Fie 5.6. Crypt size remains constant in the absence o f  Mecp2.
Fig 5,6. Crypt sije  remains constant in the absence o f  Mecp2.
The number o f cells in each crypt remains constant at around 22 cells. No differences are seen between 
Mecp2floxy Cre+ and Mecp2'y Cre* mice.
Both the Mecp2 deficient crypts, and those wild-type for Mecp2 contain around 22 cells 
(counted from the base o f the crypt up one side o f  the crypt.) If the crypt was found to be larger, 
than it would be expected to produce more dividing cells to populate a longer villus without a 
change in proliferation rates. However, no significant differences were found in crypt size, in the 
absence or presence o f Mecp2. Since no change was found in the size of the crypt, this implies 
that there are either more cycling cells in the crypt, or that the existing dividing population is 
dividing faster.
To examine proliferation rates, 3 month old age-matched m^fe Mecp2^ox/y Cre and 3 
Mecp2*/y Cre* mice were exposed to the (3-napthoflavone inducer to induce the Cre recombinase
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remove Mecp2 from the small intestine and left for 7 days. Mice were then given a single 
injection of BrdU to label proliferating cells. BrdU is bioavailable for less than 2 hours, and 
effectively labels those cells in S-phase at the time of the injection (Sansom et al 2004.) Mice 
were culled 3 hours after the BrdU injection, and guts were prepared and stained with anti-BrdU. 
The number of proliferating cells in the crypt was counted (50 crypts per mouse) and the 
positions of the BrdU labelled cells were noted. MeCP2-deficient (Mecp2 ^ox/y Cre+)  crypts 
showed a number of alterations in proliferation rates and patterns.
The absolute number o f proliferating cells in the crypt was higher in MeCP2-deficient (Mecp2 
flox/y Cre+)  crypts (fig 5.7a) showing that proliferation rates had increased by 12.9% (p= 0.0404 
Mann-Whitney.) The figure of a 12.9% increase in dividing cells correlates with the 12.5% 
increase in villus length. Hence the number of dividing cells in the crypt has increased with no 
concurrent increase in crypt size. This implies that the TA (transit amplifying) zone may have 
expanded. To determine if the TA zone had expanded, the position of BrdU-labelled cells in the 
crypt was quantified. Fig 5.7b shows that the transit amplifying (TA) zone was altered in the 
absence of MeCP2. The lower boundary of the TA zone remains stable, but the upper edge of 
the zone is expanded upwards.
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Fis 5.7a. Proliferation in the crypt is increased in the absence o f  Meco2
■ Mecp2 floxy Cre 
UMecp2 *y Cre
Fie 5 .7b. The proliferative zone (TA zone) expands upwards in the absence o f  Mecp2.
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Fig 5.7. 7 days after induction o f AH-Cre, mice were given BrdU to label cells in S-phase and then 
killed 3 hours later. A = Levels o f proliferation increase in the Mecp2^ox/yCre' intestine. B = 
Histogram showing the expansion o f the proliferative zone. The lower boundary remains constant but 
the upper boundary is expanded upwards.
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5.4.2. Loss of Mecp2 does not a lter apoptosis in the crvpt.
If the rate of apoptosis had decreased, more cells would remain in the crypt-villus system. In 
order to examine this possibility, paraffin sections from the 3 hour BrdU experiment {M ecpl^0^  
Cre+ and Mecp2+/y Cre+ mice n=6) were stained with H&E and rates of apoptosis were counted. 
An apoptotic cell has a distinctive morphology; it appears more rounded than its neighbours, and 
may have a lighter ‘halo’ around it where it has shrunk away from the surrounding cells. The 
cytoplasm stains more pinkly with H&E and the condensed chromatin within the nucleus stains 
darkly. Both the absolute numbers o f apoptotic cells in the crypt and the positions of apoptotic 
cells remained constant (fig 5.8) therefore altered apoptosis does not contribute to the villus- 
lengthening phenotype.
Fis 5.8. Apoptosis is not altered in the absence o f  Mecp2,
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Fi2 5.8. Apoptosis is not altered in the absence o f  M ecp2.
A. Absolute numbers o f apoptotic cells are not altered (p=0.38l Mann-Whitney.)
B. Positions o f apoptotic cells within the crypt are not altered (p=0.396 Mann-Whitney.)
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No alteration was seen in the rates of apoptosis in the absence of MeCP2. This shows that the 
increase in villus length is not due to decreased cell death.
5.4.3. Loss of MeCP2 in the murine intestine results in faster migration of epithelial cells 
along the villus.
In the absence of MeCP2, villi become 12.5% longer than those found in wild-type mice. 
Characterisation of the crypt showed that proliferation was increased, due to the TA zone being 
expanded up the crypt. If more cells are feeding onto the villus, the rate of migration of cells up 
the villus may be altered. In order to characterise this, proliferating cells were labelled with 
BrdU. Age matched 3 month old male Mecp2^ox/yCre+ and three Mecp2+/yCre+ mice (n=6) were 
given the p-napthoflavone inducer and left for 7 days. They were then given a single injection of 
BrdU to label cells which were proliferating in the crypt at the time of the injection. Mice were 
killed 65 hours after the BrdU injection and the intestine was removed, prepared and stained 
with anti-BrdU. The positions o f the labelled cells on the villus shows how far the labelled cells 
have migrated up the villus and can therefore be used to quantify migration rates. Results are 
shown in fig 5.9.
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Fie 5 .9. Migration alone the villus is faster in the absence o f  Mecp2.
CJc<u3oro>
Uh
|  Mecp2
|  Mecp2 + v Cre
□
30 45 60  75 90 105
Position o f  B rdJ-labelled  cell on villus
Fieure 5.9. The distribution o f  labelled cells on the villus differs between M ecp2flox/y Cre+ and Mecp2Jr/y Cre+ 
mice
The peak of the Mecp2* y Cre+ distribution lies at around position 45, whereas the peak o f the Mecp2flox/y Cre 
distribution lies at around position 75, 60% further. The majority o f BrdU-labelled cells have travelled further 
along the villus in the absence o/M ecp2, proving that migration rates are increased (p=<0.0001 Mann-Whitney.)
The distribution of labelled cells differs between the two genotypes; in Mecp2flox/y Cre+ mice 
the peak of the Mecp2+/y Cre+ distribution lies at around position 45, whereas the peak of the 
Mecp2flox/y Cre+ distribution lies at around position 75, 60% further. The majority of BrdU- 
labelled cells have travelled further along the villus in the absence of Mecp2, proving that 
migration rates are increased (p=<0.0001 Mann-Whitney.)
-170-
Is the increase in migration rate caused by the greater numbers of cells feeding onto the villus 
or is the increased proliferation in the crypt a response to the lengthening of the villus? If each 
cell has a defined ‘lifespan’ on the villus, then faster migration would lead to increased villus 
length. Is the lineage allocation in the crypt-villus unit altered (i.e. is there a change in the 
numbers of enterocytes and secretory cells?) In order to address some of these questions, the 
small intestine was characterised further using immunohistochemistry.
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5.5. Immunohistochemistrv of MeCP2-deficient and wild-type intestinal tissue. 
Fis 5.10. Loss o/*MeCP2 does not alter the crypt-villus boundary.
Fie 5.10. Loss o f  MeCP2 does not alter the crypt-villus boundary.
An alkaline phosphatase stain was used on cryofrozen sections; alkaline phosphatase stains the only the 
villus and not the crypt compartment and thus can show if  the crypt-villus boundary has moved. Red stain 
shows alkaline phosphatase A and C = Mecp2 }Cre , B and D = Mecp2 fl,,xyCre Loss o/MeCP2 does 
not alter this boundary and thus the identities o f crypt and villus are not changed.
Since alkaline phosphatase stains only the villus, staining can reveal the boundary between 
crypt and villus to determine if the boundaries o f either compartment have moved in their 
relative positions. As fig 4.11 shows, no change in the boundaries of crypt and villus was seen 
using the alkaline phosphatase stain (red.)
Next, a selection o f the various cell populations within the small intestine were stained, to 
determine whether their numbers or distribution were grossly altered.
Fis 5. / /. Loss o/~Mecp2 does not alter the number o f  eoblet cells.
A.
«■rc  * 9
* * * 20 pm 
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Fis 5.11. No alteration in the number or distribution o f  eoblet cells.
A and C -  Mecp2 yCre , B and D Mecp2 fiox/yC re'. No differences were seen in the number or 
distribution o f goblet cells in the two genotypes. Goblet cells and the mucins they secrete are stained blue 
with alcian blue.
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Goblet cells produce mucins which lubricate the intestine. A change in goblet cell number or 
distribution would indicate that the process of cell lineage allocation had been altered (i.e. 
more/fewer cells being allocated to secretory lineages.) However, no gross changes in goblet cell 
number or distribution were seen (fig 5.11), implying cell lineage allocation has not been altered.
5.5.1. The number o f enteroendocrine cells is not altered in the absence of MeCP2.
Next, the total enteroendocrine cell population was examined. Enteroendocrine cells secrete a 
variety of endocrine peptides which have affect the proliferation and growth of the gut (Potten et 
al 1997) and thus an alteration in the number o f enteroendocrine cells might be expected to lead 
to changes in gut morphology. An alteration in number or distribution of enteroendocrine cells 
might also indicate a change in cell lineage allocation in the gut.
The total enteroendocrine population o f the small intestine was stained with a Grimelius 
stain (Grimelius 2004) and the number o f enteroendocrine cells in the crypt and villus was 
counted. No significant differences were found in the numbers of enteroendocrine cells in Mecp2 
flox/y Qre+ ancj Meep2+/y Cre+ mice (fig 5.12 and 5.13.) As a comparison, the number of 
enteroendocrine cells in an Mbd2~/~ mouse is also shown (fig 5.12b) the Mbd2 f mouse shows a 
significant reduction in the total enteroendocrine cell population.
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Fis 5.12. Loss o/~Mecp2 does not alter the number o f  Enteroendocrine cells in the 
small intestine.
Fis 5.12a. Enteroendocrine cell number in the crypt.
0.8
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Fis 5.12b. Enteroendocrine cell number in the villus.
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Fig 5.12. Enteroendocrine cell number is not altered in either the crypt (a) or the villus (b) in the absence of 
Mecp2. By contrast, the MbdZ mouse shows a significant reduction in the number of enteroendocrine cells in the 
small intestinal villi.
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Fis 5.13. Enteroendocrine cells in the small intestine o f  Mecp2flox/yCre+, Mecp2+/yCre+ and 
M bd2m ice.
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Fin 5.13. Grimelius stain showing total enteroendocrine celI population.
A and C  = \1ecp2 floxyC re \ B and D Mecp2 ' yC re \ E and F = Mb d 2 ~ No  difference is seen in the 
numbers or distribution o f enteroendocrine cells in the presence or absence of  MeCP2. In contrast, loss of 
Mbd2 leads to significantly fewer enteroendocrine cells.
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5.5.2. Loss of MeCP2 does not a lte r the num ber of K-cells in the small intestine.
If the gross number o f enteroendocrine cells is constant in the intestine, the proportions of the 
various subtypes may still be altered. A specific subset of enteroendocrine cells, the K-cells, 
secrete a peptide called gastrointestinal polypeptide (Gip) involved in nutrient sensing, a process 
which has been linked to alterations in villus morphology, and so it is possible that the observed 
phenotype derives from an expansion o f the K-cells. To investigate this possibility, intestinal 
samples from the induced M ecp2^ox/y Cre+ and Mecp2+/y Cre+ mice were stained with and anti- 
GIP antibody and the numbers o f K-cells were counted.
As shown in fig 5.14, no significant differences were found in either the gross number 01 
distribution of K-cells as determined by immunohistochemistry. When the numbers of K-cel 
cells in Mecp2^ox/yCre+ and Mecp2+/yCre+ mice were counted, a slightly higher average numbei 
of K-cells was found in Mecp2flox/yCre+ mice, but this difference was not statistically significanl 
and is thus probably due to the slight increase in K-cells on a longer villus (which will not be 
significant as they are at such a low frequency on the villus.)
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Fis 5.14. No change in the number o f  K-cells in the absence p f  Mecp2.
Fie 5.14. Loss of Mecp2 does not cause a significant change in the number of K-cells.
A = Mecp2floxy Cre B=Mecp2 yCre ; no gross differences in K-cell number or distribution are visible (dark 
brown stain = K-cell, background light brown)
C. Graph showing no significant difference in K-cell number in the presence or absence o f  Mecp2 (p=0.56 
Mann-Whitney.) Mecp2 ^ C r e  induced mice do have a slightly higher average number o f K-cells, but the 
difference is not statistically significant.
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5.6. Loss of MeCP2: Sum m ary of the intestinal phenotype.
Fis 5.15. Phenotpye summary.
Faster migration 
along the villus
No change in 
apoptosis
Villi 12.5% longer
No change in crypt 
size
Proliferative zone 
expands upwards
Loss o f MeCP2
12.9% increased 
proliferation in the crypt
No change in 
enteroendocrine cells or 
goblet cells.
Loss of MeCP2 in the murine intestinal epithelium results in a stable intestinal phenotype. The 
villi become 12.5% longer. No change is observed in the size of the crypt compartment, but the 
number of proliferating cells in the crypt is increased by 12.9%, and the transit amplifying (TA) 
or proliferative zone is expanded upwards, leading to a larger population of cycling cells in the 
crypt. No changes in apoptosis are seen in the crypt, either in the number of apoptotic event, or 
in the position of apoptotic cells within the crypt. Examination of the villus itself reveals faster 
rates of migration of enterocytes along the length of the villus. No apparent changes in cell 
lineage allocation are seen, with goblet and enteroendocrine cell numbers showing no significant 
differences in Mecp2^ox/y Cre+ and Mecp2+/yCre+ intestine.
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5.7. Discussion.
5.7.1. Which factors can alter proliferation in the intestine?
A wide variety of factors are known to have effects on the growth of the intestine including 
hormones, nutrient intake, small peptides and growth factors (Walters 2004.)
Kaestner et al described how knocking out the forkhead gene, Fkh6 in the mouse alters 
intestinal epithelial proliferation (Kaestner et al 1997.) Fkh6, also known as Foxll, expresses a 
winged helix transcription factor in the mesoderm of the intestine directly adjacent to the 
epithelium (Kaestner et al 1997.) Forkhead factors appear to mediate cross-talk between the 
epithelium and the endothelium (Kaestner et al 1997.) Both the embryonic development of the 
gut and its morphology in the adult are affected by loss of Fkh6. Fkhfr1' mice have fewer, poorly 
formed villi at embryonic day El 6.5-El 8.5 when compared to wild-type littermates (Kaestner et 
al 1997.) The spatial control o f early proliferation is also altered; in normal mice the 
proliferating cells are limited to the intervillus region, whereas in null mice they are scattered 
throughout the villi (Kaestner et al 1997.) At birth, null mice have fewer, shorter and wider villi 
and many nulls rapidly lost weight and died before weaning, hinting at severe intestinal 
dysfunction (Kaestner et al 1997.) Mice that survived the weaning period however, rapidly 
gained weight, and were equal in weight to their siblings by 5 months of age (Kaestner et al 
1997.)
Abnormalities were also found in adult animals; 50-day-old F k h ^ ' mice had expanded, 
branched crypts and cell-lined, mucus-filled cystic structures (Kaestner et al 1997.) The authors 
also noted that these abnormalities were more pronounced in the proximal intestine, which 
correlates with our findings that the increased villus length of MeCP2 deficient mice is more 
pronounced in the proximal intestine. In contrast to the fewer, shorter and poorly formed villi
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seen during development, 50-day-old null mice had longer villi than their normal siblings and 
the effect was stable with age (Kaestner et al 1997.) Adult null mice showed a four-fold increase 
in the number of proliferating cells in the crypt, an increase in the size of the crypts and an 
increase in the amount of apoptosis within the mucosa (Kaestner et al 1997.) The number of 
goblet cells was slightly increased, indicating an alteration in cell-lineage specification (Kaestner 
et al 1997.) No data was available on migration rates (Kaestner et al 1997.)
A range of genes are implicated in the control of epithelial growth and regulation (Drucker et 
al 1996), although there is obviously an extremely complex web of control involving many 
genes (which in turn may interact with nutritional status, increasing the complexity of the 
system.) Tcf-4, for example, is a member of the Tcf-Lef family and expressed in developing and 
adult epithelium (Clatworthy et al 2001.) Knockout mice die soon after birth, have fewer villi in 
the small intestine and decreased numbers of epithelial cells in the intervillus region 
accompanied by a depleted stem cell compartment (Clatworthy et al 2001.) Tcf is a downstream 
effector of Wnt signalling (Clatworthy et al 2001.) Another gene known to be involved is Cdx-1, 
a Drosophila Caudal homologue; major expression is limited to the proliferating zone and is lost 
as cells differentiate and move out o f the zone (Clatworthy et al 2001.) Over-expression of Cdx- 
1 in an intestinal IEC-6 cell line has been shown to increase proliferation (Clatworthy et al 
2001.) Wnt/p-catenin is also thought to regulate Cdx-1 expression; Tcf-1 knockout mice have 
lowered Cdx-1 expression in the small intestine (Clatworthy et al 2001.) The Cdx-1 promoter 
contains Tcf binding motifs and is regulated by Tcf-l/p-catenin complexes. Stem cell function 
and proliferation are therefore linked to Wnt/p-catenin and Tcf-4 (Clatworthy et al 2001.)
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Another gene affecting crypt proliferation is Nkx2-3, deletion of which leads to increased 
crypt proliferation (Clatworthy et al 2001.) The phenotype resembles that of the Fkh-6 knockout 
but has no effect on lineage allocation with normal numbers of goblet cells present (Clatworthy 
et al 2001.) Increased proliferation in these mice is associated with decreased levels of the bone 
morphogenetic proteins Bmp2 and Bmp4 (Kaestner et al 1997.) RNA protection analysis of 
FkhC1' mouse small intestine by Kaestner et al showed no change in the expression levels of 
Cdx-1, HnJ3a, Hnf3f3 (two other forkhead factors implicated in proliferation) Tnf-a or Tgf-f3 
(Kaestner et al 1997.) Fkh6 null mice did show a 30-40% reduction of expression in Bmp2 in 
stomach, duodenum and jejunum, indicating that Bmp2 may be a direct or indirect downstream 
target o f Fkh6 (Kaestner et al 1997.)
Clearly then, forkhead factors are only part of the story. A more direct cause of villus 
lengthening, however, can be ascribed to the actions of various other intestinally-active peptides.
5.7.2. The Proglucagon-Derived Peptides.
Several peptides, including bombesin, Gpi, insulin-like growth factors I and II (Igf-I and Igf 
II) peptide YY (PYY) and transforming growth factor a /p  (Tgf-a/p) have been shown to affect 
intestinal proliferation (Drucker et al 1996.) Glp-2 is of particular interest, as it has been shown 
to have a specific and potent stimulatory effect on the intestinal epithelium (Drucker et al 1996, 
Jaleen et al 2000, Drucker 2001.)
Glp-2 (glucagon-like peptide 2) is a member of the proglucagon-derived group of hormones 
which includes Glp-1 and Glp-2, glicentin and oxyntomodulin (Drucker et al 1996, Jaleen et al
- 182-
2000, Drucker 2001.) All these peptides are derived from a single proglucagon transcript (Fig 
5.15.) which is post-translationally modified to give a range of peptides (Drucker 2001.)
Fig 5.15. Proglucaeon-Like Hormones and GLP-2.
Adapted from Drucker et al 2001.
Fig 5.15a.) Proglucaeon.
G R PP G lucagon IP-1 G L P -1 IP-2 G LP-2
Glicentin • * MPGF
Oxyntomodulin
Fig 5.15b.) Alternative Processing.
Glucagon 
Pancreas
^  MPGF
Intestine/ 
Brain
Glicentin
Oxyntomodulin
GLP-1
GLP-2
IP-2
Fie 5.15. Structure o f mammalian proslucaeon.
IP - intervening peptide. MPGF = major proglucagon fragment. GRPP = glincentin related polypeptide.
In mammals, Glp-2 is found only in certain tissues (e.g. in the brain and intestine but not the 
pancreas) due to the cell-type specific expression of prohormone convertases (Drucker et al 
1996, Jaleen et al 2000.)
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5.7.3. Glp-2 Synthesis in the Intestine.
The type and amount o f nutrients present in the gut appear to be a major determinant of both 
intestinal proglucagon gene expression and Glp-2 secretion. For example, fibre-rich diets 
stimulate Glp-2 secretion in human and rodent studies (Drucker et al 2001.) Intestinal injury also 
stimulates Glp-2 secretion (Drucker et al 2001.) Glp-2 is estimated to have a half-life in 
circulation of around 7.2 mins (Drucker et al 2001.) Two forms have been detected in 
circulation, an active Glp-2 133 that is cleaved at an alanine at position 2 to give an inactive Glp- 
2 3 33 form (Drucker et al 2001.) Administration o f Glp-2 to rats and mice results in a 
significant thickening o f the intestinal mucosa with a corresponding decrease in intestinal 
permeability (Drucker et al 2001.) Drucker et al showed that the increase in mucosal thickness 
was due to an increase in villus height (Drucker et al 1996.) Crypt size remained constant, but 
crypt proliferation increased markedly (Drucker et al 1996.) Epithelial cells also appear longer 
and narrower after Glp-2 administration, with longer and more numerous microvilli (Drucker et 
al 1996.)
Studies using the human intestinal epithelial cell line Caco-2 have shown that GLP-2 
stimulates in vitro proliferation and have suggested that the effects o f GLP-2 may be mediated 
by PI 3-kinase and the MAPK pathway (Jaleen et al 2000.) However, results obtained using 
immortalised and isolated cells lines must be treated with some caution as they cannot replicate a 
structurally and biochemically intact in vivo system.
Bjerknes and Cheng have demonstrated that administration of Glp-2 specifically increases 
proliferation of the C0 progenitor (Mills and Gordon 2001, Bjerknes and Cheng 1996.) However, 
they also demonstrate that the epithelium is devoid of Glp-2 receptors (Glp-2r) (Mills and 
Gordon 2001, Bjerknes and Cheng 1996.) Instead of eliciting a direst response, the action of
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Glp-2 is thought to be mediated via the enteric nervous system (ENS), a complex network that 
regulates blood flow, secretion and gut motility (Mills and Gordon 2001, Bjerknes and Cheng 
1996.) The crypt is richly innervated with enteric neurons lying close to the crypt base. These 
neurons express Glp-2r and respond to the Glp-2 signal by transmitting a signal to the epithelium 
(Bjerknes and Cheng 1996.) This signal can be blocked by tetrodotoxin (TTX) which blocks 
voltage gated sodium channels. The signal then somehow stimulates proliferation in the C0 
progenitor (Bjerknes and Cheng 1996.) Glp-2 itself is produced by a subset of enteroendocrine 
cells, which may act as nutrient sensors (Bjerknes and Cheng 1996.) Hence a feedback loop 
between the epithelium, nutrient status and the ENS may be formed, which can regulate 
intestinal proliferation in response to nutrient conditions (Mills and Gordon 2001, Bjerknes and 
Cheng 1996.) This is a particularly interesting result in relation to Rett syndrome, as the enteric 
neurons are part of the autonomic system, which is known to be affected by RTT (Motil et al 
1999) and could provide a mechanism for the gastrointestinal problems seen in RTT patients.
5.7.4. Glp-2 and MeCP2.
The similarity of the MeCP2-null gut phenotype to that produced by an excess of Glp-2 
suggests that removal of MeCP2 may somehow increase transcription of the proglucagon 
transcript or Glp-2 secretion. Several other peptides which promote intestinal growth, such as 
bombesin, neurotensin and keratinocyte growth factor increase Glp-2 synthesis and/or secretion, 
suggesting that their effects may be in part mediated via Glp-2 (Drucker 2001.) RNA samples 
from Mecp2pox/yCre+ and Mecp2 +/yCre+ mouse intestine will be used in array studies and
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immunohistochemistry o f frozen sections from Mecp2^ox/y Cre+ and Mecp2 +/y Cre+ mice will be 
used to ascertain if removal of MeCP2 increases Glp-2 levels.
5.7.5. Gip.
Gip, also known as glucose dependent insulinotropic polypeptide or gastric inhibitory 
polypeptide is a member of the vasoactive intestinal polypeptide (Vip)/secretin/glucagon family 
of gastrointestinal polypeptides (Meier and Nauk 2004.) Gip is a 42 amino acid peptide hormone 
that is synthesised and secreted from K cells, a subset of intestinal epithelial cells that are most 
abundant in the proximal duodenum (Cheung et al 2000, www.glucagon.com/gip.html.) K-cells 
are thought to be the ‘nutrient sensors’ o f the intestine, as they respond to glucose levels in the 
intestine (Cheung et al 2000.) K-cells secrete Gip in response to glucose in a manner that closely 
parallels the way in which insulin is released from pancreatic P-cells (Cheung et al 2000.) Like 
Gip-1, Gip stimulates glucose-dependent insulin secretion and these two peptides are thought be 
responsible for up to 60% of the total insulin secretion which occurs after a meal (Cheung et al 
2000.) Gip receptor negative (Gip/ ' ) mice also show high glucose intolerance and an impaired 
insulin secretion response to glucose (Miyawaki et al 1999.)
Recently, Gip has been linked to obesity, with the observation that Gip receptor negative 
{G ip /')  mice are resistant to weight gain on a high fat diet (Nyberg et al 2005.) This implies that 
Gip may be involved in regulating food intake and may be part of the gut brain axis. A recent 
paper has found Gip and Gip receptor expression in the adult rat brain in the hippocampus 
(Nyberg et al 2005.) All the other members of the Vip/secretin/glucagon family have also been 
found in the brain, where they are classified as neurotransmitters and are involved in a range of 
brain functions including brain development, cell cycle regulation, differentiation and regulation
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of food intake (Nyberg et al 2005.) Interestingly, Nyberg et al describe a role for Gip in 
stimulating proliferation of the progenitor cells of the rat hippocampus (Nyberg et al 2005.) Gip 
has also been found to be mitogenic in a range o f other cells types (Nyberg et al 2005), such as 
the vascular endothelium (Ding et al 2003) quiescent adrenal tumour cells (Chabre et al 1998) 
and the osteoblast-like cell line MG-63 (Zhong et al 2003.) Gip is also known to be a growth 
factor for pancreatic [3-cells (Trumper et al 2001.) Other members of the Vip/secretin/glucagon 
family are also known to have growth-stimulatory properties (Nyberg et al 2005) which again 
provides a rationale for examining the Mecp2 null intestine as it provides a link between the gut 
and the brain.
5.7.6. Igf-I.
Igf-I is synthesised in the liver and intestine and has a profound effect on small intestinal 
growth (Ziegler et al 1996.) Administration of exogenous Igf-I increases the regeneration of the 
gut in models of intestinal mucosal atrophy (Zeigler et al 1996.) Igfs are extremely potent 
mitogens, and can alter epithelial cell kinetics by stimulating proliferation and inhibiting mitosis 
(Howarth 2003.) Igf-I is thought to predominantly target endothelial and epithelial cells and 
fibroblasts in the intestine (Howarth 2003.) Igf-I administered to rats continuously for 14 days 
resulted in marked and preferential growth of the gastrointestinal tract, increasing the weight of 
the gut as a fraction of total body weight by up to 22% (Howarth 2003.) In the same study, crypt 
size increased by 33% and villus cell number by 20% (Howarth 2003.) Igf-I receptors are found 
mainly in the basolateral region of the crypt, and Igf-I is thought to exert its effect by 
accelerating progression of the proliferating crypt cells through G1 to S-phase (Howarth 2003.) 
The phenotype of Igf-I -  mediated intestinal growth has partial similarity to that seen in the 
Mecp2 null intestine; unlike the MeCP2 deficient mouse, Igf-I over-expression results in an
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increase in crypt size, and the size of both the mucosal and muscular layers is increased. In the 
MeCP2 deficient mouse, only the villus is seen to increase in size.
None of the factors which are known to increase intestinal proliferation exactly match the 
phenotype seen in the MeCP2-deficient mouse, and in many cases (such as Gip), the data on 
proliferation and migration within the crypt-villus unit is incomplete or absent. It may be that 
another, as yet unknown factor is responsible for the phenotype, or it may be that two or more of 
these factors are altered in the absence of MeCP2.
Since MeCP2 is considered to be a transcriptional repressor (Nan et al 1999), it would be 
expected that loss of MeCP2 would lead to deregulated gene expression. Microarray analysis 
will be used to examine the transcriptome o f the MeCP2 deficient small intestine. No significant 
changes in gene expression have been found to date in mouse brain (Tudor et al 2002), so any 
significant changes would be important in our understanding of the in vivo role of MeCP2. It is 
hoped that any changes found will not only be able to shed light on the intestinal phenotype of 
the MeCP2 conditional knockout, but also on the fundamental problem of how loss of MeCP2 
causes the pathology of Rett syndrome.
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Chapter 6: Molecular characterisation of the intestinal
phenotype induced by loss of MeCP2.
6.1. Loss o f MeCP2 in the murine intestine results in a stable phenotype.
Using a conditional allele of Mecp2 and an intestinal-specific Cre-recombinase (Ah-Cre) 
an intestinal phenotype caused by the loss o f MeCP2 has been characterised in chapter 5.
Removal of MeCP2 in the intestine results in the stable lengthening of intestinal villi by a 
12.5% increase in cell number. The crypt compartment is not expanded, but the levels of 
proliferation within the crypt are increased by 12.9%, with the upward expansion of the 
transit amplifying zone. Migration along the villus is significantly faster in Mecp2 null 
intestinal tissue, although apoptosis does not appear to be affected. The numbers and 
distribution of cell types in the villus do not appear to be significantly altered. This is the first 
time a role for MeCP2 outside the central nervous system has been described.
In order to further define the phenotype and to try to elucidate a mechanism of action for 
MeCP2 in the gut, a microarray-based approach was used to examine the transcriptome of 
Mecp2f]oxlyCre+ and Mecp2+/yCre+ null intestinal tissue. Since MeCP2 represses transcription 
from methylated transcripts, and MeCP2 is widespread in chromatin, it might be assumed 
that the loss of MeCP2 would lead to a significant and genome-wide alteration in 
transcription levels (Nan et al 1999.) However, transcriptome analysis of Mecp2 null brain 
tissue has revealed no significant changes in gene expression (Tudor et al 2002.) This implies 
that MeCP2 is either not a global transcriptional repressor as was originally though (Nan et 
al 1999) or perhaps that MeCP2 acts in concert with other factors to repress transcription, 
and that in its absence, some degree of compensation takes place, reducing the impact of
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MeCP2 loss. There must, however, be effects on the transcriptome, as loss of MECP2 in 
humans causes RTT, and loss of MeCP2 in the murine intestine causes alterations in 
proliferation and migration of cells. Microarray analysis of the Mecp2 null intestine has a 
number o f advantages over previous work examining the Mecp2 null brain; firstly, the 
intestinal phenotype is clearly defined in terms of proliferation and migration, which will 
make identification o f targets suggested by the array easier. Secondly, if the loss of MeCP2 
causes an effect at a specific point in the development or maturation of the brain, it may have 
a long-lasting effect on the architecture or function of the brain without the original 
transcriptional event being still detectable. In the intestine, however, cells are constantly 
cycling and so the events which lead to villus lengthening through loss of MeCP2 may be 
more easily defined.
Finally, in the murine intestine we have an extremely well characterised and easily 
accessible model. Physical changes in the intestine, such as a quantifiable change in 
migration rates, are easier to compare than behavioural traits such as hypoactivity, which 
may depend on a number of difficult to quantify variables. The use of microarrays combined 
with conditional mouse models is an extremely powerful method. The conditional allele 
allows the gene to be ablated in any tissue at any point in the life cycle of the model 
organism, while retaining the allele in other tissues. This allows any particular system to be 
looked at in isolation. RNA extracted from such tissues can be analysed with microarray 
technology, allowing a vast amount o f data to be generated. This can be statistically analysed 
to reveal specific alterations in the levels of transcription of some genes. These targets can
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then be confirmed or rejected using techniques such as immunohistochemistry, or 
quantitative real-time PCR, which allows highly accurate quantification of changes in 
expression.
6.2. Microarravs: vital tools in examining the transcriptome.
Microarray technology allows the entire transcriptome of an organism to be examined in 
a single experiment, and is capable o f revealing not just expression changes in single genes 
but also patterns of change across an entire genome (Clarke et al 2004.) Rapid advances in 
genome sequencing programs have gone hand in hand with microarray research, allowing 
gene expression array chips to be developed for a wide range of model organisms (Clarke et 
al 2004.)
Microarrays are an especially useful tool for an experiment in a mouse model, in which the 
consequences of removal of a gene are unknown. A simple analysis of a microarray set will 
provide a vast amount of data which will allow targets to be followed up. It is worth stating, 
however, that microarrays are just one o f a number of tools with which to investigate a 
phenotype. They do not in themselves provide absolute proof of gene expression changes as 
the data can be interpreted in a number o f ways, and must be followed up using quantitative 
RT-PCRs, immunohistochemistry, western blots and other, more conventional techniques, in 
order to give definite answers to a particular question. Indeed, the huge amount of data 
generated by a typical microarray can be overwhelming if it is not carefully managed and 
analysed, and may well lead to a number of false avenues of exploration.
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The Affymetrix GeneChip array (mouse U74) used in this experiment are manufactured 
using a combination o f photolithography and combinatorial chemistry 
(www.affymetrix.com.)
The designs for each probe are derived from a unique sequence at the 3’ end of each 
transcript. Two probes are prepared for each sequence; a perfect match (PM) and a mismatch 
(MM) which has a single incorrect nucleotide in the middle of the sequence. These paired 
probes act as a quality control mechanism for non-specific hybridisation.
Fie 6.1. Usine the Affymetrix  © GeneChip expresison array to analyse the transcriptome
o f the Mecp2 deficient murine intestine.
Biotin-labelled cRNA
/ X / W  AAAA Reverse
transcription
M k c p ^ 'C re '  or Mecp2* ‘ 
Cre' mouse treated with P* 
napthoflavone
Extract RNA 
from tissue
cDNA
V
Wash and stain
i i i  K
Scan and quantitate
Biotin-labelled cRNA
Fragmented, biotin- 
labelled cRN A
Hybridisation to 
microarray chip
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Biotin labelled, fragmented cRNA samples derived from the RNA from a tissue can be 
hybridised to the chip, and the chip scanned to quantify the amount of signal at each probe 
pair. Internal controls on the chip are formed by comparison with house-keeping gene 
signals, and ‘spiked’ controls (www.affymetrix.com/technology/index.affx.) The 
housekeeping genes, P-actin and Gapdh are used to measure the quality of the prepared 
sample RNA; probes are designed to the 3’, middle and 5’ portions of the transcript 
(www.afTymetrix.com/technology/index.affx.) The ratio of the 3’:5’ signals should be 1. 
Deviation from a value o f 1 indicates poor quality starting material and the sample should be 
re-derived. Other exogenous controls are also ‘spiked’ into the array to monitor washing, 
hybridisation and staining (www.affymetrix.com/technology/index.affx.) The transcript BioA 
is added at a concentration o f 1.5pM; as this is at the limits of the sensitivity of the detection 
procedure, this transcript will be detected 70% o f the time. BioB (5pM) BioC (25pM) and 
CreX (lOOpM) are also added. BioB, at 5pM, is designed to represent a transcript present at 3 
copies/cell (www.affymetrix.com/technology/index.affx.)
6.2.1. M icroarrav Analysis o f M ecv^ 0*  ^Cre+ and Mecp2¥/y Cre+ intestinal tissue.
Intestinal tissue from 3 month old age-matched male M e c p ^ox/y Cre+ (n=6) and Mecp2+/y 
Cre+ (n=5) 3 month old age-matched male mice was analysed using a microarray-based 
approach. Since MeCP2 is considered to play a role in transcriptional repression, it might be 
expected that removal of the gene would result in changes to the transcriptome, and so this 
experiment was designed to show any changes which accompany the conditional removal of 
MeCP2 in the intestine.
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Previous experiments such as those carried out by Tudor et al have failed to find any 
significant differences in expression in brain tissue in the absence of Mecp2 (Tudor et al 
2002.) However, given the strength of the phenotype in the intestine, it is reasonable to 
assume that transcriptional changes may be observed.
M ecp 'foxJy Cre+ (n=6) and Mecp2+/y Cre+ (n=6) 3 month old age-matched male mice were 
given 4 intraperitoneal injections o f p-napthoflavone (80mg/kg) and left for 7 days to allow 
the Cre to be induced and MeCP2 to be removed. Mice were then killed and the small 
intestine removed. Intestinal tissue was placed into RNAlater™ within 1 minute of the 
animal being killed. Peyer’s patches were removed because of the high levels of immune 
tissue (which would have a different transcriptional profile) within them. Total cellular RNA 
was extracted with Trizol reagent, cleaned, quantified and reverse transcribed to make 
cDNA. In vitro transcription was used to create biotin-labelled cRNA which was then 
fragmented. The fragmented cRNA was sent to the Patterson Institute for hybridisation to the 
Affymetrix ® U74 mouse microarray chip containing -12500 genes. Sample data is shown in 
fig 6.2.
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Fie 6.2. Sample Affymetrix data from the Mecp2 array.
Signal: this is the 
measure o f the 
abundance of the
Detection: shows 
whether the p-value: shows 
the level of 
significance of 
the detection 
call.
Probe name transcript.
signal is present 
(P) absent (A) or 
marginal (M.)
\ \ /
sam plel sample 1 samplel
Probe name signal detection p-value
AFFX-MurlL2_at
AFFX-MurlL10_at
AFFX-MurlL4_at
AFFX-MurFAS_at
AFFX-BioB-5_at
AFFX-BioB-M_at
AFFX-BioB-3 at
12.2 A 0.749204
34 A 0.216524
12.5 A 0.116113
109.9 P 0.000509
124 P 0.003212
335.3 P 0.000044
118.5 P 0.002275
3’:5’ ratio 
= 1.04
Fie 6.2. A set o f  sample data from the U74 eene chip array.
Data is presented in a format compatible with Word and Excel, to allow manipulation.
6.3. Analysis of Microarrav Data.
Two methods of analysis were used; as microarray data can be analysed in a number of 
different way, it was decided to use two different analysis methods and compare the results
(K
from each. Tfie first method involved normalising the data, then running it through the SAM 
(statistical analysis of microarrays) program (http://www-stat.stanford.ed uA-tibs/SAM/) The 
second method was to take the array data, normalise it using MaxD and then perform a T-test 
on each set of data points. Targets provided by these methods were then followed up using 
quantitative real-time PCR.
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6.3.1. Method 1: Analysis using SAM.
Array data was normalised against the laboratory dataset using MaxD and then analysed 
using SAM, using a delta value of 0.5144 to give a false discovery rate (FDR) of 33.23 out of 
79 genes. The SAM software runs as a macro in Excel, and applies an algorithm to the 
normalised data to show which genes it considers to be significantly up or down-regulated. 
The user can define the stringency of the procedure, by setting the false discovery rate (FDR) 
at a desired level. The FDR is the number of genes which may be falsely considered to be 
significant, and represents the amount o f error in the process.
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Fig 6.3. SAM  plot; normalised data analysed using SAM.
Significant 79
Median U false significant 33 23540 S A M  P l o t
Delta 0.51445 
Fold Change
Expected
Fie 6.3. SAM plot from normalised data analysed with SA\L
This plot shows both up (red) and down (green) regulated genes, using a value of delta o f0.51445 (which sets 
the stringency o f the algorithm and determines the FDR. o f33.24.)
SAM assigns each data point a d  value, analogous to a  p  value in a T-test, it then plots the observed set o f d  
values against the expected set o f d  values fo r the array data Values which deviate from the diagonal line are 
significantly different; downregulated genes (green, bottom left quadrant) have an observed d  value lower than 
expected and upregulated calls (red, upper right quadrant) have observed d  values which are higher than
expected.
Among the targets identified as being downregulated are Mecp2, which is being removed 
from the intestine, and Hprt. The presence o f Hprt is significant as the Mecp2 conditional 
allele was created using 7//?r/-deficient ES cells. And thus a mouse carrying the floxed allele
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would be expected to be Hprt-deficient. To further confirm the accuracy of this method of 
analysis, a semi-quantitative RT-PCR was carried out for Hprt. Mice carrying the floxed 
allele do indeed show greatly downregulated Hprt (fig 6.4) indicating a high confidence 
levels in the genes identified as being changed. However, the relatively small number of 
target genes identified and the lack of any upregulated genes prompted the use of an 
alternative method of analysis.
Fie 6.4. Hprt confirmation.
Mecp2 Cre M ecpf°x/yCre+
25 cycles 
(3-actin control
Fig 6.4. Hprt RNA levels are greatly reduced in mice carrying the conditional allele.
Since the Mecp2 conditional allele was created using Hprt-deficient ES cells, both an array and semi- 
quantitative RT-PCR should be able to detect a significant decrease in the expression of Hprt in mice carrying 
the floxed allele. Hprt RNA is undetectable at 25 cycles in Mecp2flox/yCre' mice and only becomes detectable 
when the reaction is nearing saturation, at around 33-35 cycles. This validates the array, as Hprt is among the 
downregulated targets.
The SAM plot in fig 6.3 shows both upregulated (red ) and downregulated (green) genes. 
The FDR is 33.24 of 79 genes, which means that just under half of the genes SAM considers 
to be significant are in fact false calls. Reducing delta by even a small amount dropped the 
number of significant genes to around 4, and so a higher FDR was used to give a larger
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number of targets, which will be validated using quantitative real-time PCR. The lists of up 
and down regulated genes are shown below in tables 2 and 3.
Table2. List of upregulated significant genes.
Gene Accession Fold-change
EGFbp type C Ml 7962 2.77658
Elastase 2 X04573 7.72598
kallikrein V00829 1.78947
Pancreatic ribonuclease I X60103 4.49655
Uknown AW 120579 1.87238
P6-5 gene M27347 5.56917
TCR-p AE000663 4.04397
Unknown clone AW209561 1.76602
Similar to a splicing factor AV360487 2.25502
Partial sequence of a kallikrein M133500 2.05834
Carboxyl ester lipase U37586 5.53439
EGFbp type A Ml 7979 1.96394
Chymotrypsin like protease precursor 1 AA244542 4.44722
G1 utam ine: fructose-6-phosphate CC77609 2.25440
Kallikrein 5 Y00500 1.95515
Colipase presursor AA710635 2.91832
TCR beta AE000663 4.11208
Insulin II X04724 4.14591
Chymotrypsinogen B1 AA590358 5.32154
Kallikrein 5 AV053185 1.79643
syncollin AA607809 6.97226
ARF-GEP1 AV378443 2.32600
unknown AV059956 3.68188
Cholecystokinin receptor A CCKA D85605 3.50179
Triacyglycerol lipase precursor AA674409 8.81336
Lipoxygenase 3 Y 14695 1.48666
Possible sodium channel AV336781 1.84022
glycine N-methyltransferase D89664 2.63638
makorin AW 124942 1.33024
TCR beta locus AE000664 5.66377
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kallikrein V00829 1.99685
IgE heavy chain constant. X0857 1.71576
a-amylase I J00356 3.93422
Myocyte enhancer factor 2C L 13171 1.90137
Glandular kallikrein J00389 2.01177
Col2a-l M63709 1.40886
unknown C78889 1.42932
Possible tyrosine phosphatase AW046257 1.81661
Regl D14011 4.88281
unknown AV344835 1.32866
Mrp/plf3 X I6009 2.03988
NGF-y X00472 2.14776
y -renin J03877 1.62172
Androgen binding protein-a AF039064 1.74335
Nitotinic acetylcholine receptor 5-subunit LI 0076 1.76499
Glucose-regulate protein 78 AV351546 2.08820
Phospholipase A2 presursor AI327450 2.03943
TCR AE000664 7.71579
T-complex protein 1 M3579 1.36447
Ena-vasodilator stimulated phosphoprotein AV371846
(Evl) 1.68127
Cytotoxic T lymphocyte lipase M30687 1.93626
preprotrypsin X04574 7.22785
unknown C80068 1.36033
propionyl Coenzyme A carboxylase, beta 
polypeptide
AA882332
1.51082
EBI-1 L31580 1.45606
Interleukin-6 X54542 1.68617
AMPA1 glutamate receptor AW048549 1.52968
unknown AV096879 1.46605
Testis-specific protein (Mc2) AF092208 2.24796
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Table 3. Significant downregulated genes.
Gene Accession Fold change
unknown AI850090 0.55229
unknown AA544871 0.59134
Keratin 16 AF053235 0.50347
Similar to DRE1 AA691628 0.47028
Ssc2 AI317360 0.51715
Cis-retinol androgen AF030513
dehydrogenase 1 0.55407
AI586160 0.58678
Paired IG-like receptor U96682 0.48791
Similar to NADH AV089517
dehydrogenase 0.47444
MeCP2 A J13922 0.36807
Neurotrophin 3 X53257 0.52872
unknown AI850270 0.50437
Znfl27 U19106 0.53017
Down syndrome critical region AI848178
3 0.73263
unknown AV294852 0.47640
SRY-box containing gene 17 D49473 0.55726
LDL-related protein 6 AF074265 0.55307
Aristaless 3 U96109 0.53903
6.4. Method 2. Analysis using a T-test.
The second method of analysis used involved normalising the data using MaxD, then using 
an Excel spreadsheet to calculate the fold-changes and then run a T-test on them. Data points 
were considered potentially significant if they showed a fold-change of greater than 1.5 fold 
up or down regulation and a p-value of <0.05. The SAM procedure is loosely based on a T-
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test, but it also applies its own algorithm to ‘judge’ which genes are significantly altered in 
expression. The T-test alone would therefore be expected to give a much larger number of 
significant genes, and possibly a larger FDR. As can be seen from table 4,even genes which 
had large fold changes were often not significant when analysed using the T-test (e.g. 
Dpgatl, which has a fold change of 0.09, but a p-value of 0.33, which is not significant.) 
While the statistical procedures are objective, a degree of human judgement is required to 
decide if a gene with a marginal p-value will be followed up with QRT-PCR.
Table 4. List o f significant downregulated genes found using a T-test
Gene Accession Fold-
change
p-value
Hypoxanthine guanine phosphoribosyl 
transferase K01515: 0.023543 0.014522
Complement component factor i U47810: 0.093198 0.15889
Dpagtl AV324170: 0.09816 0.337963
m46 protein AJ243503 0.099342 0.196816
unknown AV067753 0.117647 0.4621
WDNM1 X93037 0.118427 0.241908
Small inducible cytokine A2 M19681: 0.120076 0.4449
KF-1 AV336118 0.127451 0.016171
methyl-CpG-binding protein 2 A J132922 0.132566 0.039909
pigment epithelium-derived factor (PEDF) AF036164 0.16934 0.174152
unknown AI837838 0.174888 0.181826
(clone- pMATl) L31958 0.17757 0.234558
unknown AV294852 0.179012 0.030881
SH3 binding glutamic acid-rich (SH3BGR) 
gene AJ239082 0.184416 0.007537
RGR opsin (Rgr) AF076930 0.184676 0.302487
ARP-1 AV364118 0.186813 0.190737
unknown AV023068 0.189236 0.409202
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ADP-ribosaltransferase X87612.M 0.194836 0.285373
alpha-albumin protein AJ011080 0.195777 0.289661
deafness locus associated putative guanine
nucleotide factor (DeLGEF gene) AJ243952 0.196035 0.358125
unknown AV254726 0.196891 0.100122
Serum amyloid A 3 X03505: 0.199657 0.880511
unknown AI504260 0.20283 0.269253
unknown AV333272 0.208145 0.339565
How accurate is the T-test? Whereas method 1 (SAM analysis o f normalised data) 
picked out many significant upregulated genes, only one of the top 25 upregulated genes 
is significant according to its p-value from the T-test. Of the 322 genes which were 1.5 
fold upregulated or higher, only 10 were found to be significant. They are shown in table 
5.
Table 5. Significant upregulated genes (T-test method.)
Gene Accession Fold-change p-value
Plasmacytoma variant translocation 1 Z11981 2.571429 0.024318
Unknown C79525 2.148649 0.018962
Unknown AV357533 2.103604 0.03235
Unknown AV244683 2.085271 0.028013
Synaptonemal complex protein 3 Y08486 2.077922 0.031393
Unknown AI851685 1.989071 0.022
Unknown C78889 1.831395 0.025714
heat shock transcripton factor 2 X61754: 1.8223 0.017426
Unknown A J133428 1.700637 0.016744
Unknown C76472 1.585091 0.046822
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Similarly, only 5 of the top 25 downregulated genes were significant according to their p- 
values. Of the 5885 genes found to be downregulated by 1.5 fold or greater, 838 (14.2%) are 
significant according to their T-test p-value.
6.5. Identification o f targets for follow-up using quantitative RT-PCR.
The following genes were identified as targets for further investigation using quantitative 
RT-PCR. These targets are mainly those suggested by the array, with the addition of other 
targets suggested by the literature (such as Bdnf, Dlx5 and Dlx6) to be altered in the absence 
of MeCP2. Other targets, such as glucagon, were chosen as they may be altered in a villus 
lengthening phenotype. Gip was chosen as other members of the Vip/secretin/glucagon 
family are upregulated by Bdnf, and play a significant role in the interaction of brain and gut 
to modulate food intake. Dlx5 and Dlx6 are included in both columns as they are described in 
the literature as being downregulated (Horike et al 2005) but appear to be downregulated on 
the array.
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Table 6. Targets suggested by analysis of m icroarrav data and literature/villus
lengthening models.
Upregulated Downregulated
Galgt2 Mecp2
Liprin a-4 Ssc2
CCF-i Neuromedin
M46 (ghrelin) Igfbp3
CCK-A IgfbplO
Collagen PEDF
GIP Dlx5
WDNM1 Dlx6
Dlx5
Dlx6
6.6. Confirmation of Array Targets: Quantitative Real-time RT-PCR.
Quantitative real time RT-PCR is a highly sensitive tool which can reliable detect 
extremely small changes in gene expression. The method relies on a system in which the 
amount of a fluorescent signal is proportional to the amount o f DNA product in the reaction 
and the fluorescence levels in the reaction are measured after every cycle, allowing a 
quantifiable read-out of the amount of product present in realtime.
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Fig 6.5. Q uantitative realtim e PCR.
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Fig 6.5. Quantitative Real time PCR
Fluorescent traces for a series o f serially-diluted RNA samples. The amount o f fluorescence increases as the 
reaction proceeds according to normal PCR kinetics (i.e a typical sigmoid curve.) The threshold cycle (Ct) is 
measured when the reaction is in the log phase; the user sets a threshold (dotted line) above which the 
measurement is made, avoiding the noise at the lag phase o f the reaction. Each cycle represents a two-fold 
increase in the starting number o f copies o f  RNA (cDNA) in the sample, i.e. the red sample, which becomes 
visible at a Ct o f 11, has twice as many copies o f the RNA (cDNA) as the orange trace, which in turn has twice 
as many as the yellow trace and so on. B= melting curves (explanation in text.)
The fluorescent molecule used in this experiment, SYBRgreen, emits fluorescence when it 
is complexed in double stranded DNA, hence as the reaction proceeds, more double stranded 
DNA is produced and the fluorescence signal is greater. Fluorescence is measured by a laser 
after every cycle, allowing a quantitative real-time image of the reaction to be built up (fig
6.5.)
Advantages of SYBR green are its low cost, ease of use and the ability to use non-modified 
oligonucleotides as primers. The major disadvantage of SYBR green is that it is non- 
discriminatory; double stranded DNA could potentially be formed from primer dimers or
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non-specific amplification, and the signal from such DNA would not be distinguished from 
that emitted by legitimate product. This problem can largely be circumvented by careful 
examination of the melting curves o f the products (fig 6.6b.) The Chromo4 can be 
programmed to perform a melting curve on the products of the reaction; the temperature is 
increased by a small, defined amount (around 0.5°C) and the amount of fluorescence is read, 
then the temperature is increased again and the process repeated. At a certain point, the 
double stranded PCR product will denature, and the amount of fluorescence will decrease 
markedly and rapidly. A idealised melting curve is shown in figure 6.5b. Note the presence 
of two sets of lines on the graph; these are merely two ways of expressing the same data. The 
blue lines show the total amount of fluorescence, and the red/pink lines show —dl/dt where 
^luminescence and t is temperature. The red/dark blue lines on fig 6.5b represent an ideal 
melting curve; a single peak or drop representing a single PCR product. The pink/light blue 
lines represents a non-ideal melting curve, characterised by the presence of a stepped drop in 
fluorescence, or ‘shoulders’ on the peak of the melting curve this can imply the presence of 
multiple products, and means the reaction conditions must be changed. The peak of the 
melting curve should lie between 82°C and 90°C. If the peak lies at a lower temperature, it 
may indicate that the fluorescence of primer dimers is being examined.
6.7. Using ORT-PCR to examine array targets.
Quantitative real-time RT-PCR was carried out on cDNA samples derived from RNA 
samples from 3 month old age-matched male Mecp2^ox/yCre+ and Mecp2+/yCre+ mice which 
had been given 4 daily injections of 80mg/kg p-napthoflavone and left for 7 days. Primers to
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targets suggested by the array data were designed using Primer3© software 
(http://frodo.wi.mit.edu/cgi-bin/primer3_www.cgi) and the mRNA sequence data 
supplied through a search of Pubmed; (http://www.ncbi.nlm.nih.gov/entrez/ 
query.fcgi?CMD=Search&DB=Pubmed.) A full list o f primers can be found in section? /?- 
actin primers were obtained (J. Zabkiewicz, personal communication) and used as a control. 
Reactions were carried out on an MJ Research Chromo4 thermal cycler and data was 
analysed using the Opticon Monitor 2 © software. Sample data for a run is shown in figures 
6.6a and 6.6b. All reactions were carried out at least in duplicate with no-template controls. 
Controls for the absence of genomic DNA were carried out by running samples in which no 
reverse transcriptase was present in the cellular RNA->cDNA reaction. Only samples in 
which both controls were negative were used.
The reaction is measured by selecting a threshold value (Ct) at which the increase in 
fluorescence is still in the log phase (dotted line of fig 6.6a.) This gives a Ct value for each 
sample. Sample data for one of the genes examined, Igfbp3, are shown in fig 6.6a and 6.6b.
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Fig 6.6a. Sample data for Quantitative realtime RT-PCR; amplification curve for Igfbp3.
0 . 7 5 -
0 . 5 -
0 . 2 5 -L L
20 3010
Cycle
Fig 6.6b. Melting curve for Igfbp3.
-dl/dt
Total fluorescence
8060 70 90
Temperature
Fig 6.6b. Melting curve for Igfbp3.
The high quality o f the reaction is shown by the shape o f the melting curve of the products; a single sharp 
peak with no ‘shoulders’ that would indicate other products. The peak is centred at 8 4 °C, too high a 
temperature to be formed by spurious product such as primer dimers.
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6.8. Quantitative real-time RT-PCR analysis of targets suggested by microarrav analysis of 
Mecp2*/+ and M ecpI/m deficient murine small intestine.
A number of targets were suggested by the array and primers were designed to these 
sequences. QRT-PCRs were run on these samples, using p-actin as a control. Results are 
shown in fig 6.8.
Assuming equal loading (which can be controlled for by using the housekeeping gene p- 
actin) each decrease of one in the threshold cycle number at which the signal appears 
corresponds to a 2-fold increase in abundance of the original transcript, i.e. if gene A has an 
average Ct of 14 and gene B has an average Ct of 15, then transcripts of gene A are twice as 
abundant as those of gene B. Because of this relationship, data from the QRT-PCR 
experiments was analysed using the AACt method (Livak et al 2001) using the following 
equation:
Fold change = 2 'AACt
_ 2"((Ct floxed  gene)~(C t floxed  |3 -actin ))-((C t w t g en e)-(C t w t P -actin ))
Where; Ct = threshold cycle
Ct floxed gene = the Ct o f the gene being examined in the Mecp2*lox/yCre+ mouse 
Ct floxed p-actin = the Ct o f the p-actin control in the Mecp2^ox/y Cre+ mouse 
Ct wt gene = the Ct of the gene being examined in the Mecp2 +/>'Cre+ mouse 
Ct wt P-actin = the Ct of the p-actin control in the Mecp2 +/y Cre+ mouse.
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6.8.1. Example of ORT-PCR calculation: Gip.
The expression of Gip (gastrointestinal polypeptide) gene was examined in Mecp2Jlox/y 
Cre+mice and Mecp2 +/yCre+ mice (n=6), using /3-actin as a control. Results were as follows;
Fig 6.7. Sample data for Gip.
Ct gene 
(floxed)
Ct
P-actin
(floxed)
Ct gene 
(WT)
Ct P-actin 
(WT)
A Ct floxed 
(Ct gene floxed)- 
(Ct P-actin floxed)
ACt wt 
(Ct gene wt)- 
(Ct P-actin wt)
A ACT 
(A Ct floxed) 
- ( ACt wt)
2 “ A ACT
21.44 15.43 22.28 15.17 6.01 7.107 -1.093 2.133
Gip, therefore, has been upregulated 2.134-fold by the loss of MeCP2.
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Fig 6.8. Q RT-PCR Results.
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Fiz 6.8. Quantitative realtime PCR analysis o f selected array targets.
Fold-changes observed using QRT-PCR follow-up o f array targets. Significant changes are marked with 
stars. O f the genes examined Bdnf Gip, Liprina-4 and Wdnml were found to be significantly upregulated 
(stars.) and Mecp2, Pedgf, Ssc2 and lgfbp3 were found to be downregulated. Errors are calculated as the 
standard deviation of the means o f expression levels in Mecp2^oxy Cre versus Mecp2 ‘y Cre mice.
Of the genes examined, Bdnf, Gip, Liprina-4 and Wdnml were found to be 
significantly upregulated, and Mecp2, Pedgf, Ssc2 and Igfbp3 were found to be 
downregulated. A list of significantly altered genes is shown in table 7.
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Table 7. Significant changes in gene expression.
Gene Fold-change
Bdnf
Mecp2
Gip
Liprin a-4
Ssc2
Pedgf
Igfbp3
Wdnml
4.37 (+/- 0.53) 
0.47 (+/- 0.08) 
2.133 (+/-0.8) 
2A5(+ /-0.14) 
0.54 (+/- 0.044) 
0.67 (+/- 0.05) 
0.67 (+/- 0.006) 
1.81 (+/- 0.3)
Gip is found to be upregulated on the array and this was confirmed by QRT-PCR; is there 
any evidence that upregulation of Gip alone can cause the lengthening of villi? If a direct 
cause-and-effect is to be established, then Gip would need to be shown to be both necessary 
and sufficient to cause the villus lengthening phenotype. Since Gip has such a short half-life 
in vivo, this would be difficult to accomplish using exogenously administered Gip, but it 
could be accomplished by over-expressing Gip in vivo. One interesting observation which 
provides further evidence that Gip is involved in villus overgrowth was provided by a strain 
of mice which were found to have even longer villi than the MeCP2 deficient mice. The Dlb 
(Dolicos biflorus) mouse has a polymorphism at the Galgt2 locus, which lies within 0.2CM 
of the GIP locus. The Dlbl mouse was found to have villi which averaged ~95 cells, 
significantly different from the wild-type mice (fig 6.9.)
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Fig 6.9a. Mice carry ing  a polym orphism  a t the Galgt2 locus have long villi.
110
100
D lb l M e c p f ox/yCre Mecp2*yCre
g en o ty p e
Fig 6.9b. The Galst2 locus (mouse.)
[ 95537144 ► 
God $ t 2
[  95735484 ►
I ^ 2 b p l Gip<^
DllMoh34
D llt1oh35
Taken fro m :
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=retrieve&dopt=default&list uids=14607
Fig 6.9. Mice carrying a polymorphism at the Galgt2 locus, which lies extremely close to the Gip locus, have 
longer villi than wild-type mice. All other aspects o f the phenotype were identical to Mecp2pox/y Cre' mice
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The longer villi seen in the D lbl mice provide some circumstantial evidence that Gip is 
involved in the lengthening phenotype. It is not unreasonable to suppose that the 
polymorphism causes over-expression o f Gip. This is, of course, indirect evidence, and 
would need to be supplemented by expression analyses of Gip in these mice to be considered 
as proof, but it does provide circumstantial evidence that it is Gip which is responsible for the 
villus lengthening phenotype.
6.9. Discussion.
There are two primary aims in the analysis of the microarray and QRT-PCR data; the first 
is to attempt to unravel the mechanism o f villus lengthening caused by the loss o f MeCP2 in 
the intestine, and the second is to look at this mechanism, along with any other gene changes 
seen in the array/QRT-PCR data to reflect on the mechanisms which underlie the pathology 
of Rett syndrome.
6.9.1. How does loss o f M eCP2 cause the villus lengthening phenotype?
A variety o f peptides have been previously documented to cause alterations in the 
morphology of intestinal villi, for example, Igf-I, Glp-2 and bombesin. Glp-2 is derived from 
glucagon; no change in the expression of glucagon was observed. However, since Glp-2 is a 
post-translationally-derived product, this does not exclude the involvement o f Glp-2 in the 
phenotype, as alterations in the processing o f glucagon or breakdown of Glp-2 could lead to 
altered Glp-2 levels.
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Igf-I is also not itself transcriptionally altered. Igf-I is known to be a potent 
intestinotrophic factor (Zeigler et al 1996.) Although the expression levels of Igf-I did not 
appear to be significantly different on the array (the fold-change is 1.44, but the high p-value 
of 0.56 rules this out as being significant) the expression of Igfbp3 is changed on both the 
array (fold-change = 0.55, p = 0.029 T-test) and when examined using QRT-PCR (fold- 
change = 0.67+/-0.006.) IgfbplO  is also downregulated both on the array (fold-change = 0.33, 
p=0.013 T-test.) Igfbp3 is the chief binding partner for Igf-I and is antagonistic to its action. 
Decreased Igfbp3 levels could therefore cause an increase in circulating Igf-I levels with no 
change in expression levels, and the raised levels of Igf-I could cause a degree of villus 
lengthening. The increase in Igf-I is unlikely to be the main cause of the phenotype, however; 
when rats are given exogenous Igf-I, both the crypt and the villus compartment expand 
(Zeigler et al 1996), and the MeCP2 deficient phenotype does not show any increase in the 
size of the crypt compartment. Whilst increased circulating Igf-I could certainly be a 
contributor to this phenotype, therefore, it seems unlikely that it is the major protagonist. It 
would be interesting to measure whether there is an increase in circulating Igf-I and if so, to 
exogenously administer this amount to wild-type mice; in this way the contribution of Igf-I to 
the phenotype could be quantified.
Surprisingly, Bdnf showed no net alteration on the array (fold change = 1, p=0.89 T-test) 
possibly due to the fact that the levels o f B dnf appeared to be highly variable within classes 
and the SAM algorithm seems to be unable to deal effectively with highly variable data. 
However, investigation using quantitative RT-PCR showed that Bdnf was upregulated 4.36- 
fold+/-0.53 in M ecp 'fox/yCre+ mice compared with Mecp2+/yCre+ mice. The magnitude of 
this change is surprisingly large; in Mecp2-null brain, basal transcription levels of Bdnf in 
non-activated neurons raise by approximately 2-fold, from 1% to 2% of the levels found in
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activated neurons. The fold-change seen in the gut is considerably higher -  could this 
indicate a role for Bdnf in the gut?
Bdnf is already known to be part o f the brain-gut axis through its role in controlling food 
intake (Mattson et al 2004.) Many gastrointestinal hormones are also found in the brain and 
many of these hormones serve to mediate interactions between the brain and the gut (Strader 
and Woods 2005.) The possibility that the Ah-Cre has been induced in enteric neurons 
causing Bdnf upregulation to affect the neuronal plasticity of autonomic neurons in the gut 
cannot be entirely ruled out; it is known that enteric neurons can affect intestinal growth and 
development through other gut hormones such as Glp-2 (Bjerknes and Cheng 2001.) The 
possibility of extra-intestinal effects via non-specific recombination (i.e. a ‘leaky’ Cre) 
cannot be entirely ruled out. However, the transcriptional changes seen would remain valid 
even if there had been whole-body recombination.
6.9.2. Bdnf is involved in energy balance and metabolism.
Bdnf is already known to be involved in energy metabolism (Mattson et al 2004.) The level 
of expression of Bdnf is sensitive to alterations in energy balance; Bdnf levels rise in 
response to hypoglycaemia and intermittent fasting, and are lowered by hyperphagia 
(overeating) (Lindvall et al 1992, Lee et al 2002.) The Bdnf heterozygous knockout mouse is 
obese and has hyperglycaemia (Lyons et al 1999.) If these mice are subjected to dietary 
restriction, their Bdnf levels, body weights and blood glucose levels return to normal (Duan 
et al 2003.) The receptor for Bdnf is TrkB (tyrosine kinase receptor B;) TrkB knockout mice 
are also hyperphagic and become obese when fed a high fat diet (Xu et al 2003.) If Bdnf is 
knocked out conditionally in the brain after birth, mice become obese, develop elevated
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insulin and blood glucose levels and are, interestingly, hypersensitive to stress (Rios et al 
2001.) Since Bdnf is so intimately involved in the cellular regulation of energy balance, 
knocking out Mecp2 and thus deregulating Bdnf in the gut may interfere with the 
mechanisms which recognise nutrient status in the intestine.
One set of nutrient sensors in the gut are thought to be the K-cells, a specialised subset of 
enteroendocrine cells which release Gip (gastrointestinal polypeptide or glucose-dependent 
insulinotrophic polypeptide) in response to fat and carbohydrate in the gut (Cheung et al 
2001.) The release of Gip stimulates the release of insulin, and so Gip is also involved in the 
regulation o f energy balance, specifically blood glucose levels and adiposity. Gip was found 
to be upregulated by 2.13 +/- 0.6 fold in M ecpfP^C re*  mice. Is this upregulation due to 
direct repression by MeCP2 or by an indirect mechanism? To definitively answer this 
question would require studies such as those carried out by Chen et al to examine the effects 
of MeCP2 mediated repression on Gip expression. Some evidence, however, does suggest 
that the rise in Gip levels may be a secondary effect, mediated through elevated Bdnf. Gip is 
a member of the Vip/secretin/glucagon family, and Bdnf has been shown to regulate the 
expression of Vip in retinal amarcrine cells (Cellerino et al 2003.) Bdnf also increases the 
level of somatostatin (another gastrointestinal hormone) in the brain (Villuendas et al 2001.) 
Bdnf can also induce expression o f neuropeptide Y (NPY), which is a potent stimulator of 
feeding (Leibowitz et al 2005.) This shows that Bdnf is capable of directly regulating the 
expression of genes which have highly similar functions to Gip and are involved in the 
regulation of food intake controlled by the brain-gut axis. The upregulation of Bdnf may in 
turn cause an upregulation o f Gip, disrupting the normal feedback mechanisms which inform 
the brain of the nutrient status of the gut. It is known that nutrient status and villus length are 
interrelated, and so this may lead to a lengthening of the villi in the small intestine. It is
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interesting that the region o f the K-cells and the region of the highest floxing density (the 
proximal small intestine) overlap. The number of enteroendocrine cells in the MeCP2 
deficient mouse does not increase; this implies that any effects on the enteroendocrine cells 
are not due to altered lineage allocation but instead may be due altered transcription patterns 
within the enteroendocrine cells. A number o f enteroendocrine markers are altered in the 
MeCP2-deficient phenotype; somatostatin is downregulated (fold-change = 0.51, p=0.028 T- 
test) as is secretin (fold-change = 0.51, p=0.019.) Neither Viip (fold-change = 0.93, p= 0.184 
T-test) or Cck-A (fold-change = 0.43, p=0.128) were found to be altered, (Npy and Pyy were 
not found on the array.) This implies that a generalised deregulation of enteroendocrine cells 
is not occurring and hints that the effects are quite specific.
Bdnf is known to directly regulate proliferation in at least one cell type, in the rat 
hippocampal progenitors, and so may also regulate cell proliferation in the gut directly, and 
through effects on Gip. If Gip, like its family member Vip and closely functionally related 
genes somatostatin and Npy, is also regulated by Bdnf, then a mechanism for villus 
lengthening mediated via MeCP2, Bdnf and Gip, and augmented by Igf-I, could be proposed 
(fig 6.10.)
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Fig 6.10. M odel for v illus lengthening in the absence of MeCP2
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Fig 6.10. A model for villus lengthening in the absence o f  Mecp2.
A = K-cells act as nutrient sensors in the gut by releasing Gip in response to carbohydrate and fa t in the gut lumen. 
Fasting leads to villus atrophy and re-feeding to villus growth.
B = A model for the villus lengthening seen in Mecp2-deficient mice: Reduced Mecp2 leads to increased expression 
of Gip, either directly or via upregulation o f  Bdnf. Igf-I levels are increased by the decreased expression o f its chief 
binding partner, Igfbp3. Igf-I causes some villus lengthening directly, and the raised Gip levels mimic the ‘well fed' 
state, leading to greater proliferation in the crypt compartment and villus lengthening.
-220-
6.10. W hat can the data reveal about the mechanisms underlying Rett syndrome?
The combination of microarray and quantitative real time RT- PCR analysis has revealed a 
number of significant gene changes which occur in the absence of MeCP2. This is in itself 
important, as so few targets for direct or indirect regulation by MeCP2 have so far been 
found. The intestinal phenotype of the conditional Mecp2 knockout reveals the involvement 
of MeCP2, Igf-I, Bdnf and Gip in the lengthening of intestinal villi, but what conclusions can 
be drawn from the intestinal data regarding the mechanisms by which loss of MeCP2 causes 
Rett syndrome?
Changes in the intestine alone are highly unlikely to lead to Rett-like symptoms in the 
mouse. However, intestinal data may be relevant to the pathology of Rett syndrome. If the 
changes seen in the intestine in the absence o f Mecp2 are also seen in other tissues, then the 
transcriptional alterations in those tissues could be responsible for some of the features o f 
RTT. Three genes which were found to have altered expression in the absence of MeCP2 
have particular relevance to the RTT phenotype; Bdnf, Liprin-a4 and Ssc2. If these genes are 
altered in RTT patients in other tissues, they may contribute to RTT pathology.
6.10.1. Rett syndrome, synaptic plasticity and neuronal maturation; Bdnf and Liprin-a
As has been discussed previously, many of the symptoms of RTT are thought to be due to 
defects in neuronal maturation and/or survival (Neul and Zogbhi 2004.) Bdnf has previously 
been shown to be directly controlled by MeCP2-mediated transcriptional repression, with a 
higher basal level o f transcription found in Mecp2 null neurons (Chen et al 2003.) MeCP2 
binds selectively to the promoter and represses expression of Bdnf on depolarisation,
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calcium influx triggers calcium-dependent phosphorylation and release of Mecp2 and the 
gene is transcribed. B dnf was first described as a factor which promoted survival and 
differentiation of selected neuronal populations (Phillips et al 1990, Branchi et al 2004.) 
Bdnf is now considered to be a synaptic morphogen (Poo 2001, Chao 2003) whose 
expression and release is controlled by neuronal stimulation (Branchi et al 2004, Zara et al 
1990, Ghosh et al 1994 Tao et al 2002) Bdnf levels have been found to be high in the 
hippocampus and cerebral cortex, areas which show reduced dendritic complexity in Rett 
syndrome brain. One recent study has shown that Bdnf over-expression profoundly alters the 
form and stability of basal dendritic branches, which correlates with the disordered 
arborisation seen in Rett patients; clearly, it is not unreasonable to suppose that disregulated 
Bdnf levels are the cause o f at least some of the symptoms of Rett pathology.
Another gene whose product is known to be involved in synaptic plasticity is Liprin-a4, 
which is upregulated 2.15 fold +/- 0.141 according to the QRT-PCR data. Liprin-a4, also 
known as Ppfia4, is a multidomain protein which interacts with the Lar family of receptor 
protein tyrosine kinases (Serra-pages et al 1995, Ko et al 2003) and the Grip/Abp family of 
Ampa receptor interacting proteins (Wyszynski et al 2002) Mutations in the C.elegans 
homologue syd-2 (synapse defective 2 ) and the D.melanogaster homologue Dliprin-a lead 
to impaired synaptic transmission (Zhen and Jin 1999) and defective axon terminal branching 
(Kaufmann et al 2002) respectively (Ko et al 2003,) Liprin-a4 is localised to the synapse 
and reduced levels result in reduced neuromuscular bouton number. MeCP2 is also localised 
to the synapse, in the post synaptic compartment (Jarrar et al 2003.) Perhaps many of the 
symptoms of RTT are caused by defects in brain architecture at the level of the connectivity 
of individual neurons or by defects in synaptic transmission?
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Fig 6.11. M odel for action of M eCP2 deficiency in Rett syndrom e
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Fig 6.11. A putative model fo r  how some o f  the changes observed in the intestine might, i f  seen in other tissues, contribute 
to the pathology o f RTT.
Loss o f  MeCP2 may deregulate Bdnf which may have direct effects on neuronal plasticity and dendritic branching, altering 
brain architecture, and secondary effects on neuroendocrine peptides such as Gip. Increased Gip may cause increased 
proliferation o f the crypt cells and therefore increased villus length. Altered Bmp2 levels may lead to bone abnormalities. 
Alterations in the metabolism offatty acids may lead to metabolic stress, causing a further rise in Bdnf. Liprin-a levels are 
also disrupted, leading to changes in synaptic plasticity.
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6.10.2. Rett syndrom e and bone abnorm alities.
Bone abnormalities have been recorded in a significant proportion of RTT patients; one 
study found short fourth/fifth metatarsals in 65% of patients, short fourth/fifth metacarpals in 
57% and reduced bone density in the hands in 86% of cases (Leonard et al 1995.) Bone age 
was also found to be altered in RTT patients, although the effect decreased with increasing 
chronological age (Leonard et al 1995.) Bmp2 (bone morphogenetic protein 2) was found to 
be downregulated (fold-change = 0.34, p=0.002 T-test) in the intestine. Bmps are 
multifunctional growth factors o f the Tgf-p superfamily and induce the formation of both 
cartilage and bone, as well as plying a part in many non-osteogenic developmental processes 
(Chen et al 2004.) Bmp-2 interacts with Fgf-4 and sonic hedgehog in the growing limb bud 
to limit growth and induce the expression of chondrocyte and osteocyte precursors. Bmp-2 
null mice have not been studied as they are non-viable and die between E7.5 and E l0.5 with 
defects in cardiac development (Chen et al 2004.) A transgenic mouse model in which 
noggin (an inhibitor of Bmp-2) is overexpressed, however, develops osteoporosis (Chen et al 
2004.) Interestingly, the intestinal phenotype of the Fkh6 knockout mouse was also 
accompanied by a drop in Bmp2 levels. If Bmp-2 is also altered in other tissues, this would 
correlate with the observation that some RTT patients present with increased bone age and 
bone abnormalities (Leonard et al 1995), and would be worthy of further study.
6.10.3. Does Rett syndrome cause metabolic stress via defects in fatty acid metabolism?
If Bdnf knockout mice are obese, then elevated Bdnf levels might be expected to have an 
opposite effect on body mass. RTT patients are known to have lower energy balance per 
kg/body weight (Motil et al 1994.) Could Bdnf be responsible for the lower energy useage of
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RTT patients? The hypoactivity observed in these patients could then be seen as an attempt 
to conserve energy. A number of studies in Rett patients have indicated defects in basic 
metabolism (Motil et al 1994) and other studies have hinted that mitochondria may somehow 
be involved (Lappalainen and Riikonen 1994.) BDNF levels in the brain are known to 
increase in response to metabolic stress (Mattson et al 2002.) The fact that Ssc2 is 
downregulated may also be significant; Ssc2, also known as Elovl2 in the mouse, is a 
component of the long chain fatty acid elongation pathway (Tvrdik et al 2000.) A 1999 
study showed that Rett patients have reduced levels o f long chain fatty acids (VLCFAs) and 
carnitine, which is slightly ameliorated by administration of exogenous L-camitine, a 
common theraputant in Rett syndrome (Stradomska et al 1999.) Lowered VLCFAs have 
been considered a secondary effect of Rett syndrome (Stradomska et al 1999), and the 
reasons for the low levels were not known; if lowered Ssc2 levels are found in other tissues 
apart from the intestine, this may well provide part of the answer.
The lowered VLCFA levels are certainly an investigative avenue worth pursuing as it may 
lead to more effective methods o f raising VLCFA levels in Rett patients. Proof of principle 
of the contribution of VLCFA dysfunction to brain disorders can be found in the mouse 
‘quaking’ and ‘jimpy’ mutants, which both have mutations in other components of the LCFA 
elongation machinery. Recent research has explored the links between VLCFA depletion 
and brain function and has concluded that VLCFAs are essential for normal brain growth and 
function (Ruxton et al 2004.)
A generalised defect in fatty acid metabolism is hinted at by other gene changes seen on 
the array. Acetyl Coenzyme A dehydrogenase is downregulated (fold change = 0.425, p=0.01 
T-test) on the array. Acetyl CoA is used as a substrate for fatty acid synthases in the 
cytoplasm. GIP is also known to increase the activity of lipoprotein lipase (Eckel et al 1979),
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a gene seen to be upregulated on the array; lipoprotein lipase liberates fatty acids from 
triglycerides received from the gut (Keiffer et al 2003.) These fatty acids can then be 
converted to triglycerides for storage in adipose tissue.
If there are indeed defects in Rett mitochondria, carnitine levels, fatty acid metabolism 
and Ssc2 levels, then there may be fewer VLCFAs synthesised, the delivery of LCFAs to the 
mitochondria for oxidation may be impeded, and VLCFAs may be used for P-oxidation 
instead, further depleting VLCFA levels. Both the production of fatty acids and their 
breakdown may be affected. This may cause a degree of metabolic stress; and since Bdnf is 
known to rise in response to such a stress signal, the altered Bdnf levels may be both a direct 
consequence of the removal o f the MeCP2-mediated repression and also a marker of this 
metabolic stress response, and may even reinforce each other in a positive feedback loop.
Could Rett syndrome be a disease characterised by metabolic stress caused by defects in 
fatty acid metabolism? Much further work would need to be done, including a thorough 
examination of mitochondrial function. The availability of both constitutive and conditional 
models of RTT should greatly aid this process.
Further avenues of study could involve examining other tissues in the constitutive 
knockout mouse to determine whether the transcriptional changes seen in the intestine are 
also seen in other tissues. Human samples could also be investigated, although this is a 
difficult area as it involves acquisition of human tissue for which ethical consent must be 
obtained. Other avenues could involve challenging constitutive Mecp2 null mice with a high- 
glucose or high-fat diet to examine the effects of raised Gip levels, characterising the link 
between Bdnf and Gip (i.e. is Gip directly upregulated by MeCP2 loss, or is it an indirect 
effect caused by Bdnf?) Examining body weights, food intake and eating behaviour of 
MeCP2 null mice throughout life would also help to elucidate the effects of Gip and Bdnf on
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the gut brain axis. Finally, a thorough characterisation of fatty acid metabolism in MeCP2 
null mice would be valuable to examine the theory that Rett syndrome may be predominantly 
caused by alterations in neuronal growth and connectivity, perhaps caused by neuronal 
metabolic stress caused by defects in fatty acid metabolism and mitochondrial defects.
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Chapter 7: Summary.
7.1. The role of MBD proteins is diverse.
The methyl CpG binding domain (MBD) proteins are a family of proteins which ‘read’ the 
methylation marks on DNA and act upon them. As our knowledge of the MBD proteins 
increases, it is becoming apparent that they are linked to a wide variety of cellular processes, 
from tumour suppression to neuronal development. The breadth of function of these proteins 
underlines how epigenetic processes are fundamental to the cell.
The MBD family consists of 6 known members; M bdl, Mbd2, Mbd3, Mbd4, MeCP2 and 
Kaiso. Mbdl is involved in transcriptional repression (Wade 2001) and also links DNA 
methylation to DNA repair. Mbd2 has a variety of binding partners which appear to modulate 
its activity (Lembo et al 2003.) Mbd3 does not appear to bind methylated DNA (Hendrich 
and Bird 1998) but is thought to be crucial to the developmental process, as reduced levels of 
Mbd3 cause developmental abnormalities in a model system (Xenopus) (Iwano et al 2004.)
Mbd4 does not play a role in transcriptional repression, but instead appears to maintain 
the integrity of the genome (Sansom et al 2003a) through its involvement with base excision 
repair (BER) mismatch repair (MMR) and the cell cycle response to DNA damage (Parsons 
2003, Sansom et al 2003a) MeCP2 is a transcriptional repressor which can recruit chromatin 
remodelling factors to methylated DNA, remodelling chromatin into a form refractory to 
transcription and thereby silencing the gene (Nan et al 1998.) Kaiso binds p i20 catenin and 
represses genes in a methylation-specific manner (Kim et al 2004.)
The correct interpretation o f the methylation signal is vital to the normal growth and 
development of the organism, and this is illustrated by various knockout and conditional
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mouse models which have been created. M bdl'1' mice, although viable and fertile, have 
defects in hippocampal function and neurogenesis and have an elevated rate of aneuploidy in 
neurons (Zhao et al 2003.) Mbd2'f~ mice are again viable and fertile, but cannot form a 
normal MeCPl complex, leading to reduced repression from methylated promoters 
(Hendrich et al 2001.) The Mbd2~f~ mouse also has problems in carrying, delivering and 
caring for offspring (Hendrich et al 2001.) The Mbd3'A knockout is far less benign; the 
Mbd3'A allele is embryonic lethal, and embryos are severely abnormal and in the process of 
being reabsorbed by day E8.5 (Hendrich et al 2001.) Reducing Kaiso levels in Xenopus leads 
to premature activation of genes before the mid-blastula transition and developmental arrest 
(Ruzov et al 2004.)
The MBD proteins are also involved in tumourigenesis; Mbd2'u mice crossed onto an 
intestinal tumour prone ApcMm background (a model of the human cancer syndrome FAP) 
develop fewer, smaller tumours (Sansom et al 2003c.) The role of Mbd4 in tumourigenesis is 
less clear; Mbd4 repairs C-^T transitions, and thus might be expected to be protective against 
tumourigenesis (Bellacosa 2001.) Deficiency of Mbd4 has been shown to accelerate 
tumourigenesis on an ApcMm background (Millar et al 2002.) MBD4 mutations are mainly 
found in a subset of (MMR-deficient) tumours (Riccio et al 1999) and so may be that MBD4 
is not a major tumour suppressor in the human. No study has yet looked at possible 
epigenetic inactivation of MBD4 in human gastrointestinal tumours.
This project has shown that Mbd4 mediates the apoptotic response to two signals; Fas 
ligand and anoikis. Anoikis is apoptotic death triggered through the loss of normal 
attachment signals (Nagata et al 1999.) One property of a cancer cell is a loss o f sensitivity to 
such signals, making a cancer cell more resistant to apoptosis (Hanahan and Weinberg 2000.)
I have demonstrated that loss of Mbd4 results in significantly less apoptotic death in response
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to loss of attachment signals in a model using isolated murine intestinal crypts. This also 
implies that Mbd4 may have additional tumour suppressor functions through mediation of 
anoikis. In contrast, I have shown that Mbd4'A mice have an increased apoptotic response to 
Fas ligand. Since Mbd4 is known to interact with Mlhl, the apoptotic response to Fas ligand 
was also examined in M lhl'A mice, which showed a lowered apoptotic response to Fas 
ligand. These results lead to a putative model of the interaction between M lhl, Mbd4 and Fas 
signalling, in which both proteins are part of a larger signalling complex (see model in fig 
3.14.)
The role of MeCP2 in the murine mammary gland and intestine were also examined using 
conditional knockouts. Although RTT is considered to primarily affect the CNS, the presence 
of gastrointestinal problems (Motil et al 1999) and bone abnormalities (Leonard et al 1995) 
in RTT patients provided a rationale for examining extra-CNS tissues. Loss of MeCP2 in the 
murine mammary gland appeared to cause no changes in either development or involution. 
However, loss of MeCP2 in the intestine resulted in a marked phenotype; intestinal villi 
become 12.5% longer, and the proliferation and migration dynamics of the crypt-villus unit 
were perturbed. Increased levels of proliferation in the crypt were observed, characterised by 
an expansion of the transit amplifying (TA) zone with no increase in the size of the crypt. 
Migration rates were 12.9% increased and no change in apoptosis was observed.
No gross changes in cell lineage allocation were seen, with normal numbers and 
distribution of major cells types being observed. Microarray and QRT-PCR analysis revealed 
a number of transcriptional differences in the Mecp2 null transcriptome; Bdnf,\ a known target 
of MeCP2 was over 4-fold upregulated, and smaller but significant increases were also seen 
in Gip, Liprina4, and W dnml. Igfbp3, Ssc2 and Dlx5 were significantly downregulated. 
Increased Gip levels are thought to be responsible for the villus lengthening phenotype. If the
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analysis can be extended to other tissues, the results also offer possible insights into the 
mechanisms underlying RTT pathology. Bdnf may play a role in creating the neuronal 
abnormalities seen in RTT patients. Lowered Ssc2, which is involved in very long chain fatty 
acid (VLCFA) metabolism, may explain the lowered VLCFA levels seen in RTT patients. 
The bone abnormalities may be explained by the upregulation of Bmp2 seen on the array, 
although this was not followed up with QRT-PCR.
This work provides further evidence that epigenetic processes mediated by methyl 
CpG binding domain proteins are important in a number o f developmental processes and 
in the development of cancer.
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Abstract
Mouse models of human cancer are vital to our understanding of the neoplastic process, and 
to advances in both basic and clinical research. Indeed, models of many of the major human 
tumours are now available and are subject to constant revision to more faithfully recapitulate 
human disease. Despite these advances, it is important to recognize that limitations do exist to 
the current range of models. The principal approach to modelling has relied upon the use of 
constitutive gene knockouts, which can often result in embryonic lethality, can potentially be 
affected by developmental compensation, and which do not mimic the sporadic development 
of a tumour expanding from a single cell in an otherwise normal environment. Furthermore, 
simple knockouts are usually designed to lead to loss of protein function, whereas a subset 
of cancer-causing mutations clearly results in gain of function. These drawbacks are well 
recognized and this review describes some of the approaches used to address these issues. Key 
amongst these is the development of conditional alleles that precisely mimic the mutations 
found in vivo, and which can be spatially and tissue-specifically controlled using ‘smart’ 
systems such as the tetracycline system and Cre-Lox technology. Examples of genes being 
manipulated in this way include Ki-Ras, Myc, and p53. These new developments in modelling 
mean that any mutant allele can potentially be turned on or off, or over- or under-expressed, 
in any tissue at any stage of the life-cycle of the mouse. This will no doubt lead to ever more 
accurate and powerful mouse models to dissect the genetic pathways that lead to cancer. 
Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John 
Wiley & Sons, Ltd.
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Introduction
M ou se m od els o f  tum ourigenesis have been  vital in 
our attem pts to unravel the com p lex , m ultistage pro­
ce sse s  w hich  confer a neoplastic phenotype. M ou se  
m odels o f  m any o f  the major hum an cancers are ava il­
able and are w id ely  used in both basic research and 
clin ical and therapeutic trials. M ice  have m any advan­
tages as a m odel; they are sm all, easy  to h ou se , and  
have a short gestation  tim e. Our increased  understand­
ing o f  the m ouse gen om e over the last few  years has 
also been a pow erful force, a llow in g  p recise m anip­
ulation o f  the m ouse gen om e to produce ever  m ore 
sophisticated  m odels.
It is also im portant to recogn ize the lim itations o f  
the m ouse in m odelling  human p ath olog ies. M ice  have  
shorter lifespans and m any d ifferen ces in basic  c e l­
lular processes (see  Rangarajan and W einberg [ 1 J.) 
The spectrum  o f  com m on  sporadic tum ours in m ou se  
and man is also different. M ice  tend to d ev e lo p  sar­
com as and lym phom as, derived  from  m esen ch ym al 
tissues, w hereas hum ans are m ore lik e ly  to d ev e lo p  
carcinom as derived from  ep ithelia l tissu es, such  as car­
cinom as o f  the co lon , breast, lung, skin, and pancreas 
[1,2]. Im m ortalization k inetics in m ice  and hum ans are
also  d ifferent, due to the d ifferen ces in  te lom eres and 
telom erase exp ression  [1 ,3].
Certain m ou se m odels recapitu late hum an d isease  
extrem ely  w ell. For exam p le , overexp ress ion  o f  c-Myc 
in the m ou se leads to sim ilar p a th o log ies (B -ce ll ly m ­
phom as), as it d oes in m an [4 ,5 ]. H ow ever , identical 
gen etic  les ion s do som etim es p roduce very different 
p atholog ies in the tw o  sp ec ies . A  good  exam p le  o f  this 
is the retinoblastom a gen e  product Rb. Rb transduces 
anti-proliferative signals and is an im portant tum our 
suppressor [6]. In hum ans, lo ss o f  the retinoblastom a  
tum our suppressor gene RB leads to the d ev e lo p ­
m ent o f  retinoblastom a at an early age , fo llo w ed  by  
osteosarcom as and sm all ce ll lun g  cancer [7]. In m ice , 
h ow ever, lo ss  o f  Rb very rarely cau ses retinob las­
tom a [5,7]; Rb null m ice  exh ib it em b ryon ic lethal­
ity, and h eterozygotes d ev e lo p  pituitary carcinom as 
and thyroid tum ours at h igh  frequency  [5 ,7 ,8 ]. Prima 
facie , then, the m ou se m odel o f  retinob lastom a m ay  
appear to b e  o f  little  use. H ow ever, ev en  i f  the tum our 
spectra are different, the underlying ce llu lar  p rocesses  
that lead to the hum an d isease  m ay w e ll b e  sim ilar. 
For exam p le , it w as h yp oth esized  that there m ay b e  
redundancy or com p en sation  b e tw een  Rb and fam ­
ily  m em bers such as p i 07  and p i 30  [90 11]. S tudies  
by D yer et al in ch im eric m od els  [1 0 ,1 1 ] found  that
C opyright © 2005 Pathological Society o f G re a t Britain and Ireland. Published by John W iley  & Sons. Ltd.
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p i 07  w as up-regulated in the d eve lop in g  m ou se  retina 
and that Rb+/ p lO 7 - / ~ null m ice  do d ev e lo p  bilateral 
retinoblastom as at h igh  frequency [11]. T his su g g ests  a 
com pensatory m echanism  in the m ou se w hich  d o es not 
ex ist in the hum an retina. Such experim en ts sh ow  the 
com p lex ity  o f  sign alling  pathw ays and provide im por­
tant insights into their m echan ism s o f  action  in both  
the m ouse and the human.
E ven m odels w hich do not appear to recapitulate the 
hum an d isease exactly  can be valuable too ls for under­
standing the m echanism s o f  tum ourigen esis. R ecen t 
advances in gen e m anipulation such as conditional 
gen e targeting, high throughput screen in g  strategies, 
and inform atics are all facilitating a n ew  generation  o f  
m ouse m odels w hich prom ise to recapitulate hum an  
d isease  m ore faithfu lly  and so  bring us c lo ser  to the 
goal o f  curing human neoplasias.
The first generation of mouse models of 
cancer
The first generation o f  m odels w as created by con sti-  
tu tively  exp ressing  cellu lar and viral o n co g en es such  
as c-Myc [4], or by ‘knocking ou t’ tum our suppres­
sor gen es such as Rb [5 ,7 ,12 ,13 ]. T h ese  m od els co n ­
tinue to contribute greatly to our understanding o f  
the cellu lar process underlying cancer developm ent. 
H ow ever, they have a number o f  draw backs; first, 
expression  o f  an exogen ou s gen e, or ablation o f  a 
vital tum our suppressor gen e, is often  incom patib le  
w ith normal developm ent, leading to em bryonic lethal­
ity or severe developm ental disruption or sterility  in 
the adult [140 16]. Second , w hole body exp ression  or 
ablation o f  a gen e d oes not m im ic sporadic tum our  
developm ent in vivo , w here abnormal ce lls  carrying  
the genetic  lesion  are surrounded by norm al tissue. 
Third, w ith addition transgenesis there is u sually  lit­
tle control over site o f  integration and cop y  num ber. 
In these circum stances, the exogen ou s gen e  m ay affect  
gen es near the insertion site, or be affected  by en d o g e ­
nous control elem ents [140 16]. Fourth, spatial and 
tem poral control o f  the transgene is lim ited , although  
som e m odels do ach ieve good  tissue sp ecific ity  by the  
use o f  a tissu e-sp ecific  promoter. O ne such su ccessfu l 
exam ple is a m odel o f  m ouse pancreatic cancer that 
uses the S V 4 0  T -antigen under control o f  the insulin  
prom oter to drive pancreatic transform ation [17].
R ecent advances in gen e targeting tech n o logy  h ave  
led to m odels in w hich the expression  o f  s in g le  or 
m ultip le gen es can be tightly controlled , both spatially  
and tem porally. U sin g  this approach, the problem  o f  
em bryonic lethality can be circum vented , as has been  
show n  for m any gen es, includ ing the adenom atosis  
p olyp osis co li gen e (Ape) [18]. T he gen e  o f  interest 
can then be m utated in a sp ecific  tissu e  at a defined  
point in the life  cy c le , a llow in g  the e ffec t o f  rem oval 
to be precisely  defined. C ell-targeted  alteration o f  g en e  
exp ression  a lso  recapitulates the in vivo d evelop m en t
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o f  sporadic cancers [19] and a llow s the in fluence o f  
norm al surrounding tissue to b e  exam ined .
A  range o f  control system s have n ow  b een  d ev e l­
oped  w hich  a llow  the precise spatial and tem poral 
control o f  gen e  expression , and are predom inantly  
based on a bitransgenic approach, as described  in detail 
b elow . M ice  carrying a tissu e-sp ecific  inducib le  trans­
activator gen e  are crossed  to m ice  carrying the a lle le  
o f  interest w hich  has been engineered  so  as to be co n ­
trolled by the transactivator. O ffspring that carry both  
transgenic elem ents can then be treated w ith an appro­
priate inducer to express the transactivator g en e  in a 
sp ecific  tissue, w hich then acts on the desired  a lle le .
Transgenic tools. Cre-Lox and FLP: 
site-specific recombinases
C re (C auses recom bination) recom b in ase is a site- 
sp ecific  recom binase o f  the in tegrase fam ily , iso lated  
from  bacteriophage PI [20D 2 2 ]. Cre ca ta ly ses  site- 
sp ecific  recom bination betw een  defined  3 4  bp ‘Lox P ’ 
(locu s x  o f  crossover P I )  sites. I f  a g en e  is p laced  
b etw een  tw o L ox P sites and ex p o sed  to C re, then the 
g en e  w ill be ex c ised  or ‘flo x ed ’ out. A  sim ilar recom ­
binase, FLP, iso lated  from  S cerevisiae, a lso  ca ta lyses  
recom bination  from  sim ilar 3 4  bp FRT (F L P  recom ­
bination target) sites [2 0 ,2 3 ,2 4 ] . T he C re and FLP  
system s can b e  used to create tissu e-sp ec ific  con d i­
tional deletion s o f  an a lle le , o vercom in g  the problem  
o f  em bryonic lethality  or d evelopm enta l d efects [20]. 
M ice  carrying the Cre recom binase under the control 
o f  an inducib le or tissu e-sp ecific  prom oter are crossed  
w ith m ice  carrying the g en e  o f  interest that has been  
flanked by L ox P sites [20]. W hen the m ice  are g iv en  
the appropriate inducer, Cre is exp ressed  in a spatially  
defined  m anner and the g en e  o f  interest is ‘floxed  ou t’ 
in a sp ecific  tissu e  (F igure 1A ). T he C re-L ox and FLP  
system s can a lso  be used  to activate a gen e. In this 
instance, a ST O P  cassette  flanked by  L ox  P  or Frt 
sites is p laced  b efore the g en e  o f  interest, and exp res­
sion  o f  the Cre results in the cassette  b e in g  ex c ised , 
allow in g  expression  o f  the gen e  [20] (F igure IB ).
B ecau se  Cre recom binase is ex o g en o u s to the m ou se  
[25 ,2 6 ], it w as thought that exp ression  w ou ld  have  
no effects other than to target the sp ec ific  L ox P  
sites. H ow ever, recent reports sh ow  that Cre appears 
to act, a lbeit w ith lo w  affinity, w ith ‘p seu d o-L ox  P  
s ite s ’ in the m ou se gen om e [26] and its exp ression  in  
m am m alian ce lls  can have deleteriou s e ffec ts  on  the  
stability  o f  the m ouse gen om e, in clu d in g  ch rom osom e  
rearrangem ents in m ou se sperm atids [25 ]. A lthou gh  
the im plications o f  this are as yet u nknow n, th is has 
in part stim ulated the d evelop m en t o f  se lf-e x c is in g  Cre 
vectors [27].
Several form s o f  Cre d elivery  h ave b een  develop ed ;  
thus, Cre m ay b e ligand-in duced , such  as through  
creation o f  the fusion  protein CreER™ transgene, 
w hich is tam oxifen-dependent [2 0 ,2 8 ]. C re m ay a lso  
be d elivered  packaged in adenovirus [2 0 ,2 9 ] , or m ay
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Figure I. The Cre-Lox system. (A) Gene ablation: mice containing a transgenic construct in which the gene of interest is flanked 
by two Lox P sites are crossed with mice carrying a Cre recombinase gene under the control of a tissue-specific or inducible 
promoter. On activation of the Cre recombinase, the Lox P sites recombine, excising the gene of interest. (B) Gene activation: 
mice carrying a tissue-specific Cre recombinase are crossed with mice carrying a construct where the gene of interest is preceded 
by a STOP cassette, preventing transcription. Upon activation of the Cre recombinase, the STOP cassette is recombined out 
(‘floxed out’) and the gene may be transcribed. The Cre recombinase can be activated in several ways (detailed in the main text), 
allowing tight spatial and temporal control of gene expression
be p laced under the control o f  a promoter w hich has a 
w ell-defined  spatio-tem poral expression  pattern, such  
as the use o f  the WAP [30] and BLG prom otors 
to deliver Cre expression  to the m ouse m am m ary  
gland [31]. F inally, Cre activity m ay be controlled  
through the use o f  an inducible promoter; for exam p le, 
through use o f  the CyplA  promoter [32]. D esp ite  the 
apparent versatility o f  these system s, the on e caveat 
that remains is their irreversibility. T hus, i f  a m odel 
requires a gene to be sw itched on and off, then a 
m ore suitable alternative may be constructed w ith, for 
exam ple, a tetracycline-responsive system .
Tetracycline-inducible systems
The tetracycline (tet)-dependent system  d evelop ed  by 
G ossen  and Bujard [33,34] a llow s tight spatial and 
tem poral control through the use o f  a tissu e-sp ecific  
transactivator and an effector gen e (F igure 2). U n lik e  
the Cre and FLP system s, the tet system  a llo w s gen es  
to be turned on and o ff  at w ill, v ia  the adm inistration o f  
the inducer (tetracycline, or m ore usually  d o x y cy c lin e )  
T he system  can a lso  be tuned to either sw itch  on  gen e  
expression  (the ‘tet-on’ or tTA system ) or sw itch  it o f f  
(the tet-o ff or rtTA system  [35]).
The tet-on (tTA) system  uses the Tn 10-sp ecific  
tetracycline resistance operon o f  E coli (F igure 2) 
and is com posed  o f  tw o parts; a transactivator and 
an effector [35]. T he transactivator is  com p osed  o f  
the D N A  binding dom ain o f  the E coli tetR  gen e  
fused to the transactivation dom ain o f  the V P 1 6  herpes
sim plex  virion protein 16 gen e, under the control o f  a 
tissu e-sp ecific  promoter w hich  drives exp ression  o f  the  
tTA (tetR /V P 16) fusion  protein in the desired  tissue. 
T he second  com ponent is a construct contain ing the  
gen e  o f  interest driven by the m inim al prom oter o f  
human cytom egalovirus (P cm v), under the control o f  
the tet operator, tetO. In the ab sen ce o f  d o x y cy c lin e , 
the tTA protein binds tetO and activates the m inim al 
prom oter, driving expression  o f  the gen e. F low ever, 
w hen d oxycyc lin e  is added, it b inds to the tTA protein  
and causes a conform ational change w hich  prevents it 
from  binding tetO. T he prom oter is  not activated  and 
the gen e  is not expressed  [35] (F igure 2A ).
In the tet-on system  (rtTa), the secon d  com pon en t 
o f  the binary system  is identical to the te t-o ff sy s ­
tem , but the transactivator com p onent is m ade up o f  
a tissu e-specific  prom oter and a mutant version  o f  the  
tetR  D N A  binding dom ain fused  to the V P 16  trans­
activator [35]. T his produces a m utant rtTA protein: 
in the absence o f  d oxycyc lin e , rtTA d oes not bind to  
the tetO operator, and there is  no gen e  exp ression . 
W hen d o xycyc lin e  is added, the protein undergoes a 
conform ational change and can bind the operator, lead­
in g  to expression  o f  the gen e o f  interest. I f  absolute  
repression o f  a gen e is required, the transactivator can  
be constructed with a silencer w ith the K R A B -A B  
silen cin g  dom ain o f  the K idl gen e  inserted instead  
o f  the V P  16 dom ain. T his prevents leaky transcription  
caused  by the basal level o f  affinity o f  tTA for tetO  
in the absence o f  d o xycyc lin e . T he tet-on , tet-off, and 
silen cer system s can be used together to control m ore 
than on e  gen e at a tim e.
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Figure 2. The tetracycline-responsive system. (A) In the tet-off system, the DNA binding domain of the £ coli tetR gene is fused 
to the transactivation domain of the herpes simplex virion protein 16 (VP 16) gene, under the control of a tissue-specific promoter 
which drives spatially controlled expression of the tTA (tetR/VPI6) protein in the desired tissue. The effector construct contains 
the transgene of interest, driven by the minimal promoter of human cytomegalovirus (Pcmv) under the control of the tet operator 
tetO. In the absence of doxycycline, tTA binds tetO and drives expression of the transgene. When doxycline is added, it binds tTA 
and prevents it from binding tetO, stopping expression of the transgene. (B) In the tet-on system (rtTa), the second component of 
the binary system is identical to the tet-off system, but the transactivator component is made up of a tissue-specific promoter and 
a mutant version of the tetR DNA binding domain fused to the VP 16 transactivator. In the absence of doxycycline, rtTA does not 
bind to the tetO operator and there is no gene expression. When doxycycline is added, the protein undergoes conformational 
change and can bind the operator, leading to expression of the gene of interest
Other conditionally  inducible system s are under 
developm ent, although they are not as progressed  
as the tet and C re-Lox system s. T hese include sy s­
tem s based on the insect steroid m oulting horm one  
ecd yson e [36], the progesterone analogue m ifepristone  
[37], the Lac operator-repressor system  [38], and the 
G A L 4/U A S system  [39].
Modelling six of the hallmarks of cancer
In their 2000  paper [40], Hanahan and W einberg pro­
posed that cancer ce lls  can be seen  as having six  char­
acteristics, or ‘hallm arks:’ se lf-su ffic ien cy  in grow th  
signals; non-responsiveness to anti-proliferative s ig ­
nals; resistance to apoptosis; unlim ited rep licative  
capacity; an giogenesis; and the ability to m etastasize  
and invade. A spects o f  each o f  these different facets  
have been m odelled  in the m ouse, provid ing valuable  
insights into the relevance o f  these m echanism s. T he  
remainder o f  this review  w ill therefore focu s on a num ­
ber o f  exam ples relating to each o f  these ‘hallm arks’. 
We w ill also briefly d iscuss the m od elling  o f  other  
factors w hich assist or trigger carcin ogen esis, such  
as gen om ic instability or alterations o f  the ep igen etic  
imprint o f  the cell.
Self-sufficiency in grow th  signals
O ncogen es and tum our suppressor gen es (T S G s) are 
in vo lved  in regulation o f  the ce ll cy c le . T he core  
o f  the ce ll c y c le  m achinery con sists  o f  a fam ily  o f  
cyclin -dependent k inases (C D K s), w hich  drive the ce ll 
through the ce ll cy c le  by phosphorylating k ey effector  
substrates [41]. T he C D K s are prim arily p ositive ly  
regulated by the cy c lin s and n egatively  regulated  
by the m em bers o f  the Ink4 fam ily  and by p21kip  
and p l9 A rf. In turn, these primary regulators are 
th em selves regulated by m any other m o lecu les  in  
response to signals from  in sid e (eg  D N A  dam age  
surveillance) and outside (eg  grow th horm ones) the 
ce ll. T he tight control o f  ce ll grow th and d iv ision  
is vital to a m ulticellular organism  and m utations in 
these key cy c le  regulators can lead to uncontrolled  
d iv ision  —  on e  o f  the hallm arks o f  the cancer ce ll.
M ou se m odels o f  ce ll cy c le  regulators are a llow in g  
us to unravel the com plex  w eb  o f  control that d ic ­
tates w hen and how  fast ce lls  d iv ide. For exam ple, 
PTEN  (phosphotin  and tensin  h om ologu e  deleted  on  
chrom osom e 10) is  a phosphatase w h ich  an tagonizes  
the PI3K  pathw ay [42]. PTEN is  a tum our suppressor 
gen e and is mutated in a variety o f  hum an sporadic  
tum ours. C onstitutive Pten h o m o zy g o u s knockouts  
sh ow  early em bryonic lethality; Pten heterozygotes  
d evelop  a range o f  tum ours o f  the in testin e, prostate,
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m am m ary, thyroid, endom etrial, and adrenal tissu es  
[42]. Furthermore, condition al knockouts u sin g  Cre- 
L ox technology  have revealed  Pten lo ss  as an early  
event in prostate tum ou rigenesis [4 3 ,4 4 ]. H o m o zy g o u s  
conditional deletion  o f  Pten in the prostate leads to 
hyperplasia by 4  w eek s p ost-flox in g , prostate intraep- 
ithelial neop lasia  by 6  w eek s, in vasive  ad enocarcino­
m as by as early as 9  w eek s, and m etastasis as early as 
12 w eek s. T he conditional approach a lso  sh o w s het­
erozygou s Pten deletion  to result in m uch slo w er  d is­
ease progression, with failure to progress to in vasive  
carcinom a. E ven in such an ex ce llen t m od el, h o w ­
ever, caveats remain; m etastatic les ion s in m ice  w ere  
found m ainly in the lung, w hereas hum an prostate 
cancer m etastases tend to d eve lop  in bone. N on eth e­
less, the prostate Pten m odel cou ld  be used to test the 
effects  o f  other gen es on the progression  o f  the d is­
ease , or for therapeutic testing. Indeed, co-op erativ ity  
has already been dem onstrated for the ce ll c y c le  reg­
ulators Ink4aArf and Pten [45]. T he Ink4a/Arf locu s  
en cod es tw o TSG s: pl6Ink4a, w hich regulates the Rb 
pathw ay, and pl9A rf, w hich regulates p 5 3 . T he c o m ­
pound mutant ln k4a /A rf+ ,~ Pten+ /~ m ou se sh ow s  
shortened tum our latency and Ink4a/Arf~/ ~ Pten+ /~ 
m ice shorter latency still (although, in trigu ingly , pro­
gression  to in vasive carcinom a is not seen  in this 
m odel.)
M urine m odels are also illustrating h ow  in com ­
p letely  w e  understand cell cy c le  control. T hus, 
although the cell cy c le  regulators C dk4 and C dk6 have  
been considered  critical initiators o f  the ce ll cy c le , 
C dk4 has been show n to be d ispensab le for prolif­
eration in m any cell types [46 ,47]. Furtherm ore, Cdk6 
knockout m ice  are v iab le with on ly  m inor d efects  [48], 
and no synergism  has been observed in m ice  doubly  
null for Cdk2 and Cdk6. B y contrast, d efic ien cy  o f  
both Cdk4 and Cdk6 does lead to em bryonic lethal­
ity, although this is due to severe anaem ia, rather 
than a general ce ll d iv ision  defect [46]. M E Fs (m urine 
em bryonic fibroblasts) from Cdk4~/ ~ Cdk6~!~ m jce  
w ere capable o f  d iv ision  in culture (a lbeit m ore s lo w ly  
than w ild -type ce lls) and underw ent im m ortalization  
after repeated passaging. M utant ce lls  a lso  b ecam e  
quiescen t in response to serum  w ithdraw al but re­
entered the cy c le  norm ally w ith the appropriate stim ­
uli. C ells  a lso  had low ered Rb phosphorylation  —  a 
serious challen ge to the accepted theory that fu ll Rb 
phosphorylation by both C dk2 and C d k4/6  is required  
for G l/S  transition [48]. Taken together, the data from  
these m ice therefore ch a llen ge our understanding o f  
the role o f  the D -typ e cyc lin s and su ggest that alterna­
tive m echanism s are capable o f  in itiating proliferation.
c-Myc
If a ce ll has activated a gen e  a llow in g  se lf-su ffic ien cy  
in grow th factor signals, deactivating  that g en e  m ay  
lead to tum our regression . M arinkovic et al have  
used a m ouse m odel in w hich  c-Myc is con d ition ­
ally expressed  under the control o f  a lym p h o id -sp ec ific
prom oter using the te t-o ff system  [49]. Treatm ent 
w ith d o x y cy c lin e  led  to regression  o f  the tum ours, 
im ply ing  that the requirem ent for c-Myc activation  is 
continuous [46]. A  reversib le m odel o f  skin  neop la­
sia has been  created by P elengaris et al [50] using  
a m odified  version  o f  Myc (MycER™) targeted to  
skin using the involucrin prom oter. U pon  adm in is­
tration o f  the inducer 4 -h yd roxytam oxifen  (4-O H T ), 
Myc is turned on and induces proliferation in the nor­
m ally p ost-m itotic ce lls  o f  the suprabasal layer. T his  
leads to hyperplastic les ion s and papillom atous ep i­
derm al lesion s. T hese les ion s h ave not been  seen  to 
progress to m alignancy, as the d ifferentiation  pathw ay  
is thought to override the in fluence o f  M yc in these  
ce lls . D eactivation  o f  the Myc transgene leads to rapid 
regression  o f  the lesion s and their associated  vascu la ­
ture. E ven transient deactivation  o f  Myc is su ffic ien t 
to exclu d e ce lls  perm anently from  the ce ll cy c le .
Jain et al have used a tetracycline-contro lled  ‘tet- 
o f f  system  to transiently inactivate M yc in m ice  w ith  
transplanted o steogen ic  sarcom a ce lls  or transgenic  
tum ours [51]. W hen Myc w as inactivated , the sarco­
m as and o steogen ic  tum ours underw ent d ifferentiation  
to mature bone and show ed  sign ifican t regression . C u l­
tured tum our ce lls  in w hich  Myc w as subsequently  
reactivated did not resum e proliferation  but instead  
underw ent apoptosis. In all o f  th ese  tum our m od els, it 
w ill b e  interesting to see  i f  the requirem ent for c-Myc 
continues even  after other enab ling  m utations have  
occurred in the ce ll. I f  so , targeting c-M yc cou ld  be  
an extrem ely  productive therapeutic strategy for som e  
tum our types.
Ras
T he product o f  the Ras o n co g en e  is in v o lv ed  in a 
w id e range o f  cellu lar p rocesses, in clu d in g  progres­
sion  through the ce ll cy c le , transcription and trans­
lation, ce ll survival, and ap op tosis, v ia  interactions 
w ith a w ide range o f  effectors [52 ]. Severa l m ou se  
m od els w ith d efects in Ras h ave  b een  d eve lop ed , 
both conditional and con ven tion a l. K-Ras~^~ m ice  d ie  
at E l 20 E 14 from  liver d efects  and anaem ia [53 ,5 4 ], 
w h ile  N-Ras_ /~ and H-Ras~/~ m ice  are v iab le , w ith  
the form er h aving d efects in im m un e and T -cell 
function  and the latter having no ob v io u s phenotyp e  
excep t for decreased  carcinogen-induced  tum ourige­
nesis. C onditional Ras a lle les  are a rela tively  recent 
d evelopm ent. Johnson et al h ave created a m ouse  
m odel w hich  carries a latent o n co g en ic  a lle le  o f  K- 
Ras, w hich  can undergo spontaneous activation  in vivo 
[5 5 ,5 6 ,5 7 ]. O ne hundred per cen t o f  an im als carrying  
this a lle le  d evelop ed  m ultip le lung tum ours, w ith a 
high proportion a lso  d eve lop in g  thym ic lym p hom as  
and skin papillom as. T he lung tum ours appear to b e  
sim ilar to hum an non sm a ll-ce ll lung cancer (N S C L C ) 
progressing through hyperplastic and d ysp lastic  stages  
b efore progressing to carcinom a. T h e spontaneous  
and stochastic  nature o f  the activation  even ts m akes
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this m ouse an ex ce llen t m odel o f  spontaneous K-Ras- 
induced lung cancer in hum ans, and a lso  m ay m im ic  
the interaction o f  adjacent mutant and norm al tissu es  
seen  in hum an cancer in vivo.
K-Ras is w id ely  m utated in hum an tum ours, 
although this varies trem endously  w ith tum our typ e, so  
cellu lar context m ay be h igh ly  im portant [52 ]. A  recent 
paper dem onstrates this, using a K-Ras a lle le  activated  
by the C re-L ox-m ediated  rem oval o f  a ST O P  cassette  
to drive K-ras expression  [58]. Guerra et a l a lso  e n g i­
neered a b icistron ic colour marker into their system , 
and thus sh ow  that expression  o f  the en d ogen ou s K- 
Ras a lle le  appears to have no d iscern ib le  co n seq u en ces  
in m ost ce ll and tissue types [58]. A  lo w  in cid en ce  
o f  sarcom as and anal papillom as w as seen  in these  
m ice; how ever, 100% d eveloped  m ultip le lung le s io n s, 
w hich derived from  type I pn eu m ocytes, a lthough a 
sm all proportion w ere derived from  Clara ce lls . T his  
replicates the /G ras-induced  lung tum ours found  by 
Johnson et al [57], Jackson et al [59], and M eu w issen  
et al [60].
I f  Ras on cogen es are expressed  under the control 
o f  a h igh ly  active promoter, then ce lls  enter G1 arrest 
and sen escen ce  due to on cogen ic  stress [61]. H ow ever, 
the m odels o f  Johnson et al [57] and Guerra et al 
[58] sh ow  that under endogenous control, K-RasV12 
d oes not induce sen escen ce, but instead cau ses ce lls  
to acquire hyperproliferative capacity akin to that o f  
im m ortalized  ce lls . T his show s how  im portant lev e ls  
o f  exp ression  are in determ ining the exact reaction o f  
a system .
O ncogen ic  Ras has a lso  been show n to be im portant 
for tum our m aintenance. W ong and C hin have created  
a m ouse m elanom a m odel using d oxycyclin e-in d u ced  
H-RasV12G  on an Ink4a null background [62]. Induc­
tion and m aintenance o f  H-RasV12G  w ere sh ow n  to 
be absolutely  required for induction and m aintenance  
o f  m elanom as. W hen d o xycyc lin e  w as rem oved  and 
H-Ras V12G w as dow n-regulated, ex ten sive  apoptosis  
and regression  o f  tum ours w ere observed.
Lack o f response to  anti-proliferative signals
Rb is a m ajor transducer o f  anti-proliferative sign a ls  
[63 ], and m utations in RBI in hum ans produce the rare 
ch ildhood  m alignancy retinoblastom a [63]. E fforts to 
m odel this d isease  in m ice w ere ham pered by the fact 
that Rb knockout m ice do not d ev e lo p  retinoblastom a  
at high frequencies [7]. T he first true phenotyp ic  
m ouse m odel o f  retinoblastom a w as created in 2 0 0 4  
by Z hang, S chw eers, and D yer [63], and conta ins six  
engineered  alleles: R bl, p53  and p i 07  null a lle les;  
floxed  p53  and Rb alleles; and a Chx 10-Cre w hich  
targets retinal progenitors. R etinal progenitor ce lls  
lacking Rb and p i 07  keep  proliferating past the tim e  
w hen they should undergo term inal c e ll-c y c le  ex it, 
sh ow in g  that p i 07  com p en sates for lack  o f  R b by  
preventing deregulated proliferation. T um ours w h ich  
lacked Rb, p l0 7 , and p53 w ere h igh ly  ag g ress iv e  and 
m etastatic; hence p53-m ed iated  apoptosis m ay a lso  be
a barrier to aggress ive  retinoblastom a form ation in 
the m ouse. T his m odel w ill no doubt be extrem ely  
use for preclin ical research and is b e in g  refined still 
further —  a k ey d ifferen ce betw een  the m urine and 
hum an d iseases is that the num ber o f  R b inactivation  
even ts in the hum an retina is m uch low er, lead ing to a 
sm all num ber o f  foca l, clonal tum ours. In an attem pt 
to m im ic this in the m ouse, a retrovirally delivered  
C re is b ein g  used to target sm all num bers o f  c e lls  and 
increase the accuracy o f  the m odel [63].
Evading apoptosis
E nd ogenou s and exogen ou s D N A  dam age are co n sid ­
ered key initiators o f  the apoptotic response [40], and 
m any T SG s are invo lved  in either the repair or se n s­
ing o f  D N A  dam age. It is now  w id e ly  assum ed  that 
c e lls  with dam aged D N A  w ill attem pt repair, but if  
this is not p ossib le , they m ay defau lt to an apoptotic  
pathw ay. A voidance o f  this pathw ay is  a frequent fea ­
ture o f  neop lastic  ce lls , w hich  m ay progress through  
the ce ll c y c le  regardless o f  dam age, resu lting  in m uta­
tion or karyotypic alterations [40 ]. O ne k ey  m ediator  
o f  the apoptotic response is p53 , w hich  integrates c e l­
lular stress sign a ls and triggers ap op tosis, repair or 
sen escen ce .
P53
C onstitu tive d efects in hum an p 5 3  are associa ted  w ith  
the L i-F ra u m en i syndrom e, w hich  pred isp oses to  a 
w id e  range o f  tum ours [64] and the first m ou se  m od ­
e ls  o f  p53 d efects w ere null a lle le s  w h ich  d ev e lo p ed  a 
variety o f  n eop lasias [6 5 D 6 9 ]. A lth ough  L i-F ra u m en i 
patients m ainly d ev e lo p  ep ithelia l tum ours [70 ], p53  
null m ice  predom inantly d ev e lo p  lym p h om as [71]. 
T he short lifespan  o f  p53  null m ice  due to early- 
on set lym phom a has largely  precluded the study o f  
tum ours w ith longer la tencies. It w as a lso  soon  real­
ized  that m ost spontaneous and fam ilia l hum an m uta­
tions o f  p53 are m issen se  m utations in  the D N A  b ind­
ing dom ain  (D B D ) [72] and so  the con ven tion a l null 
a lle les  w ere not a faithful m od el o f  p 5 3  m utation  
in vivo. M issen se  p53  m utations associated  w ith can ­
cer are generally  ga in -o f-fu n ction  m utations, w hich  
have been ascribed dom inant n ega tive  e ffec ts  [73].
Several n ew  m ou se m odels o f  p 5 3  function  are 
therefore b e in g  d evelop ed  w hich  better m im ic  the real 
(and d iverse) range o f  hum an m utations. For exam p le , 
Liu et al have produced a p53  D B D  m issen se  m uta­
tion that carries a com m on m utation (R 1 7 2 H ) and a lso  
a sp lice  variant that reduces exp ression  le v e ls  to a lm ost 
w ild  type [74]. C lear d ifferences w ere found  b etw een  
the p 5 3 +/~ and p 5 3 RX12H gain  o f  fu nction  m ou se, 
w ith the latter d evelop in g  few er lym p h om as and m ore  
carcinom as, with a higher degree o f  m etastasis in the 
tum ours observed .
A nother engineered  version  o f  the p 53  protein  
sh ow s the sheer com p lex ity  o f  the e ffec ts  each  o f  the  
m utations in p53  m ay have in vivo. L o za n o ’s group
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have recently created a m o u se  carrying a version  o f  
p53  w hich  cannot induce ap op tosis but can  still ind uce  
ce ll cy c le  arrest [75 ]. M ic e  h o m o zy g o u s for this m uta­
tion ( /? 5 i515r/515<’) h ave sign ifican tly  d elayed  tum our 
on set w hen com pared w ith p 5 3  null m ice . Tum ours 
w hich  arose in the p 5 3 5l5c/ c m ice  sh ow ed  a lon ger  
latency and had m ore stable g en o m es than th ose  aris­
ing in p53  null m ice. C e lls  from  p53  null m ice  
had ex ten sive  aneuploidy and ch rom osom e breaks and 
abnorm alities, w hereas ce lls  from  p 5 3 5l5c/5l5c m ice  
w ere generally  2N , 4N  or 8N  w ith m any few er  abnor­
m alities. T his su ggests that the p 5 3 5]5c m utation is 
capable o f  suppressing gen om ic in stab ility , and a lso  
argues strongly that abrogation o f  the apoptotic pro­
gram m e d oes predispose to m alignancy.
It is not ju st specific  m utations in p 5 3  that need  
to be exp lored , but a lso  its basic function s. It had 
been  questioned w hether lo ss  o f  h eterozygosity  (L O H ) 
o f  the rem aining w ild -typ e p53  a lle le  w as an im por­
tant factor in tum ourigenesis in L i-F ra u m en i patients 
[70]. In p 5 3 + /~ m odels [76], around 50%  o f  tum ours 
sh ow ed  LO H , but in the p 5 3 Rll2H m odel, o n ly  9%  
o f  tum ours exh ib ited  LO H , im ply ing  that L O H  is not 
absolutely  necessary for tum our form ation (although  
it m ay still represent a significant route to tum ouri­
g en esis  in a subset o f  tum ours). A nother im portant 
m echanistic question answ ered by new  p53 m od els  
is w hether the transcriptional transactivation activ ity  
o f  p53 is essentia l for p53-m ediated  apoptosis and 
tum our suppression [69]. A  m ou se m odel has been  
d evelop ed  with m issen se m utations in the transacti­
vation dom ain by Jim enez et al (p5 3 L25Q/W26S) [11]. 
T he mutant p53 protein produced still has a fu n c­
tional D B D . M ice  carrying this m utation h ave lo w ­
ered p53-m ediated  apoptosis in thym ocytes in vivo and 
their cultured em bryonic fibroblasts b ecom e n eop las­
tic. T his strongly argues that transcriptional transac­
tivation is indeed essentia l for p530s function  as a 
tum our suppressor gene.
A lthough  these studies therefore support d iffering  
roles for p53 in tum our suppression (w hich  in cludes  
a role in in itiating apoptosis), the precise re levance o f  
p53-m ediated  apoptosis to tum our suppression  rem ains 
som ew h at unclear. T he original observation  that p53  
m ediates the apoptotic response to D N A  dam age gave  
rise to the sim p le hypothesis that p53 m ed iates its 
primary tum our suppressive activ ities through in iti­
ation o f  the apoptotic response, and that failure to 
delete  c e lls  harbouring D N A  dam age w ould  result in 
increased mutation and thereby to accelerated  tum ouri­
g en esis. T his h ypothesis has, h ow ever, been  som ew h at 
difficu lt to prove, w ith clear tissu e-sp ecific  d ifferen ces  
in the role o f  p53-m ediated  apoptosis. For exam p le , it 
appears that the loss o f  p53-dependent ap op tosis is a 
good  predictor o f  m utation burden and tum our pred is­
position  w ithin the haem atolog ica l system  but not the  
intestine [78].
D esp ite  these co m p lex itie s , con ven tion a l m od els  
and null a lle les  still have a central role in p53 research. 
For exam ple, com binatorial u se o f  a lle les  null for p53
and p l9 A rf  and ectop ica lly  exp ressed  Mdm2 h ave  
been  used to exp lore the in vivo  interactions b etw een  
th ese  gen es [79]. Increased A rf lev e ls  are know n to 
inhibit M dm 2-m ediated  proteolytic degradation o f  p53  
[8 0 ,8 1 ], and A rf expression  can lead to increased  
o n co g en ic  sign alling , such as overexp ression  o f  c-M y c  
or activation  o f  Ras [82 ,83]. Various com b in ation s o f  
the three a lle les  have been  used  to in vestiga te  co -  
operativity b etw een  the three g en e  products [78 ]. T hus, 
p l9 A r f  d efic ien cy  accelerated tum our d evelop m en t in 
the M Jw 2-overexp ressin g  m ouse, w h ilst the principal 
T S G  activ ity  o f  A rf  appears to b e  p53-dependent.
Angiogenesis
A s a so lid  tum our grow s, its s iz e  ex ceed s  its b lood  
supply  and the inner part o f  the tum our m ay b eco m e  
h yp ox ic  [84 ,85 ]. To m aintain its rate o f  grow th, 
the tum our m ust estab lish  its ow n  b lo o d  supply  to  
ensure a constant supply o f  o x y g en  and to rem ove  
catabolites. A n g io g en esis  is d ifficu lt to m od el in vivo", 
m any m odels require tissue to b e  transplanted into the 
m ouse, w h ich  cau ses injury, one o f  the norm al triggers 
o f  apoptosis [84].
A lthou gh  R as and M yc are im p licated  in a n g io g en ­
e s is , the process is m ore co m p lex  than m ay h ave first 
been  appreciated. B oth  o n co g en ic  K -R as and H -R as  
can stim ulate V E G F  exp ression  [62]. In the m ou se  
m odel o f  m elanom a d evelop ed  b y  W ong and C hin  and  
described  earlier [62], decreased  exp ress ion  o f  H -R as  
resulted in vascular regression  b efore  the m ain tum our 
regression . H igh  rates o f  apop tosis w ere seen  in  ce lls  
lin in g  tum our-associated  v e sse ls , ind icating  that co n ­
tinued activation  o f  R as m ay b e n eed ed  for a stable  
tum our vasculature. W ong and C hin  a lso  sh o w ed  that 
lo ss  o f  R as-stim ulated  V E G F  exp ression  is  not respon­
sib le  for tum our regression  and that h igh  V E G F  le v e ls  
are not su fficient to m aintain the tum our vasculature  
i f  H -R as is absent. T here m ust therefore b e  another  
m echan ism  b y  w hich  R as prom otes an g io g en es is .
M odulation  o f  an g io g en esis  can  a lso  occu r through  
deregulation  o f  throm bospondin  1 (T S P 1), an in h ib i­
tor o f  an g iogen esis. T hus, exp ression  o f  T SP1 can be  
inhibited by m any o f  the o n co g en es  a ssocia ted  w ith  
m alignant progression , nam ely  o n co g en ic  Ras, c-Myc, 
v-Src, c-Jun and Idl [85]. Furtherm ore, exp ress ion  o f  
T SP1 has recently b een  sh ow n  to  b e  under the control 
o f  T S G s such as p53  and Pten [86].
A lth ough  the m echanism s w h ich  control a n g io g en ­
e s is  are still in com p letely  understood, e v id en ce  is 
grow in g  for the ex is ten ce  o f  an ‘a n g io g en ic  sw itc h ’, 
w hereby the normal ba lance o f  inhibitors and prom ot­
ers o f  an g iogen esis is disrupted, a llo w in g  the tum our 
to  form  a n ew  vasculature [84 ,85 ].
Unlimited replicative potential; avoiding 
senescence
I f  a ce ll acquires m utations that a llo w  it to  supply  
its ow n  grow th signals and ignore anti-proliferative
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and pro-apoptotic s ign a ls , then in theory, that ce ll 
should  be capable o f  un lim ited  grow th  and d iv is io n  
[40]. In reality, som atic  c e lls  h ave a lim ited  num ber  
o f  d iv is ion s ‘p rogram m ed’ into them , w ith  the ab so ­
lute num ber o f  d iv is io n s  varyin g  w ith tissu e  and ce ll 
type [87]. C ultured ce lls  w ill proliferate for  a num ­
ber o f  generations and then enter se n escen ce . T his  
state can be o v ercom e by  various m utations, in clu d in g  
those in p53  and Rb , lead in g  to further grow th  and 
div ision  until c e lls  enter a ‘c r is is ’ phase. T h is is  char­
acterized by karyotypic abnorm alities such  as chro­
m osom e fu sion s and a h igh  proportion o f  c e ll death  
[88]. In a population o f  such c e lls , c lo n e s  w ill em erge  
w hich are im m ortalized  and cap ab le  o f  rep licatin g  
indefin itely. T he m ech an ism s surrounding im m orta l­
ization appear to be largely  dep en d en t on  m aintain ing  
telom eres [89]. T elom eres stab ilize  ch ro m o so m es by  
preventing recom bination  and fu sio n  ev en ts , and a lso  
by preventing the ce ll from  reco g n iz in g  the en d  o f  
the chrom osom e as a double-strand  break [90 ]. W ith  
every ce ll d iv ision , the ends o f  ch ro m o so m es p rogres­
siv e ly  ‘fray o f f ,  countin g  o f f  the c e ll gen era tion s until 
they reach a certain n o n -p erm iss iv e  lim itin g  length  
w hich triggers sen escen ce  or ap op tosis  [910 9 3 ]. In 
order to overcom e this, a ce ll m ay eith er  acquire acti­
vating m utations in the telom erase  g en e , w h ich  acts to  
maintain telom eres and is stron gly  repressed  in norm al 
c e lls , or activate a m ech an ism  that m ain ta ins te lom eres  
through recom bination  [89].
M ice  have very lon g  te lom eres (400  6 0  kb as 
opp osed  to 10 kb in hum an) and a lso  h a v e  a w ider  
pattern o f  exp ression  o f  te lom erase  than in the hum an  
[94]. For a hum an ce ll to  e sca p e  rep lica tive  se n e s ­
cen ce , it m ust acquire m utations in  the te lom erase  
m aintenance system , but th is restraint apparently d oes  
not apply to m ouse ce lls  [94 ]. M ice  en g in eered  to have  
shorter telom eres have a h igh er rate o f  spon tan eou s  
tum ourigenesis [94]. O ne p o ss ib le  reason  w h y  m ice  
and hum ans have d ifferent tum our spectra w as hinted  
at w hen these short-telom ered  m ice  w ere  cro ssed  onto  
a late-generational p 5 3  null a lle le . T h e resultant m ice  
d evelop ed  a high rate o f  ep ith e lia l-d er ived  carcinom as, 
sim ilar to the tum our spectrum  in hum ans [95 ].
M ice  have a lso  been  generated  w h ich  provid e  
insights into the relationsh ip  b etw een  te lo m eres, pre­
mature ageing, and cancer [96]. C hang et al gen erated  
m ice null for both the te lom erase  R N A  com p on en t  
Terc, and Wrn. Inactivation  o f  W R N  (a RecQ  h e li-  
case  fam ily  m em ber) cau ses W erner syn d rom e, w h ich  
presents with prem ature age in g , g en o m ic  in stab ility , 
and an increased in c id en ce  o f  can cer [9 7 ,9 8 ] . C ells  
with WRN d efic ien cy  have an increased  rate o f  te lo m ­
ere lo ss and undergo prem ature se n escen ce , w h ich  
can be rescued by forced  ex p ress io n  o f  Tert [9 9 ,1 0 0 ]. 
D oubly  null Wrrc~/_  Terc~/ " m ice  ex p er ien ce  pre­
mature agein g , cataracts, and hair lo ss , as w e ll as 
increased chrom osom al in stab ility  and in c id en ce  o f  
non-epithelial can cers such as osteosarcom as and so ft  
tissue sarcom as [96]. In terestingly , the e ffec ts  o f  the  
Wrn d efic ien cy  on Terc null m ice  increased  through
subsequent generations, w ith the first and second  gen ­
erations o f  Terc~t~ m ice being  unaffected by Wrn 
status. In contrast, by the fourth to sixth generations, 
7erc_ / “ Wm~!~ m ice had low er body w eigh ts and 
a shorter life  expectancy than Terc~/~ W m + /~ m ice  
[96]. Later generations o f  Terc_ l~ Wm~/~  m ice  also  
sh ow ed  age-related degeneration in m esenchym al tis­
su es, unlike Terc~l_  m ice, w hich show  phenotypes in 
the h igh ly  proliferative com partm ents o f  skin, b lood , 
and intestine. T he low er im pact o f  Wrn d efic ien cy  in  
ep ithelia l tissu es could be due to higher telom erase  
activ ity  or functional redundancy in the RecQ  h e licase  
fam ily  such as the B loom  h elicase.
T he nature o f  the checkpoints w hich m onitor telom ­
ere length are still not understood in detail, and no  
doubt new  m ouse m odels such as the Wm/Terc null 
m ou se w ill be vital in unravelling the m echanism s by  
w hich  ce lls  acquire unlim ited replicative capacity. Fur­
therm ore, desp ite the clear im portance o f  telom eres, 
they are not so le ly  responsib le for inducing sen es­
cen ce , as ev id en ced  by  the fact that som e m ouse ce ll 
cultures can undergo sen escen ce  w ith telom eres o f  
5 0  kb or m ore rem aining [101].
O n e gen e  recogn ized  to induce cellu lar sen escen ce  
is p53 [64]. In this light, it is intriguing that m ice  
w ith a d eletion  o f  the first six  exon s o f  p 5 3 ,  w hich  
en co d es a truncated R N A  form ing a carboxy-term inal 
p53 fragm ent, have been show n  to have an altered  
lifesp an  [102 ]. T his m utation confers som e proper­
ties o f  activated p53, and the m ice  disp lay an early  
agein g  phenotype including reduced lifespan , o steo ­
p orosis, w eigh t lo ss , lordokyphosis (hunched spine), 
and m u scle  lo ss. N otab ly , none o f  the m ice d ev e l­
op ed  tum ours, com pared w ith around 45%  o f  w ild  
typ es. T h ese  data argue for a role for p53 in regulat­
in g  sen escen ce  in vivo and a lso  su ggest that there m ay  
be a ‘p a y -o f f  betw een  increased lifespan  and tumour 
su scep tib ility .
Invasion and metastasis
In order to m etastasize, a tum our m ust break dow n  
surrounding tissue such as a basem ent m em brane to 
esca p e  its tissue o f  origin; it m ust then travel w ithin  
the bod y and re-establish  itse lf  at a new  site, supplying  
its ow n  grow th factors [40]. It m ust be resistant to 
an oik is (apoptosis induced by lack o f  correct positional 
inform ation) and establish a new  vasculature at the 
distant site. M etastases are the cause o f  an estim ated  
90%  o f  cancer deaths [40] and thus the study o f  
m etastatic progression is  o f  vital im portance.
Several types o f  adhesion m olecu le  are altered in  
m any cancer ce lls , such as the calcium -dependent 
cadherins, w hich m ediate c e l l - c e l l  interaction, and 
the integrins, w hich m ediate ce ll-ex tra ce llu la r  matrix 
(E C M ) interactions [103].E -cadherin m ediates c e l l -  
ce ll adhesions in epithelial tissues; the intracellular 
dom ain  interacts w ith /T caten in  to transduce anti­
proliferative signals such as those relayed via the
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L ef/T cf system . L oss o f  E -cadherin  ex p ress io n  is  a sso ­
ciated  w ith de-d ifferen tia tion  and in vasion  in a variety  
o f  hum an cancers [1 0 4 ,1 0 5 ] —  the forced  exp ress ion  
o f  E -cadherin in a transgen ic m od el o f  pancreatic p~ 
ce ll carcin ogen esis has already been  sh ow n  to prevent 
the transition from  adenom a to carcinom a, underlin ­
ing the im portance o f  correct ad h esion  and p osition al 
signals in in vasion  and m etastasis [106 ].
Integrins con sist o f  a n o n -co v a len tly  lin k ed  a  and  
P subunit (there are 18 k now n a  and e ig h t k n ow n  p  
units) w hich  spans the m em brane and transduces in for­
m ation about the c e l l ’s en v iron m en t into the c e ll [107 ]. 
D ifferent com b in ation s o f  a  and p  subu n its h a v e  d if­
ferent affin ities for E C M  co m p o n en ts . T h e ex p res­
sion  profiles o f  so m e integrins are k n ow n  to ch an ge  
during tum ourigen esis, a llo w in g  the c e ll to alter its 
m igration and adhesion; for ex a m p le , ctbpA  and a 2 p 5  
are know n to be up-regulated  during tu m ou rigen esis , 
w hereas reduced exp ression  o f  arl, ct6, p i  or  p 4  is 
associated  w ith breast ep ithelia l n eo p la sm s [1 0 7 ]. T he  
a 3 p 5  integrin binds a w id e range o f  E C M  com p on en ts  
and is considered  an attractive target for  therapeutic  
intervention, as it is exp ressed  at lo w  le v e ls  in resting  
endothelia l c e lls  and at h igher le v e ls  on  vascu lar  c e lls  
in tum ours [1 0 7 ,1 0 8 ].
Integrins are a lso  thought to  p lay  a k ey  ro le  in  
directing tissu e  rem od ellin g  via  their ab ility  to  acti­
vate M M P  precursors. a 3 p 5  in teracts w ith  M M P 2, 
a k ey player in tissue rem od ellin g . M M P 2  k n ock ou t  
m ice sh ow  reduced a n g io g en es is  and tu m ou rigen esis  
[109] and inhibitors o f  the M M P 2 a -o :3 /? 5  in terac­
tion are potent suppressors o f  a n g io g e n e s is , g lio m a s, 
and m elanom as [1 1 0 ,1 1 1 ]. H o w ev er , k n ock ou t m ice  
lack ing p3  or p 3 and p 5  subunits, gen erated  by  
R eynolds et al, sh ow  en han ced  tum our grow th  and  
enhanced a n g io g en esis  w ith in  the tum ours that form  
[108]. T his sh ow s that the a 3 p 5  and a v /3 5  in tegrins, 
w hich w ere thought to be v ital for a n g io g e n e s is , are in 
fact not essen tia l. T he apparent d iscrep an cy  b e tw een  
the effects o f  antagonists and k n ock ou ts m ay b e due  
to com pensation , or the an tagon ists b e in g  n o n -sp ec ific  
[108]. H ow ever, it seem s m ore lik e ly  that w e  sim p ly  
do not yet have a co m p le te  en ou gh  u nderstanding o f  
the com p lex  interactions b etw een  c e ll and strom a that 
are vital in driving in vasion  and m etastasis.
Genomic instability, a helping hand on the  
road to  cancer
A lthough not on e o f  the s ix  hallm arks id en tified  by  
Hanahan and W einberg, g en o m ic  in stab ility  is in creas­
ingly being identified  as a m ajor contributor to m any  
cancer types. G en om ic in stab ility  is seen  in m any can ­
cer ce lls , either as an in itia ting  ev en t or as a later 
stage. It is estim ated  that up to 30%  o f  g e n e s  in  
the gen om e c o d e  for proteins that regu late g en o m ic  
fidelity  [112] and m any inherited  can cer syn d rom es  
are due to m utations in th ese  g en es  [eg  L i-F r a u m e n i
(p53 , Chk.2 [113]; OM IM  # 1 5 1 6 2 3 ) , B lo o m  syn ­
drom e (BLM\ OM IM  # 2 1 0 9 0 0 ) , N ijm egen  breakage  
syndrom e (NBS1; OM IM  # 2 5 1 2 6 0 ) , ataxia telang­
iectasia  (ATR/ATM; O M IM  # 2 0 8  9 00 ), and H N PC C  
(O M IM  # 1 1 4 5 0 0 ;  the M M R  system )]. G enom ic insta­
b ility  can have many causes: hypom ethylation , in ef­
fic ient M M R  (m ism atch repair), increased m itotic  
recom bination, chrom osom al translocations or defects  
in gen es w hich code for proteins that m onitor and 
repair les ion s, or m onitor genom ic fidelity  through the 
ce ll cy c le  [40].
C hrom osom al translocations frequently g iv e  rise to 
fu sion  proteins w hich m ay participate in the ce ll cy c le  
and drive clonal expansion  o f  the tumour. For exam ­
ple, translocations at hum an l l q 2 3  can fuse the 5' end  
o f  the M L L  (m yelo id  lym phoid  leukaem ia) gene to  
a range o f  potential gen es, g iv in g  rise to a diverse  
num ber o f  leukaem ia aetio log ies [114]. Forster et al 
have d evelop ed  a h igh ly  elegant m odel w hich  accu­
rately m im ics the translocation that fu ses the M LL  
and E N L  gen es to g iv e  rise to m yelo id  leukaem ia  
and m ixed  m yelo id /lym phoid  leukaem ia [114]. Forster 
et al p laced  L ox P  sites at defined  breakpoints on  
separate chrom osom es. Cre recom binase w as then  
exp ressed  under the control o f  the haem atopoietic pro­
m oter Lmo2, leading to inter-chrom osom al reciprocal 
translocations and the rapid on set o f  m yelo id  tumours 
w ith h igh  penetrance. T his accurately recapitulates 
the random ly occurring spontaneous translocations and 
clon a l exp ansion  o f  the hum an leukaem ia and is the 
first m odel to  generate both translocation products.
G en om ic instability  can a lso  b e  caused  by hypom e­
thylation , as recently show n  by G audet et al [115]. T he  
D n m tl protein m aintains m ethylation  in som atic ce lls  
and is required for em bryonic d evelop m en t —  D n m tl 
null m ice  d ie  during gestation  [11 6 ,1 1 7 ], so  Gaudet 
et al created a heterozygous D n m tl m odel w ith one  
D n m tl null a lle le  and on e D n m tl hypom orphic a lle le  
(Dnm tl chipl~) T h ese  m ice  are estim ated  to have on ly  
10% D n m tl activ ity  and have substantially reduced  
le v e ls  o f  gen om ic  m ethylation. T he m ice  developed  
ag g ress iv e  T -ce ll lym phom as at around 4D 8 m onths o f  
age. Array C G H  (com parative gen om e hybridization) 
sh o w ed  an increased rate o f  chrom osom e gains, m ost 
notably gain  o f  chrom osom e 15 and the c-Myc gene, 
w hich  it carries. T his sh ow s that m ethylation levels  
can d irectly  contribute to tum ourigenesis via genom ic  
instability .
T he role o f  m ethylation in tum ourigenesis is, h o w ­
ever, com p lex . Thus, lo ss o f  D N M T 1 can a lso  be  
sh ow n  to h ave a tumour protective e ffect w ith in  the 
in testine, presum ably as a con seq u en ce o f  b lock ing  
transcriptional repression o f  T SG s [118]. Sim ilarly, 
San som  et al [119] used a m ouse m od el (Ape**"1) o f  
the hum an intestinal cancer syndrom e FA P (fam ilial 
adenom atous p olyposis co li) to sh ow  that constitu tive  
lo s s  o f  the Mbd2 gene (a m em ber o f  the m ethyl b ind­
ing dom ain fam ily) in the intestine results in greatly  
reduced tum our burden. C learly, the role o f  m ethyla­
tion  patterns in cancer develop m ent is  com p lex , and
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m ouse m od els o f  altered ep ig en etic  states w ill no  
doubt provide in sigh ts in to  these d ivergen t m ech a­
nism s.
Large-scale mutagenesis screens: 
identifying novel m utations
T he few  thousand m utant m ou se  strains in e x is ten ce  
represent on ly  about 10% o f  the total g en es  o f  the 
m ouse gen om e [120 ]. A lth ou gh  w e  h ave  a lm ost c o m ­
plete seq u en ce inform ation  ava ilab le  for the m ou se , w e  
still do  not know  the b io lo g ica l fu n ction s o f  m ost o f  
these gen es [120]. F unctional annotation  o f  the m ou se  
gen om e w ill necessarily  be s lo w er  than seq u en cin g , 
g iven  the vo lu m e o f  w ork n eed ed  to characterize  
mutant phenotypes. H ow ever , severa l con certed  pro­
gram m es are n ow  underw ay [ 121 □ 123] to  sy stem a t­
ica lly  m utate each  g en e  in the m o u se  g e n o m e  u sin g  
high throughput approaches such  as E N U  (eth y ln i-  
trosourea) m utation. y E N U  is a potent a lk y la tin g  agen t 
w hich cau ses point m utations at h igh  freq u en cy  in 
m any tissu es [120]. W hen  m ale m ice  are in jected  w ith  
E N U , point m utations occu r in the p re-m eio tic  sper- 
m atogonial stem  ce lls  [120 ]. T he F I progen y  can  then  
be screened for dom inant p h en otyp ic  abnorm alities  
(behavioural or b ioch em ica l) or bred for  a further tw o  
generations to exp ose  rece ss iv e  p h en otyp es. T h e  E N U  
approach has a num ber o f  advantages: point m utations  
can often  produce both null a lle le s  and h yp om orp h ic  
a lle les , w hich  are m ore in form ative  than nu ll a lle le s  
alone; novel functions in both k n ow n  and u n know n  
gen es can be exp osed ; and the w h o le  approach is  
‘phenotype-driven’, rem ovin g  any b ias tow ards k n ow n  
or expected  gen e  functions. A  la rg e-sca le  E N U  m uta­
gen esis  program m e (esp ec ia lly  o n e  screen in g  for  d o m ­
inant and recess iv e  m utations) is , h o w ev er , a m as­
sive  log istica l undertaking, requiring co -ord in a tion  o f  
anim al resources, personnel, and in form atics. S everal 
such projects are n ow  underw ay and w ill no doubt 
provide a vast num ber o f  n ovel m utant lin es, m any o f  
w hich w ill aid in the study o f  tu m ou rigen esis .
Conclusions and future directions
The current generation  o f  m ou se  m o d els  is ex trem ely  
sophisticated , y ie ld in g  in sigh ts into the fundam ental 
processes underlying norm al ce ll p h y s io lo g y  and ca n ­
cer. Future m ou se m od els w ill no  doubt p rovide m ore  
precise control over g en e  exp ress ion  at various stages  
o f  develop m en t. A s w e  understand m ore about the 
exp ression  profiles o f  g en es  through em b ry o g en es is , 
it is a lso  b ecom in g  p o ss ib le  to activate m utant a lle le s  
at precise points in the d eve lop m en ta l program m e, for  
exam ple through the u se  o f  in d u cib le  C re-L ox  tech ­
nology  [1 2 4 ,1 2 5 ]. In ev itab ly , so m e  p rob lem s rem ain  
with these tech n o lo g ie s . For exam p le , certain  C re- 
exp ressin g  lin es are ‘le a k y ’ and d rive recom b in ation  
in tissu es other than the target tissu e . T h is is su e  w ill
need  to be carefully addressed, although it cou ld  itse lf  
be used as a useful tool. U ltim ately , it is possib le  
to en v isage the developm ent o f  a m odular ‘to o lb o x ’ 
contain ing a range o f  defined transgenes and sy s­
tem s w hich  w ill permit controlled gen e expression  o f  
m any different a lle les o f  a g iven  gene throughout all 
stages o f  the life  cy c le  o f  an organism . W ith novel 
reporter system s and im aging tech n o log ies [126], it 
should  a lso  be possib le to fo llo w  the initiation and 
spread o f  tum ours in vivo and to integrate all these  
data w ith a b io-inform atic database. Indeed, the inte­
gration o f  such inform atics w ill be key in a llow ing  
the fu ll potential o f  the m ouse (and hum an) gen om es  
to be exp lo ited . F inally , it should be stressed that the 
primary purpose o f  these system s is the m od ellin g  o f  
hum an d isease , and by im plication  the resolution o f  
hum an d isease. T he need to d evelop  coh esive , produc­
tive  links betw een  the basic m urine studies described  
here and translational and clin ical research cannot be 
overstated .
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Fas-associated death domain protein (FADD) is an adaptor protein 
bridging death receptors with initiator caspases. Thus, its function 
and localization are assumed to be cytoplasmic, although the 
localization of endogenous FADD has not been reported. Surpris­
ingly, the data presented here demonstrate that FADD is mainly 
nuclear in several adherent cell lines. Its accumulation in the 
nucleus and export to the cytoplasm required the phosphorylation 
site Ser-194, which was also required for its interaction with the 
nucleocytoplasmic shuttling protein exportin-5. Within the nu­
cleus, FADD interacted with the methyl-CpG binding domain pro­
tein 4 (MBD4), which excises thymine from GT mismatches in 
methylated regions of chromatin. The MBD4-interacting mismatch 
repair factor MLH1 was also found in a complex with FADD. The 
FADD-MBD4 interaction involved the death effector domain of 
FADD and a region of MBD4 adjacent to the glycosylase domain. 
The FADD-binding region of MBD4 was downstream of a frame- 
shift mutation that occurs in a significant fraction of human 
colorectal carcinomas. Consistent with the idea that MBD4 can 
signal to an apoptotic effector, MBD4 regulated DNA damage-. Fas 
ligand-, and cell detachment-induced apoptosis. The nuclear local­
ization of FADD and its interaction with a genom e surveillance/ 
DNA repair protein that can regulate apoptosis suggests a novel 
function of FADD distinct from direct participation in death recep­
tor signaling complexes.
D NA damage-induced apoptosis signals originate in the nucleus. For example, double-strand DNA breaks activate 
the ATM/ATR (1) and c-abl-related kinases (2), leading to 
activation of the p53-family proteins (3, 4) and subsequent 
apoptosis. Other forms of DNA damage that are repaired by the 
mismatch repair (MMR) complex (reviewed in refs. 5 and 6) can 
promote apoptosis through the MMR component MLH1. Thus, 
MLH1 defects in tumor cells cause apoptosis resistance with 
regard to several DNA-damaging drugs (7-11). In fact, all five 
major types of DNA repair complexes are thought to signal to the 
apoptotic machinery (reviewed in ref. 12), although the mech­
anism of signaling is largely unknown.
Interestingly, several apoptosis-regulatory proteins are in the 
nucleus constitutively or conditionally. These include PEA-15 
(13), DEDD 1-3 (14-16), DEDAF (17), p84N5 (18), caspases-2 
(19) and -6 (20), Daxx (21), and (under conditions where nuclear 
export is inhibited) TRADD (22). Possible roles for these 
proteins in nuclear apoptotic signaling remain to be determined.
Recently, we have identified an additional link between a 
DNA repair protein and apoptosis (O.J.S. and A.R.C., unpub­
lished data), namely the protein methyl-CpG binding domain 
protein 4 [MBD4 (23), also known as MED1 (24)]: MBD4 
promoted the apoptotic response to DNA-damaging agents. The 
N-terminal conserved MBD of this protein targets it to bind 
methylated regions of DNA, whereas the C terminus is a 
uracil/thymine-N-glycosylase. The latter excises spontaneously 
deaminated cytosine (i.e., uracil) or methylcytosine (i.e., thy­
mine) from G-T/U mismatches (25-27), the major individual
source of point mutations in the human genome (28). MBD4 
interacts with the mismatch repair/tumor suppressor protein 
MLH1 (24); both are mutator genes (29,30). The inactivation of 
either gene causes increased apoptosis resistance with regard to 
DNA-damaging agents (refs. 7-11; O.J.S. and A.R.C., unpub­
lished data), implying possible apoptotic signaling functions for 
both proteins. As with MLH1 (reviewed in ref. 30), MBD4 and 
also frequently mutated in certain human tumors (6,31-34). The 
mechanistic link between MBD4, MLH1, and apoptosis will be 
important to elucidate.
Fas-associated death domain protein (FADD) is known 
mainly for its death receptor adaptor function at the cell surface 
(35-37). Thus, it is widely assumed that FADD is primarily or 
solely a cytoplasmic protein. However, there are no published 
data clearly supporting this assumption (see Discussion). Indeed, 
FADD has been implicated in potentially death receptor- 
independent apoptotic responses such as DNA damage and 
anoikis (38-42) that would not necessarily require FADD to be 
cytoplasmic. Moreover, cell-matrix adhesion can protect against 
Fas ligand (FasL)-induced apoptosis (R.A.S. and S.M.F., un­
published observations; refs. 43 and 44), suggesting that certain 
Fas-interacting proteins might be subject to relocalization by 
extracellular signals. We therefore examined the subcellular 
localization of FADD in the hope of revealing additional func­
tions of the protein. Here, we report that FADD primarily 
localized to the nucleus, implying that the nuclear-cytoplasmic 
transport of FADD must be actively regulated and that FADD 
may have a novel nuclear function. We report that exportin-5 is 
a candidate nucleocytoplasmic transport protein for FADD and 
that a genome surveillance protein, MBD4, interacts directly 
with FADD and modulates apoptosis, suggesting a novel link 
between genome surveillance and apoptosis.
Materials and Methods
Cell Lines, Cell Culture, and Transfections. The normal human 
mammary epithelial cell line MCFlOa was used for most exper­
iments in this article. M B D 4 - /— mouse embryo fibroblasts 
(MEFs) have been described (29). Cells were transfected by 
using lipofection or infected with retroviruses based on MSCV- 
ires-zeo (45), and expression of transgenes was checked by 
Western blotting.
Apoptosis Assays (Cell Culture Experiments). Cells were maintained 
in low-attachment wells for the indicated times (for anoikis); 
some cell samples were exposed to recombinant FasL in the 
presence of enhancer antibody (for FasL). Cell lysates were
A bbreviations: MBD4, methyl-CpG binding dom ain  p ro te in  4; FADD, Fas-associated d e a th  
dom ain  pro tein ; FasL, Fas ligand; YFP, yellow  fluorescen t p ro te in ; HA, hem agglu tin in ; NLS, 
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prepared and assayed fluorimetrically for Ac-DEVD-AFC  
cleavage activity.
Apoptosis Assays (in Vivo Experiments). M B D 4 + /+  or M B D 4—/ — 
mice were injected with the Fas-agonistic antibody Jo-2. Histo­
logical sections of the indicated tissues were stained with hema- 
toxylin/eosin and analyzed for apoptosis as described (46).
Antibodies. Most antibodies were obtained from commercial 
sources; additional FADD polyclonal antibodies were prepared 
against bacterially produced GST-FADD protein, and a sheep 
anti-MBD4 was prepared against the C-terminal 180 aa of 
recombinant MBD4 protein. A detailed characterization of 
antibodies is presented in Fig. 5, which is published as supporting 
information on the PNAS web site, www.pnas.org.
Nuclear-Cytoplasmic Fractionation. Nuclear-cytoplasmic fraction­
ation was accomplished by homogenization of cells in hypotonic 
buffer followed by low-speed (800 X  g ) centrifugation.
Indirect Immunofluorescence. Indirect immunofluorescence was 
performed on formaldehyde-fixed, Triton X-100-permeabilized 
cells by using fluorescently tagged secondary antibodies.
Short-Interfering RNA. Short-interfering RNA was introduced by 
using lipofection of commercially synthesized RNA duplexes.
FADD Export Assay. WT or mutant forms of FADD were ex­
pressed with N-terminal yellow fluorescent protein (YFP) tags 
and C-terminal nuclear localization signals (NLSs) derived from 
simian virus 40 virus. After transfection, cells were detached for 
15 min before formaldehyde fixation and cells were scored 
for nuclear vs. cytoplasmic localization on a fluorescence 
microscope.
Cell Surface Fas Coimmunoprecipitation/Western Blotting. Cell sur­
face Fas coimmunoprecipitation/Western blotting was per­
formed by incubating cell cultures with the Fas-agonistic anti­
body 2R2 (Roche Molecular Biochemicals) followed by cell lysis 
in Triton X-100-containing buffer, precipitation with protein 
A-Sepharose, and Western blot analysis.
Yeast Two-Hybrid Screening, Protein Interactions in Vitro, Western 
Blotting, and Immunoprecipitation. Yeast two-hybrid screening, 
protein interactions in vitro, Western blotting, and immunopre­
cipitation were performed by using standard methodology as 
described in Supporting Methods, which is published as support­
ing information on the PNAS web site.
See Supporting Methods for detailed materials and methods.
Results
FADD Localizes to the Nucleus in Several Cell Lines. In the course of 
examining the basis for protection against FasL-induced apo­
ptosis by cell adhesion (R.A.S. and S.M.F., unpublished work), 
we observed that FADD was predominantly nuclear by using a 
mAb (Fig. 1). Nuclear FADD staining was blocked by preincu­
bation of the antibody with recombinant antigen. We then 
generated two monospecific anti-human FADD polyclonal an­
tibodies, which confirmed that FADD was primarily nuclear 
(Fig. 1). FADD was also primarily nuclear in several cell lines 
(HT1080 fibrosarcoma, Caco-2 colorectal carcinoma, HaCat 
keratinocytes, human umbilical vein endothelial cells) represen­
tative of diverse attached cell types (data not shown); lympho­
cytes were not examined in this study. This staining pattern was 
not seen with antibodies against another death receptor adaptor 
protein TR ADD (data not shown) in the absence of leptomycin, 
in agreement with a previous report (22). It was unlikely that 
fixation and permeabilization selectively leached a non-nuclear
FADD mAb DAPI FADD pAb DAPI
DAPIMBP-FADD
 FADD
1 U
MBP-Jun
Fig. 1. FADD localizes primarily to  th e  nucleus. (Top) MCF10a cells w ere 
analyzed fo r FADD localization by im m unofluorescence using a mAb and a 
polyclonal an tibody (pAb); a second pAb produced similar results (data not 
shown). Nuclear location is indicated by 4',6-diam idino-2-phenylindole (DAPI) 
staining. (Middle) Im m unofluorescent staining was carried ou t a fte r incuba­
tio n  o f th e  prim ary antibody (mAb) w ith recom binant m altose-binding pro­
te in  fusion pro te ins of FADD or c-jun. (Bottom) MCF10a cells w ere infected 
w ith  a retrovirus containing HA-tagged FADD and stained w ith anti-HA 
antibody. (Inset) F ixation/perm eabilization did no t ex tract a de tectab le  pool 
o f FADD. A fter fixation (lane 2) or fixation plus perm eabilization (lane 3) the  
insoluble fraction  was dissolved in SDS sam ple buffer and analyzed for FADD 
by W estern b lo tting . Lane 1 contains th e  soluble fraction  from  fixation plus 
perm eabilization .
FADD population, because no FADD was found by immuno- 
blotting of the extracted material obtained during these proce­
dures (Fig. 1). Treatment of MCFlOa cells with FADD short- 
interfering RNA reduced both the FADD signal on a Western 
blot and the average signal intensity of nuclear immunofluores­
cence (Fig. 6a, which is published as supporting information on 
the PNAS web site). To confirm the specificity of the nuclear 
signal, we also generated a monospecific anti-mouse FADD 
antibody and compared the immunofluorescence micrographs 
by using FADD-knockout MEFs versus FADD-expressing cells 
(47). The nuclear FADD signal obtained with an anti-mouse 
FADD polyclonal antibody was reduced to background levels 
in FADD-knockout MEFs (Fig. 6a). Also, certain mutants of 
FADD (described below) were found in the cytoplasm under the 
same fixation conditions, further excluding the possibility of a 
“fixation artifact.”
We then tested whether FADD was nuclear by a cell frac­
tionation approach. Hypotonic lysates were subjected to low- 
speed (800 g) centrifugation, yielding a pellet that was highly 
enriched for nuclei. Equal cell equivalents of nuclear and 
cytoplasmic fractions were assayed for FADD content by West­
ern blotting (Fig. 6b), indicating that the majority of FADD 
protein was in the nuclear fraction, as was the majority of c-jun 
protein. By contrast, the cytoplasmic protein procaspase-3 was 
mainly in the cytoplasmic fraction. It is not yet clear whether the 
small percentage of FADD found in the cytoplasmic fraction in 
some experiments was caused by leakage from the nucleus 
during the extraction procedure, the extent of which varies 
widely among nuclear proteins (48, 49), or represented a minor 
cytoplasmic pool that escaped immunofluorescent detection.
Taken together, the data strongly indicated that the primary 
localization of FADD is in the cell nucleus of adherent cell lines.
Exportin-5 Is a Potential FADD-Shuttling Protein. FADD functions at 
the membrane as a death receptor adaptor protein, implying that 
either a minor cytoplasmic pool is maintained constitutively or
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Fig. 2. C haracterization of FADD nuclear im p o r t/ex p o r t, (a) M u tation  of th e  
Ser-194 phosphorylation site o r o f th e  DED (am ino acids 1-80) o f FADD 
increases its cytoplasmic accum ulation. HA-FADD expression  constructs  con­
ta in ing  th e  indicated FADD m utan ts  w e re  tra n sfec ted  in to  MCF10a cells, 
which w ere  th en  im m unostained  w ith  anti-HA a n tib o d y  a f te r  being  m ain­
ta ined  in a ttach ed  conditions. R epresen ta tive  HA -stained cells an d  th e  posi­
tions of th e ir nuclei (4 ',6-diam idino-2-phenylindole, DAPI) a re  show n, (b) The 
sam e m utations o f FADD th a t  cause cytoplasm ic accum ula tion  also p rev en t 
induction o f export a fte r nuclear localization  has b e en  experim en tally  e n ­
forced. YFP-FADD-NLS expression constructs co n ta in ing  WT FADD or m u ta n t 
FADD sequences linked to  th ree  sim ian virus 40 NLSs w e re  tra n s fe c ted  in to  
MCF10a cells. A ttached or (15 min) d e ta ch e d  cells tre a te d  in th e  p resence  or 
absence o f a Fas-agonistic an tibody  (2R2) w e re  th e n  scored  fo r nu c lear (N) o r 
nuclear plus cytoplasmic (N + C) localization o f  th e  flu o rescen t ta g ; rep re sen ­
tative im ages used to  score th e  cells a re  show n (Top), a n d  q u a n tita tio n  o f th e  
results is show n in th e  histogram  (Middle). The p e rc en tag es  o f NC cells un d er 
a ttached  conditions (w ithout 2R2) w ere  o n  av erag e  2%  g re a te r  fo r YFP- 
FADD-NLS th an  for YFP-NLS. (A, YFP-NLS; B, YFP-FADD (WT)-NLS; C, YFP- 
FADD (S194A)-NLS; D, YFP-FADD (A1-80)-NLS.] (Bottom) D e tach m en t o f  cells 
from  m atrix p rom otes th e  recru itm en t o f e n d o g en o u s  FADD p ro te in  to  cell 
surface Fas-FasL complexes. Cells w ere  in cu b a ted  w ith  a Fas agon istic  mAb 
(2R2) under a ttached  (A) or suspended  (S) cond itions fo r  th e  ind ica ted  tim es; 
complexes w ere im m unoprecip ita ted  an d  analyzed  fo r  FADD by W estern  
b lo tting.
that conditions that sensitize the cell to FasL trigger a rapid 
export of some fraction of FADD from the nucleus. In either 
event, we suspected that FADD’s nucleocytoplasmic transport 
was likely to be performed actively by a transport protein rather 
than occurring by diffusion. To investigate the transport mech­
anism, we noted that FADD is phosphorylated at Ser-194 (50, 
51). The function of this phosphorylation is unknown; it is not, 
however, required for the interaction of FADD with caspase-8 
or Fas (50).
When hemagglutinin (HA) epitope-tagged FADD was trans­
fected transiently into MCFlOa cells, most cells showed mainly 
nuclear staining. However, the mutation of Ser-194 to alanine 
caused the FADD to be almost uniformly distributed throughout 
the cell (Fig. 2a). Among other mutants tested, the only other 
alterations similarly affecting FADD localization were either the 
deletion of the death effector domain (DED) (amino acids 1-80) 
or point mutation of Phe-25 to a glycine, which disrupts DED 
homotypic interactions (52). Despite this finding, there was no 
obvious basic amino acid-containing NLS present in the region 
of Ser-194 or in the DED, suggesting an unusual import mech­
anism (discussed below).
We then established an assay for the nuclear export of FADD 
in which YFP-labeled FADD was forced to assume a nuclear 
localization at time 0, regardless of FADD mutations, caused by 
three simian virus 40 NLSs appended to the C terminus. This
assay allowed us to assay mutants that were potentially defective 
in both import and export for export specifically. We found that 
a brief period of cell detachment from matrix caused the WT 
YFP-FADD-NLS to partially export from the nucleus, produc­
ing a nuclear-plus-cytoplasmic signal in <=20-25% of the cells in 
15 min, whereas the control YFP-NLS remained in 95% of the 
nuclei (Fig. 2b) This export may contribute to the increased FasL 
sensitivity of suspended compared with attached MCFlOa cells 
(R.A.S. and S.M.F., unpublished work), which remains to be 
established. The export was not caused by anoikis-induced 
breakdown of the nuclear envelope, as evidenced by the afore­
mentioned YFP-alone control, the fact that export preceded 
detectable caspase activation by several hours, and the insensi­
tivity of export to the pan-caspase inhibitor zVAD-fmk (data not 
shown.) Moreover, the detachment of from matrix promoted the 
recruitment of endogenous FADD to cell-surface Fas-Fas an­
tibody complexes (Fig. 2b), validating cell detachment as a 
stimulus for FADD export.
We used this assay to compare the export capabilities 
of various mutants of FADD. Interestingly, the S194A and 
DED mutations (that inhibited import) also inhibited ex­
port of FADD. Although the DED contained a leucine-rich 
sequence that was a potential signal for crml-mediated export 
LTELKFLCL, mutations of the leucines in this sequence did not 
affect export; also, the crml inhibitor leptomycin B did not af­
fect export of YFP-FADD-NLS at doses that completely pre­
vented export of the crml-cargo, protein kinase A-inhibitor 
(data not shown), suggesting that crml did not export FADD.
The observation that the same mutations prevented both 
FADD import and export and that a phosphorylation site was 
required for both suggested the involvement of a nucleocyto­
plasmic shuttle protein that interacted preferentially with phos­
phorylated cargoes. Such a protein has been identified recently 
in human cells: hmsn5/exportin-5 (53). Although this protein 
was originally dubbed an exportin, it was subsequently shown to 
act as an importin as well (54). FADD interacted efficiently with 
exportin-5/hmsn5 but not with crml in cotransfection experi­
ments in 293T cells (Fig. 7, which is published as supporting 
information on the PNAS web site). Interestingly, the mutants of 
FADD that did not transport to or from the nucleus efficiently, 
SI94A and A1-80, also did not interact efficiently with exportin- 
5/hmsn5. Furthermore, GST-FADD protein recovered from 
transfected 293T cells interacted in vitro with purified exportin- 
5/hmsn5 protein in the presence of activated Ran protein [in 
accordance with the role of activated Ran in nuclear transport 
by exportin-5 (53)]; however, the same FADD protein first 
subjected to dephosphorylation did not (Fig. 7). Taken together, 
exportin-5/hmsn5 is a candidate FADD-shuttling protein, which 
remains to be confirmed by protein ablation experiments (com­
plicated by the fact that exportin-5 is required for viability). 
Nevertheless, the data clearly define a role for Ser-194 phos­
phorylation in determining the localization of FADD protein.
FADD In te ra c ts  w ith  MBD4. We hypothesized that FADD may carry 
out a novel function in the nucleus. Thus, a cDNA library derived 
from MCF-7 mammary adenocarcinoma cells was screened for 
FADD-interacting proteins in a yeast two-hybrid system.
Surprisingly, about one-third of the positive clones were 
fragments of MBD4. MBD4’s interaction with FADD was highly 
specific in yeast, as several unrelated bait proteins failed to 
interact with it (Fig. 8a, which is published as supporting 
information on the PNAS web site). Using MBD4 deletion 
mutants expressed in the yeast two-hybrid system, we mapped 
the interacting region of MBD4 to amino acids 400-455, which 
is immediately upstream of the glycosylase domain (Fig. 8b). The 
regions of FADD required for MBD4 interaction were mapped 
similarly, indicating that the DED (amino acids 1-80) was 
required for the interaction but the carboxyl-terminal tail region
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Fig. 3. FADD in teracts w ith MBD4 in m am m alian  cells. (Upper) MCFlOa 
lysates w ere  im m unoprecip ita ted  (IP) w ith  sh eep  anti-M BD4 an tib o d y  (M), 
anti-FADD polyclonal Ab (F), o r p re im m u n e  serum  (pre). Im m unoprecip ita tes  
w ere  analyzed by W estern b lo ttin g  using  FADD mAb an d  a heavy v chain- 
specific anti-m ouse secondary an tibody . (Lower) Lysates from  32P-labeled 
MCFlOa cells w ere  im m unoprec ip ita ted  as ab o v e  an d  th e  p roduc ts  w ere  
de tected  by au to rad iography . N ote th a t  o n e  o f th e  tw o  m ajor an tibody- 
specific bands precip ita ted  w ith  anti-FADD an tib o d y  co m ig ra ted  w ith  MBD4 
(com pare lanes M and F). The ^90-kD a b an d  p rec ip ita ted  w ith  FADD an tib o d y  
was suspected to  be  MLH1, which w as confirm ed  below . All o f  th e  lanes show n 
w ere derived from  th e  sam e gel; in te rven ing  lanes w ere  d e le ted  fo r  clarity.
(needed for exportin-5 interaction as shown above) was not 
required (Fig. 8c). To test the sufficiency of the DED for MBD4 
interaction, noting that the DED alone was not expressed well 
in yeast or 293T cells, the interaction was assayed in vitro by using 
recombinant proteins. Interestingly, the DED of FADD was 
reproducibly found to interact more efficiently with MBD4 than 
did full-length FADD (Fig. 8c). The involvement of the DED of 
FADD suggested that MBD4 and caspase-8 might compete 
against each other for binding to FADD, which was confirmed 
in vitro (data not shown).
To test the FADD-MBD4 interaction in mammalian cells, we 
first cotransfected epitope-tagged forms of the two proteins into 
293T cells, pulling down one protein on glutathione beads and 
probing a Western blot for the other in both combinations (Fig. 
9a, which is published as supporting information on the PNAS 
web site). FADD and MBD4 interacted efficiently and specifi­
cally by this criterion. We then assayed for the interaction of the 
endogenous proteins by coimmunoprecipitation (Fig. 3). A 
sheep polyclonal antibody was prepared against the C-terminal 
domain of bacterially expressed human MBD4 and its specificity 
was confirmed (Fig. 5d). This antibody was used to immuno- 
precipitate MBD4 from MCFlOa lysates. These immunoprecipi­
tates (in contrast to those with preimmune sheep IgG) contained 
a FADD signal that was readily detectable on Western blots with 
exposure times of <10 s. To perform the converse experiment 
(noting that the sheep anti-MBD4 did not work well for Western 
blot detection and that both FADD and MBD4 are phospho- 
proteins), cellular proteins were metabolically labeled with 32P, 
and lysates were immunoprecipitated with our polyclonal FADD  
antiserum. The immunoprecipitates were analyzed by autora­
diography of an SDS gel, revealing a specific band that precisely 
comigrated with MBD4 immunoprecipitated from parallel ly­
sates, as well as a band of the molecular mass of MLH1 («*87 
kDa). Indeed, endogenous FADD immunoprecipitated from 
MCFlOa cells revealed the presence of MLH1 protein by 
Western blot analysis (Fig. 9b), and 293T cotransfection con­
firmed that the DED was required for this association as well. 
These data indicate that endogenous FADD and MBD4 proteins 
interact in MCFlOa cells.
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Fig. 4. MBD4 regulates FasL-induced apoptosis. MBD4 knockout or WT 
mice w ere  injected w ith th e  agonistic Fas antibody Jo-2, and  a t th e  tim es in­
d icated, intestinal crypt cells o r hepatocytes w ere analyzed for apoptosis as 
described (47).
MBD4 A ffec ts  A p o p to s is . The interaction of MBD4 with the 
caspase-8-activating protein FADD suggested that MBD4 might 
be capable of regulating apoptosis. To test this, we used our 
previously described MBD4 knockout mouse model (29). We 
recently observed evidence for a proapoptotic role of MBD4 
with respect to DNA-damaging agents (O.J.S. and A.R.C., 
unpublished data). In light of the primary role of FADD in death 
receptor-induced apoptosis, WT control or MBD4 knockout 
mice were injected with the Fas-agonistic antibody Jo-2, which 
induces apoptosis rapidly in intestinal and hepatic epithelial cells 
that can be scored readily by histological analysis. Interestingly, 
the MBD4 knockout mice were reproducibly more sensitive 
(=>5.5-fold in the small intestine) to apoptosis in this context (Fig. 
4). To examine the effect of MBD4 on FasL responses in MEFs, 
we rescued M B D 4 - /— MEFs with an HA-mouse-MBD4 ret­
rovirus, generating mixed populations that expressed MBD4 at 
3-fold above the WT MEF level (but substantially lower than the 
levels in established cell lines such as MCFlOa; data not shown). 
This approach circumvented the comparison of cells from dif­
ferent embryos, which was confounded by variability. Surpris­
ingly, MBD4 sensitized these cells, in contrast to the intestinal 
cells in vivo, to FasL-induced apoptosis (Fig. 10a, which is 
published as supporting information on the PNAS web site). This 
finding suggested that the effect of MBD4 on FasL-induced 
apoptosis depended on the cell type or the precise MBD4 
expression level (which may in turn affect protein complex 
composition or MBD4 posttranslational modifications). Inter­
estingly, MBD4 reexpression sensitized these MBD4-knockout 
cells to anoikis-related caspase activation as well (Fig. 106).
Discussion
N u c lea r L o ca lizatio n  o f  FADD. FADD couples death receptors with 
initiator caspases (35-37). Thus, FADD is assumed to be pri­
marily cytoplasmic. However, the evidence to support this 
assumption is limited to overexpressed FADD, which aggregates 
into “death effector filaments” (55, 56). These structures have 
not been observed for endogenous FADD, and, unlike endog­
enous FADD (R.A.S. and S.M.F., unpublished data) are Triton- 
insoluble (56). Thus, the localization of endogenous FADD 
protein was unexplored to our knowledge until the present 
report. The localization of FADD reported here does not imply 
that 100% of FADD is nuclear: clearly, the well-documented 
death receptor adaptor function of FADD logically implies that 
this is not the case. Thus, either there is a constitutive but minor 
cytoplasmic pool of FADD for this purpose or costimulatory 
signals for Fas signaling such as lack of cell-matrix adhesion 
(R.A.S. and S.M.F., unpublished data; refs. 43 and 44) stimulate 
the nuclear export of FADD. The latter is consistent with our 
results (Fig. 26); thus, it will be interesting to determine how 
extracellular signals regulate FADD localization, as this could 
potentially modulate death ligand sensitivity. Control of Ser-194
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phosphorylation, which is required for import/export and ex­
portin-5 interaction, is likely to play a key role.
Significance of the FADD-MBD4 Interaction. MBD4 and FADD 
interacted with each other, suggesting a novel linkage between 
genome surveillance/DNA repair and apoptosis. Consistent 
with this finding, MBD4 was shown herein to control apoptosis. 
Preliminary data (not shown) using short-interfering RNA to 
reduce MBD4 protein levels in epithelial cell lines support this 
conclusion. The fact that MBD4 regulates FasL responses clearly 
implicates a functional connection between MBD4 and FADD, 
although more mechanistic information will be needed to 
conclude that MBD4 controls apoptosis by its direct FADD 
interaction.
Metazoan cells couple genome surveillance to apoptosis (re­
viewed in refs. 1, 12, and 57) to eliminate genetically aberrant 
and potentially neoplastic cells. We propose that MBD4- 
mediated genome surveillance is coupled directly to nuclear 
FADD, an adaptor protein implicated in multiple apoptotic 
responses (36-42). MBD4 is thought to specifically repair GT 
mismatches resulting from the spontaneous deamination of 
methylcytosine (25), the most frequent cause of point mutations 
in the human genome (28). In fact, MBD4 knockout mice show 
a mutator phenotype that leads to enhanced spontaneous car­
cinoma frequency in the min background (29). Thus, one 
compelling function for the M BD4-FADD complex would be to 
couple extensive “GT mismatch signals” to apoptosis.
The ability of MBD4 to regulate apoptotic responses to diverse 
DNA lesions (O.J.S. and A.R.C., unpublished data) or stimuli 
not apparently causing DNA damage is more challenging to 
explain. First, MBD4 interacts with MLH1 protein, and the latter 
promotes apoptosis triggered by a wide variety of DNA damage 
types (7-11), possibly because of its involvement in a large 
multifunctional DNA repair complex (58). Second, although 
FasL and anoikis are not considered DNA-damaging, they 
rapidly activate caspases, in turn activating nucleases that cause 
double-strand DNA breaks (59, 60). The latter would elicit DNA 
damage signals, thus activating caspases further in a feed­
forward loop that finalizes the cell’s commitment to apoptosis. 
The possible involvement of FADD and MBD4 in this amplifi­
cation process, which would explain the proapoptotic effects of 
MBD4, remains to be determined.
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